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ABSTRACT 
 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in 
developed countries. Men have a higher incidence and an earlier onset of CVD than age-
matched women. It has been shown that young women have lower CVD incidence than 
young men and the increase in CVD rates in older (post-menopausal) women when 
estrogen levels decline suggests that estrogens are cardioprotective. This theory has been 
extensively investigated demonstrating a favourable reduction in LDL, reducing 
expression of cell adhesion molecules and promoting vasodilatation by inducing nitric 
oxide (NO) production in endothelial cells. However, not many studies have explored 
the alternate theory that male sex hormones, androgens (T & DHT), may promote CVD. 
Investigators examining male androgens in vivo have shown inconsistent results, with 
both adverse and protective effects on atherosclerosis formation. This study aimed to 
elucidate the role of androgens and their effects on the formation and progression of 
atherosclerotic plaque in males and females.  
 
Chapter 3 describes the establishment of the en face Oil Red O for quantitating 
atherosclerotic plaque. The Oil Red O technique was employed to compare the 
reliability and the consistency of the plaque area to the already established H&E staining 
method. This chapter focuses on the en face Oil Red O staining technique to see if the 
new method could give a faster, more efficient and reliable alternative to the very labour 
intensive H&E staining. From this study the en face Oil Red O staining technique was a 
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more time and labour efficient method that is a reliable method to the already establish 
H&E staining when investigating atherosclerotic plaque levels. 
Chapter 4 examines the effect of exogenously administered male sex hormones, 
testosterone (T) and dihydrotestosterone (DHT), on atherosclerosis in male and female 
ApoE-/- mice. The aim of this experiment was to examine if the androgens had a dose- 
and or gender- specific effect on the plaque formation in the animals. The experimental 
design involved the use of three different doses of high (1cm implant), medium (0.5 cm 
implant) and low (0.25 cm implant) T or DHT and the mice were treated for a period of 
16-weeks. The results showed that T had gender- and dose- specific effects. Briefly, 
there was no effect of T treatment on plaque formation in females. However, in males, 
the high dose of T decreased plaque but at the low dose T had the opposite effect by 
increasing plaque levels. The DHT results differed to the T results indicating different 
pathways of action. DHT treatment in the females demonstrated atheroprotective effects 
at the high and medium dose. The males had no effect at the high dose of DHT but the 
low dose was atherogenic.  
 
Chapter 5 aimed to explore the effect of DHT treatment in cells involved in early 
atherogenic processes using male and female HUVEC and MDM and to ascertain if AR 
cofactors are hormonal regulated. The results showed that there was no hormonal 
regulation in the MDM by DHT. Alternatively, in HUVEC there was a significant up-
regulation of ARA24, ARA54, ARA160 and SRC-1 mRNA levels with DHT treatment 
and a down-regulation of p300 and NCoR1 mRNA levels. In particular, this chapter also 
investigated protein expression of the cofactor SRC-1 in HUVEC, which was increased 
in males with DHT treatment. SRC-1 protein levels were also examined with in vivo 
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studies. Different doses of T and DHT were administered to male and female ApoE
-/- 
mice. The 0.5 cm and 1 cm dose of T in the male showed an increase in the SRC-1 
protein level and DHT, at the 0.25 cm and 0.5 cm implant increased SRC-1 protein 
levels. SRC-1 levels in female animals did not change with any dose of DHT, whereas 
the 0.25 cm T showed an increase in SRC-1 and 0.5 cm T implant decreased SRC-1 
protein levels. This study demonstrates that AR cofactors can be hormonally regulated 
by androgens at the mRNA and protein level.  
 
Overall, male sex hormones have an effect on atherosclerosis formation. Androgens 
have important gender- and dose- specific effects on plaque formation, and can 
hormonally regulate AR cofactors at the mRNA and protein level. The results of this 
thesis have produced more questions than it has answered. This study requires further 
investigation into the benefits and consequences of using androgens, examining the 
underlying molecular pathways that may be involved with the AR cofactors and the use 
of exogenous androgen treatment for both men and women.  
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Chapter 1 - Literature Review 
 
1.1 Introduction 
 
Cardiovascular disease (CVD) is the leading cause of death in the Western world today 
and is predicted to remain so well into the next century [1]. According to the World 
Health Organisation (WHO) report of 2003, CVD mortality accounted for 29.2% of all 
deaths globally and it was predicted that 11.1 million deaths will occur from CVD 
annually by 2020 [2]. 
 
The term CVD encompasses several pathologies including coronary heart disease, 
cerebrovascular disease, hypertension, heart failure and rheumatic heart disease [3]. 
According to large population studies such as the Framingham Heart Study and the 
Münster Heart Study [4, 5] there are a number of risk factors that predispose people to 
CVD incidence including hypertension [6, 7], high blood cholesterol, diabetes mellitus 
[8, 9], smoking [10] and/or obesity [11, 12]. Additionally other lifestyle–associated risk 
factors including a fibre-poor diet [13, 14], physical inactivity [13, 14], stress [13, 14] 
and age [15, 16] have been implicated as risk factors for CVD. In addition, inherited 
genetic disorders including familial hypercholesterolemia predispose to CVD [17]. Male 
gender has also been identified as a key risk factor [18-20]. In that men have a 2.2-fold 
increase in the occurrence of CVD compared to women across all ages. However, this 
gender gap decreases with age especially after the onset of menopause [21-23]. 
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Figure 1.1 Gender difference in the incidence of cardiovascular disease 
 
A: Number of deaths from CVD show that while the slopes are parallel for men and 
women, the curves are offset by 10 years with men having an earlier onset of disease. B: 
CVD death rates show that men have a higher mortality rate from CVD with respect to 
women. The gender gap exists across all age groups although it closes with each decade 
after menopause (adapted from Tunstall-Pedoe [21]). 
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The male predisposition to CVD exists across different nations and cultures strongly 
suggesting, that despite variable lifestyle factors and population genetics, men 
consistently have higher death rates from CVD than age-matched women [24]. 
Underlying reasons for the gender dichotomy in CVD incidence may include genetics, 
lifestyle differences between genders or different endogenous sex hormones. 
 
It has been suggested that hormonal differences between men and women may be a 
possible explanation for the gender dichotomy in the incidence of CVD [25]. To date, 
research has focused on the potential cardioprotective effects of the female sex 
hormones, estrogens [26]. Given the coincident decline in estrogen levels with the 
increase in CVD incidence, a long-held hypothesis that emerged was that estrogens 
protect young women against CVD. Estrogens are high in younger women (<50), but 
fall dramatically at the age of menopause, which coincides with the development of 
CVD (Figure 1.1) [21]. Accordingly, many studies have examined the protective effects 
of estrogen on CVD. However, far fewer studies have investigated the alternative theory 
that male hormones, or androgens, may promote CVD in men [27].  
 
In this work, both in vivo and in vitro approaches were used to examine the role of 
androgens in the pathogenesis of atherosclerosis which is the primary cause of CVD. 
The in vivo approach involved treating ApoE 
-/- 
mice (a mouse model of atherosclerosis) 
with the two major male hormones, testosterone (T) and dihydrotestosterone (DHT), and 
examined whether these androgens affects the rates of atherosclerotic plaque 
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development. The in vitro experiments were aimed at examining molecular mechanisms 
that may be important for androgen action in the vasculature.  
 
1.2  Sex hormones and CVD 
1.2.1 Female sex hormones (estrogens) and CVD 
That young women (<50) have a lower CVD incidence than young men (<50), and that 
there is an increase in CVD rates in older (post-menopausal) women when estrogen 
levels decline suggests that estrogens are cardioprotective [26, 28]. There have been 
numerous in vitro studies investigating the effects of estrogen on vascular cells and the 
collective findings implicate protective effects of estrogens. The effects of estrogen 
include favourably reducing and preventing the oxidation of low density lipoprotein 
(LDL) and high density lipoproteins (HDL) [29-33]; reducing endothelial cell 
expression of cell adhesion molecules [34, 35]; reducing the Ang II type 1 (AT1) 
receptor expression [26, 36], as well as promoting vasodilatation by inducing nitric 
oxide (NO) production in endothelial cells (ECs) [37, 38]. For example, two vascular 
endothelial cell types, human umbilical vein endothelial cells (HUVEC) and bovine 
arterial endothelial cells (BAEC), responded to estradiol administration with increased 
NO production [39]. Using animal models of atherosclerosis, estrogen administration 
has also predominantly shown cardio-protective effects with a decrease in 
atherosclerotic lesions, myointimal thickening of the arteries and/or altering LDL and 
HDL levels (summarised in Table 1.1). However co-administration of progestins can 
attenuate the protective effects of the estrogens [40, 41]. 
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Table 1.1 In vivo animal studies examining effects of estrogen treatment on atherosclerosis 
Animal model Treatment 
groups 
Length of 
treatment 
Endpoint Effect on 
atherosclerosis (AT) 
Reference 
Cholesterol-fed Cynomolgus monkeys    
 ethinyl estradiol 
+ norgestrel 
16 wks Atherosclerotic 
lesions 
E2 ↓ [42] 
 ovx + estrone 24 mths 
Atherosclerotic 
lesions 
No effect [43] 
 ovx+E2 24 mths Atherosclerotic 
lesions 
E2 ↓ [44] 
 E2 ± nomegestrol 
acetate 
12 wks Aortic cholesterol 
content 
No effect [45] 
 ovx+CEE 30 mths Atherosclerotic 
lesions 
CEE ↓ AT (37%) [46] 
 E2 ± LNG 28 days Atherosclerotic 
lesions 
E2 ↓ 
E2 + LNG ↓ 
LNG alone ↑ 
[47] 
Cholesterol-fed New Zealand White Rabbits    
 
estrone, E2, 
ethinyl estradiol 
 
4.5 mths (I.M.), 
1.5 mths (oral) 
 
Atherosclerotic 
lesions  
 
Estrogens ↓ (I.M.)  
E2 ↑ (oral) 
 
[48] 
 
 
 ovx+E2 27 wks Atherosclerotic 
lesions 
E2 ↓ [49] 
 ovx+E2 ± P 12 wks Aortic cholesterol 
accumulation  
E2 ↓ 
P attenuated E effect 
[41] 
 
E2 
 
12 wks 
 
Atherosclerotic 
lesions  
E2 ↓ 
 
[50] 
 
 ovx + E2 
(percutaneous), 
ovx + E2 (oral) 
12 wks Atherosclerotic 
lesions 
E2 (percutaneous) ↓  [51] 
 ovx+E2, 
ovx+raloxifene 
 
39 wks 
Atherosclerotic 
lesions 
E2 ↓ 
raloxifene ↓  
 
[52] 
 E2 10 wks 
Atherosclerotic 
lesions 
E2 ↓ [53] 
Other animal models    
New Hampshire-
Columbian 
crossbred chicks 
E2 2 mths 
 
Lipids and SMC 
death 
E2 ↑ [54] 
White leghorn 
cockerels 
E2 ± P, 
P alone 
8-7 days 
 
Intimal thickness 
Atherosclerotic 
lesions 
No effect on plaque 
formation and intimal 
thickness 
[40] 
 
Wistar Rats 
 
odx/ovx + E2 
 
2, 4, or 8 wks 
 
Aortic cholesterol 
esterase activity 
No effect 
 
[55] 
 
Sprague-Dawley 
rats 
odx + E2 
 
2 wks 
 
Myointimal 
thickening 
E2 ↓ 
 
[56] 
 
LDLR-/- mice 
(western diet) 
odx + E2 
 
8 wks Atherosclerotic 
lesions 
E2 ↓ 
 
[57] 
 
ApoE-/- mice odx + E2 
 
8 wks 
 
LDL and HDL, 
Atherosclerotic 
lesions 
E2 ↓ [58] 
E2: 17β-estradiol; LNG: levonorgestrel; odx: orchidectomised male mice; ovx: ovariectomised female mice; I.M.: 
intramuscular injection; SMC: smooth muscle cell. 
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Observational human studies have collectively demonstrated that hormone replacement 
therapy (HRT) with estrogens in post-menopausal women improved cardiovascular 
outcomes [59], therefore, upholding the estrogen protection hypothesis. However, more 
recent findings from prospective randomised controlled HRT studies (RCT) 
(summarised in Table 1.2) have brought the hypothesis into question. Two trials in 
particular, the Heart and Estrogen/progestin Replacement Study (HERS) [60] and the 
Women’s Health Initiative (WHI) study [61], failed to show cardiovascular benefit as 
was expected from the results of the observational studies. Indeed, the RCT studies 
showed that in the first few years of HRT there was increased cardiovascular risk. Post-
hoc analysis suggested that the lack of cardiovascular benefit observed in the WHI and 
HERS studies may be due to the timing of treatment [62]. 
 
 It is now hypothesised that estrogens may have protective effects on early lesion 
development but that this protection is lost when hormone treatment is started after the 
development of advanced lesions [63]. Many of the observational HRT studies have 
showed cardiovascular benefit in women who started HRT at the onset of menopausal 
symptoms. The HRT was implemented in younger women, prior to the development of 
any significant vascular disease, these women still had protection from higher 
endogenous estrogen levels [64]. By contrast, the HERS study, was established as a 
secondary prevention trial that targeted women already carrying significant disease [60]. 
The WHI study was a primary prevention trial and therefore included only women with 
no prior history of CVD [61]. The average age of women in the study, however, was 65 
at the commencement of treatment. Therefore, these women were 15 years past the 
average age of menopause and may have had underlying atherosclerosis, which had not 
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yet shown clinical signs. To summarise, endogenous estrogens may protect younger 
women against early onset CVD. Estrogen therapy may be beneficial but only if started 
prior to disease development. 
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Table 1.2 Clinical HRT studies  
Randomised  
Controlled 
Clinical 
Studies 
Type of 
Estrogens 
Progestin Age 
(years) 
Increase 
in CVD 
Risk 
Adverse  
Effects 
Beneficial 
Effects 
Ref. 
HERS CEE MPA 67 # yes yes  [60] 
WHI CEE MPA 50-79 no yes  [61] 
 CEE - 50-79 no    yes *    
PEPI E2 -      yes *   [65] 
 E2 Progesterone 56.1#     
EPAT  E2 -  no  yes [64] 
WELL-HART E2 - 63.5 # no   no *  [66] 
 E2 MPA  no   no *   
PHOREA E2 Gestodene 40-70     yes *  [67] 
WISDOM CEE MPA     [68] 
 CEE -      
E2: 17β-estradiol; CEE: conjugated equine estrogens; MPA: medroxyprogesterone 
acetate HERS, Heart and Estrogen/progestin Replacement Study, WHI, Women’s 
Health Initiative; EPAT, Estrogen in the Prevention of Atherosclerosis; WELLHART, 
Women’s Lipid Lowering Heart Atherosclerosis Trial; PEPI, Postmenopausal 
Estrogen/progestin Intervention; PHOREA, Postmenopausal HormOne REplacement 
against Atherosclerosis; WISDOM, Women’s International Study of long Duration 
Oestrogen after Menopause. (* = not significant) (# = average age)  
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1.2.2 Male sex hormones (androgens) and CVD 
The protective effect of estrogen serves to decrease the risk of CVD in women and may 
account solely for the gender difference in CVD onset and incidence [25]. However, it 
cannot be excluded that, in men, male hormones may have pro-atherogenic effects that 
also contribute to the gender difference. This hypothesis comes from reported evidence 
that there is increased CVD is associated with anabolic steroid use [69-74] and also 
occurs in women with polycystic ovary syndrome (PCOS) that have elevated levels of 
endogenous androgens [75-80]. Despite the theories and reported evidence, few studies 
have examined the effects of androgens on the cardiovascular system in men or women 
[81-83]. In men, low levels of endogenous testosterone (T), rather than high, have been 
associated with increased CVD events [84-90]. Beneficial effects of T treatment have 
been reported in short term studies where men were administered supraphysiological 
doses of T and were found to have increased arterial dilation that, in turn, increased 
blood flow in patients with coronary heart disease [90]. 
 
While there are no clinical studies evaluating long-term androgen treatment on CVD 
risk, many animal model studies have been performed assessing the effects of exogenous 
androgen treatment on the rate of atherosclerotic plaque development. The majority of 
animal studies have concluded that while exogenous T treatment protects against early 
lesion development in males, it none the less promotes atherosclerosis in females 
(summarised in Table 1.3 and Table 1.4). However, this is not true for all studies with 
neutral or adverse effects reported, especially for males [40, 48, 54, 56, 91-94]. The 
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variable results may be related to whether low or high doses [57] were administered; the 
route of administration [54, 95, 96]; whether the animals were gonadectomised; and if 
so, the method used for gonadectomy (eg surgical, genetic or chemical) [50, 92, 97, 98]. 
Additionally, variability may be a result of whether the androgen used was aromatisable 
[99, 100] or non-aromatisable [92, 96]. Indeed, there is growing evidence that the 
atheroprotective effects of T in male animals is via its aromatisation to 17-beta estradiol 
(E2) [57, 97, 101, 102]. Despite the variability, at the present time it remains that animal 
studies would suggest that endogenous exposure to androgens and exogenous T 
treatment is protecting males against atherosclerosis.  
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Table 1.3 Androgen replacement studies in animals models: 
 
 MALE ANIMAL STUDIES NULL EFFECT OR ATHEROGENIC 
 
Reference Animal model 
Treatment 
groups 
Dose and route of 
administration 
Length of 
treatment 
Endpoint 
Effect on 
atherosclerosis 
[54] 
 
 
New Hampshire-
Columbian crossbred 
chicks  
T  
(intact males) 
 
0.1% oral in food 
 
2 mths 
 
Lipids and 
SMC death 
 
T ↑ 
 
[103] 
 
 
White Leghorn chicks 
 
 
Low dose T  
High dose T  
(intact males) 
30 mg/day oral  
150 mg/day oral 
 
7 wks 
 
 
Plasma lipids,  
Atheroscleroti
c  
 lesions 
 
T ↑ 
 
 
[92] 
 
 
ApoE-/- mice 
 
 
Cetrorelix 
T  
(intact males) 
Cetrorelix =  
100 µg injection / 48 hrs 
T = 35 mg implant 
8 wks 
 
 
Atheroscleroti
c lesions 
 
Exogenous T ↑ 
Endogenous T 
↓ 
[40] 
 
 
White leghorn cockerels 
 
 
 
T 
(intact males) 
 
 
0.12 mg injections 
twice/wk 
 
 
87 days 
 
 
 
Intimal 
thickness/ 
Atheroscleroti
c lesions 
No effect 
 
 
 
[94] 
 
Cholesterol-fed New 
Zealand White rabbits 
Stanozolol  
(odx males) 
5 mg daily for 6 wks 
then 10 mg daily for 6 
wks, oral 
12 wks 
 
HDL and LDL 
levels 
Atheroscleroti
c lesions 
No effect 
 
[48] 
 
Cholesterol-fed New 
Zealand White Rabbits 
T  
(odx males) 
1 mg orally in food or  
1.5 mg IM once/wk 
28 wk (IM) 
6 wk (oral) 
Atheroscleroti
c lesions 
No effect 
 
[95] 
 
Cholesterol fed Danish 
Country strain rabbits 
T  
(odx males) 
25 mg IM twice/wk 
 
17 wks 
 
Aortic 
cholesterol 
content 
No effect 
 
[56] 
 
Sprague-Dawley rats  
 
T 
(intact) 
(odx  males) 
1.5 cm implant 
 
2 wks 
 
Myointimal 
thickening 
No effect 
 
 
 
T: testosterone; DHT: dihydrotestosterone; odx: orchidectomised males; IM: intramuscular injection; TC: total cholesterol; 
TP:testosterone propionate; TE: testosterone enanthanate; TU: testosterone undecanoate 
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Table 1.4 Androgen replacement studies in animals models: 
MALE ANIMAL STUDIES: CARDIOPROTECTIVE 
Reference Animal model Treatment groups 
Dose and route of 
administration 
Length of 
treatment 
Endpoint 
Effect on 
atherosclerosis 
[99] 
 
 
Cholesterol-fed New 
Zealand White 
rabbits 
DHEA 
(odx males) 
 
0.5 % orally in food 
 
 
12 wks 
 
 
Atherosclerotic 
lesions 
 
DHEA ↓ 
 
 
[104] 
 
 
Cholesterol-fed New 
Zealand White 
rabbits 
DHEA 
(odx  males) 
 
0.5% orally in food 
 
 
5 wks 
 
 
Graft 
Atherosclerotic 
lesions 
DHEA ↓ 
 
 
[100] 
 
 
Cholesterol-fed New 
Zealand White 
rabbits 
DHEA 
TU, TE  
(odx males) 
 
DHEA (500 mg/day 
oral); TU (80 mg/day 
oral); TE (25 mg 
twice/wk IM) 
30 wks 
 
 
Serum lipids 
Atherogenic 
lipoproteins 
Atherosclerotic 
lesions 
Androgens ↓ 
 
 
[50] 
 
 
Cholesterol-fed New 
Zealand White 
rabbits 
TE 
(odx males) 
 
25 mg/kg/bw. once/wk 
IM 
 
12 wks 
 
 
Atherosclerotic 
lesions 
 
T ↓ 
 
 
[96] 
 
Rats 
 
T, DHT 
(odx males) 
40 mg implants 
 
13 wks 
 
Total cholesterol 
 
T and DHT ↓ 
 
[98] 
 
 
C57BL/6, BALB/c 
and C3H mice 
 
T (high fat) 
 
 
30 mg implant 
 
 
14 wks 
 
 
 
HDL 
Atherosclerotic 
lesions 
 
T ↓  
 
 
[105] 
 
ApoE-/- mice 
  
T 
(odx males) 
 
7.5 mg implant 
 
 
8 wks 
 
 
 
TC, LDL, HDL 
Atherosclerotic 
lesions 
 
T ↓ 
 
 
[101] 
 
ApoE-/- mice 
 
 
T or DHT 
(odx males) 
 
T & DHT  
1 cm implant 
 
8 wks 
 
 
Atherosclerotic 
lesions 
 
T ↓  
No effect with 
DHT  
[97] 
 
 
Tfm mice (AR-) 
 
 
 
T 
(Male Tfm = low 
endog T) (intact 
males) 
10 µL of 100 mg/100 
mL) IM / fortnight 
 
 
28 wks 
 
 
 
Aortic fatty 
streaks 
 
 
Tfm phenotype 
(low endogenous 
T ↑) 
T replacement ↓  
[102] 
 
 
Cholesterol-fed New 
Zealand White 
rabbits 
DHEA 
± aromatase inhibitor  
 
0.3% in food/day 
fadrazole:= 2.0 
mg/kg/d/ IM 
10 wks 
 
 
Atherosclerotic 
lesions 
 
DHEA ↓, 
attenuated by 
aromatase 
inhibitor 
[57] 
 
 
 
LDLR-/- mice 
(western diet) 
 
 
T ±  aromatase 
inhibitor 
(odx males) 
 
T = 1 cm implant 
anastrazole = 10 
mg/kg/day orally 
 
8 wks 
 
 
 
Atherosclerotic 
lesions 
 
 
T ↓, 
attenuated by 
aromatase 
inhibitor  
 
T: testosterone; DHT: dihydrotestosterone; odx: orchidectomised males; IM: intramuscular injection; TC: total cholesterol; 
TP:testosterone propionate; TE: testosterone enanthanate; TU: testosterone undecanoate 
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Table 1.5 Androgen replacement studies in animals:  
FEMALE ANIMAL MODELS 
Reference Animal model 
Treatment 
groups 
Dose and route of 
administration 
Length of 
treatment 
Endpoint 
Effect on 
atherosclerosis 
[50] 
 
 
 
Cholesterol-fed 
New Zealand 
White rabbits 
(ovx females) 
TE 
 
 
 
25 mg/kg/bw. 
IM 
once/wk  
 
12 wks 
 
 
 
Atherosclerotic 
lesions 
 
 
T ↑ 
 
 
 
[43] 
 
 
 
Cholesterol-fed 
Cynomolgus 
monkeys 
(ovx females) 
AD or T  
 
 
 
AD=2.5 cm implant 
T = 3 x 3.5 cm implant 
 
 
24 mths 
 
 
 
Atherosclerotic 
lesions 
 
 
T ↑ 
 
 
 
[106] 
 
 
 
Cholesterol-fed 
Cynomolgus 
monkeys 
(ovx females) 
Nandrolone 
 
 
 
25 mg IM every 3 wks 
 
 
 
1-2 yrs 
 
 
 
Plasma lipid 
Lumen area, 
atherosclerosis 
 
Nandrolone ↑* 
 
 
 
[101] 
 
ApoE-/- mice 
(ovx females) 
T or DHT 
 
T & DHT  
1 cm implant 
8 wks 
 
Atherosclerotic 
lesions 
T ↑  
No effect with 
DHT  
[105] 
 
ApoE-/- mice  
(ovx females) 
T 7.5 mg implant 8 wks 
TC, LDL, HDL 
Atherosclerotic 
lesions 
T ↓ 
[92] 
 
ApoE-/- mice 
(intact females) 
 
Cetrorelix 
T  
 
Cetrorelix= 
100 µg injection / 48 hrs 
T =35 mg implant 
8 wks 
 
 
Atherosclerotic 
lesions 
 
T ↓ in females 
 
 
T: testosterone; DHT: dihydrotestosterone; odx: orchidectomised males; IM: intramuscular injection; TC: 
total cholesterol; TP:testosterone propionate; TE: testosterone enanthanate; TU: testosterone undecanoate; 
AD: androstenedione 
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1.2.3 Testosterone metabolism and its role in plaque development 
The lack of agreement between animal studies may be explained by the metabolism of 
T. The primary active metabolites of T are estradiol (E2) and dihydrotestosterone 
(DHT), (Figure 1.2). E2 is formed from T by cytochrome P450 aromatase activity [107, 
108]. Metabolism of T to E2 diversifies its action as E2 acts through binding and 
activation of either of the estrogen receptor (ER) isoforms, ERα or ERβ, resulting in 
activation of a completely different set of genes to that regulated by T binding its 
cognate receptor, the androgen receptor (AR). T can also be reduced by 5α-reductase 
enzymes to DHT, a non-aromatisable androgen [109]. This metabolism amplifies T 
action as DHT is a more potent androgen having a greater affinity for the AR than T 
[110-113].  
 
 
 
 
 
 
 
 
 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Metabolism of steroids 
The pathways involved in the aromatisation and reduction of testosterone to estradiol 
and dihydrotestosterone [114]. 
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Findings in male animal models suggest that the aromatisation pathway to E2 underlies 
the protective effects of T, as aromatase inhibitor administration either completely or 
partially abrogated the protective effect of testosterone [57, 115-117]. Nathan et al 
(2001) [57] treated LDL -/- mice, a atherosclerotic mouse model, with T thereby 
decreasing plaque formation compared to the controls. When an aromatase inhibitor 
(anastrazole) was administered in conjunction with the T it attenuated the protective 
effects of T alone. Nettleship et al (2007) [97] demonstrated that testicular feminised 
(Tfm) mice, which possess an X-linked single based pair deletion in the gene encoding 
the classic androgen receptor (AR), destabilising the AR mRNA, showed a decrease in 
atherosclerotic lesions with T treatment compared to control litter mates [97]. The 
atheroprotective effect of T treatment was attenuated with the co-administration of the 
aromatase inhibitor anastrazole. Similarly, a different aromatase inhibitor, fadrazole, co-
administrated with T to New Zealand white rabbits, abolished the atheroprotective 
effects of T [102]. 
 
DHT has also been used to demonstrate the involvement of the aromatase pathway in the 
protective effects of T. DHT is a non-aromatisable androgen that cannot be metabolised 
to E2. DHT can, however, be metabolised to 5α-androstane-3β,17β-diol (3β-
androstanediol) by the action of the 3α- or 3β-hydroxysteroid dehydrogenases (3β-
HSDs) [118]. DHT can also be metabolised via 17βHSD3,5 to 5α-androstanedione 
[114]. The steroid 5α-androstanediol has been shown to bind and activate estrogen 
receptor β (ERβ) [119] in both the brain and prostate [120, 121], however, its 
importance in vascular tissue has not been established. Hence, DHT is considered to act 
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primarily in the vasculature via an AR-dependent pathway, and it is included alongside 
T in studies examining effects on plaque formation to distinguish between direct (AR) 
and indirect (estrogen-ER) effects.  
 
Previous studies from our own laboratory [122] demonstrated that T decreased 
atherosclerotic plaque area in gonadectomised male mice but increased it in 
ovarectomised female mice. This concurs with the majority of animal studies examining 
T effects on atherosclerosis (Tables 1.3 and 1.4). DHT treatment, however, resulted in 
the opposite effects to T, increasing plaque formation in males while having null or 
beneficial effects in females [122]. Interestingly, decreased plaque formation was 
associated with a local increase in aromatase expression in the aortic tree of male mice. 
By contrast, increased plaque formation in female mice was associated with decreased 
local aromatase expression but increased 5α-reductase-, and AR, expression. These 
results indicate that mechanisms of T action vary with gender and further suggest that T 
elicits protective effects via the aromatase/ER pathway in males but pro-atherogenic 
effects via the AR/5α-reductase pathway in females.  
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The above results were intriguing and consistent with many studies examining T effects 
on plaque formation in animals. Yet the question remains why these studies found T 
protective in males in contrast to the anecdotal evidence. Given that in men, low 
endogenous levels of T were associated with CVD but supraphysiological doses 
appeared to give short-term benefit it was hypothesised that androgens at varying doses 
may have differential effects on plaque development. This may explain some of the 
variability between animal studies. 
 
The hypothesis for the first part of this thesis was therefore: 
 
“That androgen dose has gender-specific effects on atherogenesis”. 
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1.3  Effects of androgens on atherosclerotic plaque formation 
 
Atherosclerosis is the major cause of CVD. It is a complex pathological process that 
involves the formation of fatty plaques within the vasculature [123, 124]. It begins in 
childhood with the formation of fatty streaks which progress into intermediary fibro-
fatty lesions and finally, to larger, more complex, atheromas with fibrous caps and 
necrotic cores [125-127]. 
 
At the molecular level, androgens may have both beneficial and harmful effects on the 
process of plaque formation. However, in combination, these may ultimately result in 
predominantly pro-atherogenic or anti-atherogenic effects. Several in vitro studies have 
demonstrated specific pro-atherogenic effects of androgens in two cell types important 
in plaque development: endothelial cells and monocyte-derived macrophages (MDM) 
[126, 128, 129]. The role of these two cell types in atherogenesis will be described.  
 
1.3.1 Endothelial response-to-injury hypothesis 
Endothelial cells are thought to be involved at the very onset of atherogenesis. The 
pathogenesis of atherosclerosis is initiated by injury to the vascular endothelium, 
resulting in endothelial dysfunction [127]. Injury to the endothelium can be caused by a 
number of factors: shear stress (hypertension); modified lipids such as oxidised low 
density lipoproteins (oxLDL) [130]; dyslipidemia; diabetes [131, 132]; and chronic 
infectious agents such as Chlamydia pneumoniae [133] (Figure 1.3). After injury to the 
vessel wall has occurred the endothelial cells become activated. Activation involves the 
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endothelium expressing a series of adhesion molecules, cytokines, growth factors and 
nitric oxide (NO) (an important vasodilator) to initiate the healing process [134-136]. 
The factors expressed by the activated endothelial cells also have an autocrine effect: 
they further stimulate the production of integrin complexes and increase the expression 
of selectins (such as P- and E-selectin) and specific cell adhesion molecules (CAMs) on 
their luminal surface [137, 138]. These CAMs include intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) [139] and platelet-endothelial 
cell adhesion molecule-1 (PECAM-1). The expression of these factors is one of the most 
critical early factors in lesion establishment and development [140]. The endothelium-
expressed selectins interact with the L-selectins on circulating inflammatory cells such 
as monocytes and T-lymphocytes causing them to slow and roll along the surface of the 
vessel wall [129]. The CAMs then form firm bonds with the inflammatory cells allowing 
transmigration into the intimal space [141].  
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Figure 1.3  Inflammatory responses to endothelial injury 
A number of factors can lead to endothelium dysfunction resulting in the up-regulation 
of cell adhesion molecules (VCAM-1, ICAM-1, PECAM, E-selectin and P-selectin) that 
can bind circulating monocytes. The selectins cause the monocytes to roll along the 
endothelium allowing them to form bonds with the CAMs expressed on the endothelial 
cells. Monocytes then transmigrate into the sub-intimal space where they differentiate 
into macrophages and secrete a number of cytokines and chemoattractants such as 
monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor-α (TNF-α), and 
interleukin-1 (IL-1). 
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1.3.2 Role of monocytes in atherosclerotic lesion formation 
Monocytes are part of the immune response and their normal role within an organism is 
to clear injured tissue of debris. Monocytes are attracted to sites of damage by cytokines 
and chemoattractants, such as monocyte chemoattractant protein-1 (MCP-1) and oxLDL 
secreted by the activated endothelium [131] (Figure 1.3). After binding to the 
endothelium, the monocytes transmigrate and accumulate within the intracellular intima 
where they differentiate into macrophages [142]. The monocyte derived macrophages 
(MDM) in the arteries express cell surface receptors for LDL that increases the influx of 
cholesterol. Normally a negative feed-back mechanism limits the amount of cholesterol 
taken up, and the macrophage then migrates back to the circulation and clears the tissue 
[127]. In atherosclerosis lesion development, however, LDL particles that may be 
trapped in arteries are subjected to various enzymatic and chemical modifications [143]. 
Modification of LDL  acts to enhance the inflammatory response by increasing the 
expression of scavenger receptors for modified LDL (CSRA, CD36 and CD68) that 
allow the MDM to ingest modified lipids [144]. The modified lipids do not auto-regulate 
these receptors and hence uptake becomes unregulated. This allows the macrophages to 
accumulate vast amounts of lipid that form large droplets that resemble foam within the 
cytoplasm, hence these cells are termed “foam cells” [145] (Figure 1.4). These large 
cells then become trapped within the intima and express inflammatory cytokines, growth 
factors and chemoattractants that stimulate further uptake of monocytes. Continued 
cycling of the whole process occurs, resulting in a chronic inflammatory response [146].  
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Eventually, continued accumulation of macrophage-derived foam cells in the centre of 
complex lesions, and their eventual apoptosis due to the toxic nature of the accumulated 
lipid, results in the formation of a central lipid-rich core [131]. These lipid-filled 
atheromatous plaques are highly unstable. As lesions progress and start to protrude into 
the vessel lumen the increased shear stress can result in elevated risk of rupture. 
Subsequently a release of the highly thrombogenic lipid-rich plaque components can 
occur [147]. 
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Figure 1.4 Foam cell formation 
Plaque progression is produced by a pro-inflammatory response which is promoted by 
the movement of LDL and proteins into the sub-intimal space of the vessels. The 
accumulation of MDMs is exacerbated by the secretion of macrophage-colony 
stimulating factor (M-CSF) from the MDMs. These MDMs have altered cholesteryl 
ester accumulation. They are able to uptake modified lipids through scavenger receptors. 
MDMs that have accumulated large amounts of cholesteryl esters are called “foam cells” 
due to the “foamy” appearance. Eventually, this pathological process produces lesions 
that occlude the vessel into the luminal space, where the pressure of the blood can erode 
the plaque causing it to rupture. Further occluding the blood vessel and reducing blood 
flow [148]. 
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1.4  Androgens effect the regulation of vascular cells 
 
The expression of CAM on vascular endothelial cells, and subsequent monocyte 
adhesion to the endothelium, are important steps in early lesion development. Similarly, 
lipid uptake by MDM is a critical step in the progression of atherosclerosis. In vitro 
studies have shown that androgens can regulate these early atherogenic processes. A 
study by McCrohon et al (1999) [149, 150] demonstrated that the potent non-
aromatisable androgen, dihydrotestosterone (DHT), could increase macrophage 
cholesteryl ester content in male-derived cells in a dose-dependent manner. DHT has 
been shown to increase monocyte binding to ECs and significantly increase VCAM-1 
expression in ECs in culture [150, 151]. DHT-treatment of MDM only from male donors 
resulted in an increase in atherogenic gene expression [152]. Interestingly, these studies 
show that DHT treatment effects were found to be greater in male-, compared to female-
, donor cells and were mediated through the androgen receptor (AR). McCrohon et al 
(1999) [150] showed that the AR had greater expression levels in the male donor then 
the females donor cells. 
 
The higher AR expression levels in males, then females, may play a role in the 
regulation of these early processes in atherogenesis [149, 150]. Androgen action in any 
cell-, or tissue-, type has specific targets and is controlled by various factors such as 
serum hormone levels or local hormone metabolism [153]. Regulation of receptor 
expression and/or activity is an important modulator of androgen action, particularly in 
non-gonadal tissues such as the vasculature where receptor expression is relatively poor 
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[153]. The AR itself can be auto-regulated by the naturally occurring male hormones (T 
and DHT) in both a positive and negative manner, depending on the cell or tissue 
context [149, 153-155]. Regulation of AR occurs at both the mRNA and protein levels 
[156-158] giving added complexity. Tissue-specific actions are thought to be a result of 
these variable regulatory effects.  
 
A third layer of complexity to AR action in any tissue is the ability of cellular cofactors 
to influence AR action. There is increasing evidence that AR cofactors have an 
important role in the androgen response in many cell types. Some of these studies have 
used cofactor protein knockout mice to observe the developmental and endocrine 
dysfunctions produced in these models [159]. For example, one of the major cofactors is 
steroid receptor coactivator-1 (SRC-1). A transgenic mouse with an inactivated SRC-1 
gene showed retarded growth and development of the sexual reproduction organs 
including the uterus, prostate, testis and mammary glands. The results demonstrated that 
SRC-1 mediated the steroid hormone response and a loss of the cofactor led to a partial 
resistance to sex hormones [159]. Other studies have also shown that modulation of the 
activity of other cofactors can alter AR action [160-163]. 
 
In order to understand how the cofactors interact with the AR in more detail, an in depth 
discussion of the functional features of the AR is needed to understand how the protein-
protein interactions affect the regulation of AR transcriptional activities [164].  
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1.5 The Androgen Receptor (AR) 
 
The androgen receptor (AR) is part of the nuclear receptor superfamily [165]. The 
superfamily includes the progesterone receptor (PR), estrogen receptor (ER), 
glucocorticoid receptor (GR), retinoic acid receptor (RAR) and the thyroid hormone 
receptor (TR). All of these nuclear receptors have a similar structure with each 
containing three common domains: a central DNA-binding domain (DBD); an N-
terminal domain (NTD) that is involved in transcriptional activity; and a C-terminal 
domain that contains the ligand-binding domain (LBD) (Figure 1.5). Nuclear receptors 
typically form ligand-induced homodimers. Upon binding the ligand at the C-terminus, 
nuclear receptors typically dimerise and the homodimer ligand complex then 
translocates into the nucleus. In the nucleus the nuclear receptor complex binds DNA at 
a specific inverted repeat known as a hormone response element (HRE), and either 
activates or represses the transcription of specific target genes [165-167]. 
 
1.5.1 Androgen receptor structure 
The AR gene is located on the X chromosome between Xq11 and Xq12 on the 5’ end 
towards the centromere. It spans a 90 kb region of DNA encoding a 2,757 base pairs 
(bp) open reading frame. Expression of the open reading frame produces a 918 amino 
acid protein of molecular weight 110 kD [168].  
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The gene consists of 8 exons (Figure 1.5) [169]. The first exon encodes for the entire 
NTD. The NTD region of the protein regulates transcription of its specific target genes. 
The second and third exons contain the DBD, which is made up of two DNA binding 
zinc fingers. The zinc finger structures are highly conserved among all members of the 
hormone receptor superfamily [169, 170]. The distal end of the first zinc finger has a 
region known as the “P Box”, which recognises the androgen response element (ARE) 
on target genes. The ARE in DNA is composed of two palindromic hexa-nucleotide half 
sites separated by a spacer [171]. Multiple AREs in target gene promoter regions allows 
for tandem promoter binding and increases the activity of AR specificity and action 
[172]. Therefore the binding of specific nucleotides on the second zinc finger recognises 
the spacing between the ARE sites on the DNA allowing the AR complex to bind the 
correct DNA sequences. Location, sequence and number of AREs are associated with a 
given variations of gene. The third exon also contains specific nuclear targeting 
sequences that interact with other nuclear proteins. The fourth exon codes for the hinge 
or D region that contains the bipartite nuclear targeting sequence needed for the ligand-
bound receptor to translocate into the nucleus. The C-terminal domain contains the 
LBD, encoded by exons 5-8 (Figure 1.5). This domain is predominantly hydrophobic 
with high methionine content, which is important for ligand recognition and binding 
[173].  
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Figure 1.5  Primary structure of the androgen receptor 
The androgen receptor consists of four functional domains: 1) N-terminal domain 
(NTD), exon 1; 2) DNA binding domain (DBD), exons 2-3; 3) Bipartite nuclear 
targeting signal within the hinge or D region, exon 4; 4) The C- terminal region 
containing the ligand-binding domain (LBD), exons 5-8 (Adapted from [170]). 
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The C-terminal domain is also important for interactions of the AR with cofactor 
proteins and heat shock proteins (HSP)/chaperones [174]. Other important functions of 
this region include dimerisation and hyper-phosphorylation that induce conformational 
changes required for transactivation [170]. 
 
The AR has two areas of activation. The first being activation function-1 (AF-1) located 
in the NTD and activation function 2 (AF-2), which is within the LBD. Interaction 
between the N- and C- terminal regions occurs in a ligand-dependent manner via two 
LXXLL-like motifs (leucine-rich α-helical motifs - FXXLF and WXXLF) in the AF-1 
domain [175-177]. The AF-2 is a hydrophobic groove that interacts with these motifs 
and hydrophobic interaction between the two stabilises the receptor/activator interaction, 
which is required for transactivation by AR. Cofactors are required to facilitate AF-1 
and AF-2 interactions and help to stabilise bound ligand [178-180]. Proteins that interact 
with this surface also contain multiple repeats of this conserved sequence [181, 182].  
 
1.5.2 Androgen receptor activation and the role of cofactors 
The AR interacts with androgens to enable it to activate specific target genes. The 
androgen binds to the AR in the cytoplasm of the cell with the AR having 33% more 
affinity for DHT than T [110, 111]. In its inactivated state, AR is not bound to any 
androgens, but instead is bound by heat shock proteins (HSP) in the cytoplasm (Figure 
1.6). The hormone dependent phosphorylation of the LBD in the C-terminal region 
initiates the dissociation of the HSP causing a conformational change that allows the 
protein to secure the hormone ligand [183]. Liganded-AR then dimerises and 
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translocates to the nucleus. Once in the nucleus, AR binds the ARE via the DBD that 
encodes a pair of zinc fingers that recognise and bind specific sequences within the ARE 
[184]. Once bound to the DNA, AR hyperphosphorylates the DNA that facilitates 
recruitment of a preinitiation complex in the promoter region of a target  gene [169]. The 
preinitiation complex is made up of transcriptional machinery including RNA 
polymerase II [185], which associates with the AR through DNA loops and in doing so 
stabilises and greatly enhances the transcription rate. Therefore, AR activation and 
function is a complicated process. For all steps involved in the androgen induced process 
such as ligand binding, nuclear translocation and DNA binding, there are specific 
cofactor proteins that either augment or repress AR activation [164, 186-188]. 
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Figure 1.6  Activation of the androgen receptor by androgen binding 
The heat shock proteins (HSP) keep the androgen receptor (AR) in the correct 
conformation in the cytoplasm until the ligand binds. When testosterone (T) (or any 
androgen) diffuses into the cell, it binds to AR in the cytoplasm thereby initiating a 
complex cascade that ultimately leads to the translocation of AR into the nucleus where 
it binds to androgen response element (ARE). In turn, this induces transcription of 
specific target genes that elicit a change in cellular function, or the “androgen response”.   
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1.6 AR Cofactor Proteins 
Cofactor proteins can either activate (co-activators) or inhibit (co-repressors) the 
signalling between the androgen receptor (AR) and basal transcription machinery. A 
multitude of cofactor proteins have been identified that affect the transcriptional 
activation of genes by the nuclear receptors [185, 189-193]; (also see 
http://www.mcgill.ca/androgendb). Androgen receptor coactivators can be divided into 
two classes: those that interact with the AR in the nucleus (Class I); and those that 
interact with AR in the cytoplasm (Class II) [194]. Cytoplasmic coactivators can 
function in many ways including promoting correct receptor folding of AR for ligand 
recognition, helping to stabilise the AR-androgen complex and affecting cell 
compartment distribution. Similarly, the cofactors located within the nucleus can be 
involved in many functions including chromatin remodelling, the recruitment of general 
transcription factors and/or RNA polymerase II homocomplex formation, or 
receptor/cofactor recycling. Corepressors, as the name suggests, inhibit the expression of 
androgen target genes in several ways. For example, they can bind AR, thereby, 
sterically hindering androgen interaction, or ARE interaction and thus preventing 
translocation or transcription respectively. It has been postulated that agonist activation 
may be dependent on the balance between corepressor and coactivator expression in any 
particular cell type [195].  
 
The AR cofactors that are most pertinent to this study are listed in Table 1.5. Their 
putative roles in AR transactivation are demonstrated in Figure 1.8 and will be outlined 
in the following section.  
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Table 1.6  Coactivators and corepressors of AR included in this study 
Coregulator Class Function 
A1B1 
 
Activator 
 
Enhances the binding of the AR complex to recruit 
transcription factors (member of SRC family of 
coactivators) 
ARA 24 Activator 
Transports AR from the nucleus to the cytoplasm for 
recycling 
ARA 54 Activator 
Stabilises AR ligand complex for translocation to the 
nucleus 
ARA 70 Activator Stabilises AR ligand binding domain 
ARA 160 Activator Involved in recruiting transcription factors 
FHL2 
 
Activator 
 
Interacts specifically with AR specifically targets the 
FXXLF motif to enhance transcription 
p300 
 
Activator 
 
Involved in recruiting transcription factors (member of 
SRC family of co-activators) 
SRC-1 
 
Activator 
 
Enhances the binding of the AR complex to the ARE. 
Remodels chromatin (member of SRC family of co-
activators) 
 
NCoR1 
 
Repressor 
 
 
Binds to the ligand-bound AR. Prevents binding to the 
ARE 
SMRT 
 
Repressor 
 
Binds to the ligand binding domain of the AR. Prevents 
ligand binding 
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Figure 1.7  Cofactors regulate AR activity 
AR is stabilised in the cytoplasm by heat shock proteins (HSP 40, 70, 90). Androgens 
diffuse into the cells where they bind the AR in the cytoplasm. Cofactors interact with 
AR in the cytoplasm to stabilise the receptor ligand complex (ARA 54, ARA 70), and 
facilitate its translocation into the nucleus. In the nucleus, more coactivators (eg SRC-1) 
increase AR activity by recruiting transcription factors (RNA pol II) and/or inducing 
chromatin remodelling. There are also specialised cofactors that facilitate the recycling 
of the AR back into the cytoplasm from the nucleus. Corepressors also exist that act to 
bind AR thereby blocking ligand (SMRT) and/or DNA (NCoR1) interaction. Final AR 
activity ultimately results from a balance between the expression and activity of 
coactivators versus corepressor proteins. 
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1.6.1  AR transcriptional activity can be regulated by coactivators 
As outlined above, class I coactivators play a pivotal role in regulating AR-mediated 
transcription in the nucleus. Chromatin remodelling represents one of the primary 
regulatory steps for regulation of transcription [196, 197] because the binding of 
transcription factors requires unwinding of the tightly-coiled chromatin. Unwinding 
occurs by acetylation of the N-terminal region of histones, resulting in destabilisation of 
the contacts between histones and DNA [198]. Several coactivators are known to have 
intrinsic histone acetylation transferase (HAT) activity. This includes the nuclear 
receptor specific p160 family of coactivators [199] in particular the coactivator CBP 
(CREB-binding protein)/p300, which are involved in multiple signalling pathways 
[200].  CBP and p300 are large, structurally conserved, nuclear proteins that interact 
with numerous transcriptional activators such as CREB, Stat proteins, NF-κB, p/CAF. 
As well as general transcription factors TFIIB and TBP [201-206] that have greater HAT 
activity than that found in p160 proteins [207] and have also been shown to acetylate the 
p160 proteins themselves upon prolonged hormone treatment resulting in dissociation of 
the coactivator complex and transcription attenuation [208]. 
 
The p160 proteins are encoded by 3 closely related genes: SRC-1 (also known as NCoA-
1); TIF2/GRIP1/SRC2/NCoA-2 and AIB1/SRC-3/Rac3/ACTR/TRAM-1/p/CIP [209-
212]. The p160 coactivators contain a conserved C-terminal activation domains 
responsible for recruitment of CBP/p300 [213, 214] as well as for recruitment of 
arginine methyltransferases (CARM-1 and PRMT-1/-2) [215] that methylate histones at 
their arginine residues. This large complex interacts with ligand bound AR bringing 
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HAT and methyltransferase activity together to disrupt histone-DNA interaction and 
allow access to downstream transcription machinery. 
 
For an androgen to recognise and bind the AR, the receptor must be appropriately 
folded. Un-liganded AR is held in the cytoplasm in an appropriate conformation for 
ligand recognition by a chaperone heterocomplex [216] consisting of several heat shock 
proteins (hsp70, hsp 90, hsp 40) and immunophilins [217]. Ligand binding then induces 
an amino/carboxy terminal interaction in the AR mediated by an FXXLF motif present 
in the AF-1 region of the NTD and the LBD region. Several coactivators play a role in 
stabilising this interaction. These cofactors also have an FXXLF motif that is necessary 
for AR stabilisation through amino/carboxy terminal interactions [218]. Mutations in the 
FXXLF motif reduce the ability of the cofactors to enhance transcription [179]. 
 
Several of the AR-stabilising coactivators belong to the AR-associated (ARA) protein 
family. The AR-associated proteins (ARAs) are a large group of cofactors that include 
ARA24, ARA54, ARA55, ARA70, ARA160 and ARA267-α [194]. The ARA proteins 
were initially thought to interact specifically with the AR [219], however, recently it has 
been shown that all, except ARA24, have some weak interaction with other receptors 
[220, 221].  
 
ARA70 is a 70 kD protein that interacts with the LBD of AR and has a role in nuclear 
localisation. ARA70 is able to increase the rate of transport of AR to the nucleus after 
the AR-ligand complex is formed and enhances the protein stability of the ligand-bound 
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AR [218, 222]. ARA24 is also involved in AR trafficking namely receptor localisation 
and recycling and was first identified as the export factor RAN GTPase (RAN) [161]. 
ARA24 binds specifically to a polyglutamine (CAG) stretch in the N-terminus of the AR 
[221].  
 
FHL2 (four and a half LIM-only protein 2) is another AR-stabilisation cofactor that 
exhibits the FXXLF motif, however, its exact function is unknown. This coactivator is 
of interest as this one specifically interacts with the AR, whereas most cofactors are not 
specific for any one nuclear receptor [223, 224]. It belongs to a family of zinc-finger 
proteins termed LIM proteins which consist of cysteine- and histidine- rich regions 
responsible for protein-protein interactions involved in cell identity, differentiation and 
growth control [176]. LIM domain proteins usually function as bridging molecules 
between transcription factors [225]. FHL2 is highly expressed in the myocardium of the 
ventricles in the heart as well as the epithelial cell layer of the prostate [163].  
 
Regulation of AR activity also occurs at the level of turnover of the receptor-cofactor 
complexes. Degradation of proteins often involves ubiquitination and subsequent 
breakdown by 26S proteosome [226]. Several AR cofactors, including ARA54 have 
shown to have ubiquitin ligase activity [227].   
 
The precise functions of several cofactors that were included in this study, ARA55, and 
ARA160 are not fully understood. ARA55 has been identified as a coactivator of AR, 
GR and PR that mediates the transduction of signals from cellular focal adhesions within 
the extra-cellular matrix to the nucleus [228, 229]. ARA55 is activated by 
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phosphorylation. Once activated is able to interact with other proteins, kinases and 
cofactors [228] suggesting that ARA55 may be involved in regulating cell growth and 
migratory responses.  
 
1.6.2 Corepressors can regulate AR transcriptional activity 
Corepressors of steroid receptor transactivation effect AR transactivation by inhibiting 
DNA binding or nuclear translocation, recruiting histone deacetylases (HDACs), 
interrupting interaction between AR and coactivators. Corepressors are able to interrupt 
N- and C- terminal interactions, function as scaffolds for other AR cofactors or targeting 
basal transcriptional machinery [230].  
 
Many of the cofactors that have been identified as repressors of AR transactivation are 
either histone deacetylases (HDACs) or have the ability to recruit them [203, 204]. 
HDACs down-regulate the activity of numerous transcription factors implicating 
deacetylation in general transcription regulation [231]. SMRT (silencing mediator for 
retinoid and thyroid receptor) [203] and NCoR1 (nuclear receptor corepressor) [232] are 
well characterised corepressor proteins that attract the histone deacetylases, HDAC1 and 
HDAC2, and together with the mSin3 repressor protein form a repression complex that 
inhibits transcription by AR, as well as other nuclear receptors [233].  
 
Interestingly, the mechanism of repression by NCoR1 varies depending on the nuclear 
receptor involved. For AR, thyroid receptor (TR) or the retinoic acid receptor (RAR), 
NCoR1 binds in the absence of a ligand and is dislodged once the ligand attempts to 
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bind [234, 235]. For ER, PR and GR, NCoR1 does not interact with steroid receptors 
when they are unoccupied. However, will interact only when the receptor is ligand-
bound, to inhibit transcription [236, 237]. The interaction of NCoR1 and SMRT with the 
AR remains unclear but it is possible that transcription repression may occur through the 
formation of a non-productive interaction with general transcription factors [238]. The 
corepressors, NCoR1 and SMRT interact with the nuclear receptors via a LXXLL motif 
similar to motifs found on other cofactors. This interaction of corepressor and the AR 
could interrupt the signalling between the N-terminus and the LBD, destabilising the 
structure and resulting in inhibition of transcriptional activity [239]. Alternatively, the 
corepressors may alter AR transactivation via the inhibition of the N/C terminal 
interaction or by competition with coactivators [240]. 
 
1.6.3 Tissue specific expression of AR cofactors 
To date, it has been shown that cofactor expression is important in regulating AR 
activity [191, 194, 199, 228, 230, 241-246]. Cofactor expression has mainly been 
studied in endocrine responsive tissue, including breast, prostate and endometrial tissue. 
In these reproductive tissues, cofactor expression appears to be ubiquitously expressed 
[246-251]. However, the expression of the AR cofactors can vary between different 
tissue types, even between the different regions within the tissue [241]. For example, 
SRC-1, ARA55, and ARA54 have been shown to be prominently expressed in endocrine 
responsive tissue samples such as breast, endometrial and prostate compared to other 
cofactors such as TIF2 and AIB1. Studies conducted have demonstrated that cofactor 
expression in these endocrine responsive tissues can be modulated in certain pathologies 
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such as cancer. One study showed that after androgen deprivation therapy, recurrent 
prostate cancers expressed high levels of AR and two AR coactivators, transcriptional 
intermediary factor 2 (TIF2) and SRC-1 [252]. Over-expression of these cofactors was 
shown to increase AR transactivation at physiological concentrations of adrenal 
androgen [155, 244, 252, 253]. The expression levels of the cofactors ARA54 and SRC-
1 were also observed to be significantly higher in endocrine, cancerous cells [241, 242]. 
The cofactors mentioned above are highly expressed and hormonally regulated in 
endocrine responsive tissues by androgens making them good candidates for further 
investigation.  
 
To date, it has not been examined whether any of these cofactors are expressed, or 
whether they play a significant role in AR activation in vascular tissue. The ability of 
various AR-interacting cofactors, whether coactivators or co-repressors, to be 
hormonally regulated may be an important modulator of androgen action in vascular 
cells and may influence the ability of androgens via the AR to effect early steps in 
atherogenesis. Hormonal regulation has been seen for an array of cofactors in endocrine 
tissue (see Table 1.6). Therefore, as part of this project it was hypothesised that many of 
these same factors may be hormonally regulated in the key vascular cells that have 
pivotal roles in the early steps of atherogenesis.  
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Table 1.7 Hormonal regulation of AR cofactors 
Cofactor Cell type Effect of hormone treatment on 
mRNA/protein 
Reference 
  E2 T DHT T3  
SRC-1 LNCaP ↔  ↔  [246] 
 PNT2 ↑  ↓  [246] 
 Pituitary* ↓    [249] 
 GH3 ↓   ↑ [249] 
 MCF7 ↔    [251] 
 Rat 
uterus* 
↔    [248] 
ARA54 LNCaP ↔  ↔  [246] 
 PNT2 ↑  ↓  [246] 
ARA55 LNCaP ↔  ↔  [246] 
 PNT2 ↑  ↓  [246] 
ARA70 LNCaP ↔  ↔  [246] 
 PNT2 ↑  ↓  [246] 
 PNT2 ↑  ↑  [254] 
 Cancer ↑  ↑  [254] 
   ↔ ↔  [255] 
P300 Rat 
uterus* 
↔    [248] 
 MCF7 ↑    [251] 
 Pituitary* ↔   ↔ [249] 
 GH3 ↔   ↔ [249] 
CBP LNCaP  ↓(R1881)•    [246] 
SMRT Rat 
uterus* 
↔    [248] 
SMRT GH3    ↔ [249] 
NCoR1 GH3 ↔   ↔ [249] 
LNCaP-prostate cancer cell line, PNT2 – preneoplastic epithelial, MCF7 – breast cancer 
cells, *in situ hybridisation to mRNA, GH3-rat pituitary, PC-3 prostate cancer cell line, 
DU-145 prostate cancer cell line; •R1881= potent androgen. 
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Therefore, in this study, the expression and hormonal regulation of a subset of known 
AR cofactors is examined in two cell types critical to atherogenesis, ECs and MDMs. 
More specifically, it is examined whether the potent androgen DHT, which acts through 
an AR-dependent mechanism, is able to regulate cofactor expression in these cells. 
Further, it is examined whether these cofactors are regulated gender-specifically, which 
may account for some of the gender-specific effects of androgens found in previous 
studies that act via the AR [149, 150, 152, 154]. The AR cofactors are A1B1, ARA24, 
ARA54, ARA70, ARA160, FHL2, SRC-1, p300, NCoR1, SMRT. These cofactors were 
chosen for this study as they were shown to interact with AR to regulate specific gene 
transcription. Some cofactors were also observed to be hormonally regulated in 
endocrine tissues and cell types.   
 
The hypothesis for this section of work was:  
“AR cofactor proteins are hormonally regulated by dihydrotestosterone in vascular 
cells.” 
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1.7 Hypotheses & Aims  
The background knowledge discussed in this chapter has provided an understanding of 
the effects of androgens on atherogenesis, AR structure and the regulation of its activity 
by cofactors. From the gaps in our knowledge about these topics, several questions have 
arisen which have led to the hypotheses for this thesis. 
  
The hypotheses for this thesis were; 
“That the systemic level of androgens has differential gender-specific effects on 
atherogenesis” and “AR cofactor proteins are hormonally regulated by androgens in 
vascular cells.” 
 
This study aimed to provide some insight into how androgens may influence the 
formation of atherosclerotic plaque in an AR- and gender-specific manner by; 
 
• Establishing the en face Oil Red O staining method in this laboratory. This will 
allow the visualisation of atherosclerotic lesion area in vascular tissue from 
ApoE 
-/- 
mice. The project aims to compare the Oil Red O staining method to the 
already established H&E technique. 
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• Exploring how the natural androgens, testosterone (T) and dihydrotestosterone 
(DHT) affect atherosclerotic plaque formation in ApoE-/- mice. The aim was to 
compare the effects of different systemic T and DHT levels on plaque 
progression in both male and female ApoE
-/- 
mice. 
 
• Elucidating whether DHT treatment regulates the expression of AR cofactors in 
human endothelial cells and monocyte-derived macrophages, two key cell types 
involved in atherogenesis. 
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CHAPTER 2 - General Materials & Methods 
 
This chapter contains the materials and general methodologies used to undertake the 
experimental work for this thesis. Specific methodologies are described in each of the 
Results chapters (3-5). 
2.1 Materials 
 
Hanks buffered salt solution (HBSS) (Sigma-Aldrich, Castle Hill, Australia) 
5 mM   KCl 
0.3 mM  KH2PO4 
138 mM NaCl 
4 mM  NaHCO3 
0.3 mM Na2HPO4 
5.6 mM D-glucose 
Distilled water to a final volume of 5 L, media was filter sterilised through a 0.2 µm 
filter (Millipore Corporation, North Ryde NSW Australia). 
 
M199 medium (Sigma-Aldrich) 
M199 powder  
10 g   NaHCO3 
24 g   HEPES 
Distilled water to a final volume of 5 L (pH 7.5-7.6) 
Media was filter sterilised through a 0.2 µm filter (Millipore). 
 
RPMI medium 1640 (Sigma-Aldrich) 
RPMI powder  
10 g   NaHCO3 
24 g   HEPES 
Distilled water to a final volume of 5 L (pH 7.5) 
Medium was filter sterilised through a 0.2 µm filter (Millipore). 
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Phenol-red free RPMI medium (Sigma-Aldrich) 
Modified RPMI powder  
NaHCO3  2 g 
Distilled water to a final volume of 1 L (pH 7.5) 
Medium was filter sterilised through a 0.2 µm filter (Millipore). 
 
Antibiotic solution 
10 000 U/mL  Penicillin 
10 mg/mL   Streptomycin 
Antibiotic solution was made in 1 mL distilled water, filter sterilised through a 0.2 µm 
filter (Millipore). 
 
Phosphate-buffered saline (PBS)  
137 mM  NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.5 mM KH2PO4 
(pH 7.2-7.5)  
Distilled water to a final volume of 5 L, media was filter sterilised through a 0.2 µm 
filter (Millipore). 
 
TE buffer  
10 mM  Tris HCl 
1 mM   EDTA 
(pH 8.0) 
 
SYBR Green II molecular probes  
(Invitrogen, Mount Waverly VIC Australia)  
Working solution was made by diluting stock solution of SYBR Green II 1:10,000 in 50 
ml of TE buffer. 
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RIPA lysis buffer  
1%   Nonident P-40 
0.1%   sodium dodecylsulfate (SDS) 
0.5%   deoxycholate 
150 mM  NaCl 
50 mM  Tris 
1 µg/mL Protease inhibitor cocktail (Sigma-Aldrich) 
(pH 8.0) 
Distilled water to a final volume of 500 mL 
 
SDS polyacrylamide gel 
7.0%   Acrylamide  
27%   water 
0.4 M  Tris HCl (pH 8.8) 
0.1%   SDS 
0.03%  APS 
0.04%   TEMED 
 
SDS polyacrylamide stacking gel 
70%   water 
0.13 M  Tris HCl (pH 6.8) 
5%  Acrylamide 
0.1%   SDS 
0.1%  APS 
0.1%   TEMED 
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Protein sample loading buffer 
37.5%   water 
12.5 mM Tris HCl (pH 6.8) 
20%   glycerol 
2%  SDS 
2.5%  Bromophenol blue 
5%  β2-mercaptoethanol 
 
Protein electrophoresis buffer 
3 g   Tris HCl 
14.4 g   Glycine 
1 g   SDS 
Distilled water to a final volume of 1 L  
 
Tris–buffered saline (TBS-T) 
6.1 g  Tris base 
1.4 g   Tris HCl 
6 g   NaCl 
0.5 mL  Tween20 
Distilled water to a final volume of 1 L 
pH 7.5-7.6, 0.05 % Tween  
 
Transfer buffer 
3.0 g   Tris HCl 
14.4 g   Glycine 
Distilled water to a final volume of 1 L 
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Stripping solution 
500 mM  Tris base (pH 7.4) 
1.6%    SDS 
2.8 µL   β-mercaptoethanol 
Distilled water to a final volume of 500 mL 
 
Acid alcohol wash 
10 mL   Hydrochloric acid 
70% ethanol to a final volume of 1 L 
 
Antigen retrieval buffer 
0.5 g   Disodium EDTA 
0.3 g   Trisodium citrate 
0.25 g   Tris base 
Distilled water to a final volume of 1 L 
 
10x Wash buffer  
14 g  Tris Base 
61 g   Tris HCl 
61 g   NaCl 
Distilled water to a final volume of 1 L 
(pH 7.5-7.6) 
 
Tris–buffered saline (TBS) 
6.1 g  Tris base 
1.4 g   Tris HCl 
6 g   NaCl 
0.5 mL  Tween20 
Distilled water to a final volume of 1 L 
pH 7.5-7.6 
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TBS-T (1x) 
Tween 20, 0.5 mL per L of 1 x TBS  
 
TNB 
TBS was used to dissolve 0.5% blocking powder from a TSA kit by heating the soultion 
to 60°C until all powder was dissolved. Once dissolved the solution was aliquoted into 
50 mL Falcon tubes and stored at -20°C. Before using the TBS the Falcon tubes were 
thawed to 37°C. 
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2.2 In vivo studies 
 
2.2.1 Animal housing 
 
The mice used for the experimental procedures were ApoE knockout (ApoE
-/-
) using a 
C57Bl/6 background mice from the breeding colony housed at the Heart Research 
Institute. They were housed in cages with a 12-hour light cycle, at 55 ± 5 % humidity 
and room temperatures of 20 ± 2°C. The mice were fed on a normal chow diet, and 
given acid-treated autoclaved water. The study and procedures performed were approved 
by the Sydney South West Area Health Services Animal Welfare Committee, (# Heather 
2004/002). 
 
2.2.2 Orchidectomy 
Orchidectomy (odx) was performed under anaesthesia using Methoxyflurane (Medical 
Developments International, Sydney, Australia) administered by nose cone, until there 
was an absence of the pedal reflex. The scrotum was first sterilised with Betadine 
(Mundipharma B.V, Netherlands). A small incision was made through the scrotum and 
the testes were isolated. The blood supply to the testicles was blocked via ligation of the 
blood vessels using absorbable sutures before the testicles were excised. The scrotum 
was then closed with non-absorbable sutures. Local anaesthetic 2% spray/jelly 
Xylocaine (AstraZeneca, Sydney, Australia) was applied post-operatively to the area for 
pain management. 
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2.2.3 Ovariectomy 
Ovariectomy (ovx) was performed under Methoxyflurane (Medical Developments 
International) administered by nose cone until there was an absence of the pedal reflex. 
The hair just below the ribs and above the hind limb was removed by shaving and the 
area sterilised with Betadine (Mundipharma). Using thin forceps and small scissors an 
incision was made through the skin and muscle layer. The connective tissue and blood 
supply to the ovaries was ligated using absorbable sutures and the ovaries removed. The 
same suture material was used to close the muscle layer. An intraperitoneal injection of 
Temgesic (Reckitt Benckiser; Berkshire, UK) was administered for pain management.  
 
2.2.4 Steroid treatment  
After orchidectomy or ovariectomy, the area behind the head was shaved and sterilised 
with Betadine (Mundipharma). An incision was made through the skin and forceps used 
to separate the skin from the muscle. A silastic implant filled with either crystalline T or 
DHT supplied by Professor David J. Handelsman, (ANZAC Research Institute, 
Concord, Australia [256]) was then inserted into the pocket created under the skin; the 
incision was closed with non-absorbable sutures. 2% spray/jelly Xylocaine 
(AstraZeneca) was applied to the area post-operatively for pain management. M. 
Jimenez at the ANZAC Research Institute was responsible for preparing the implants. 
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2.2.5 Treatment groups 
Male and female ApoE
-/-
 mice at 3-4 weeks of age were assigned to 8 treatment groups. 
Post gonadectomy, the mice had the hormone-filled silastic implants, inserted 
subcutaneously into the back of the neck under anaesthetic. The 3 different lengths of 
implants used were 1 cm, 0.5 cm and 0.25 cm to achieve a range of steroid hormone 
concentration. Treatment was for a period of 16 weeks and mice were sacrificed at 20 
weeks of age. Treatment groups are summarised in Table 2.1 
 
Table 2.1 Experimental groups 
Groups 
(male) 
Group 
size 
Groups  
(female) 
Group 
size 
Normal (intact) 6 Normal (intact) 6 
Odx 6 Ovx 6 
Odx + 1 cm T 6 Ovx + 1 cm T 6 
Odx + 0.5 cm T 6 Ovx + 0.5 cm T 6 
Odx + 0.25 cm T 6 Ovx + 0.25 cm T 6 
Odx + 1 cm DHT 6 Ovx + 1 cm DHT 6 
Odx + 0.5 cm DHT 6 Ovx + 0.5 cm DHT 6 
Odx + 0.25 cm DHT 6 Ovx + 0.25 cm DHT 6 
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2.2.6 Isolation of heart tissue 
Each mouse was anaesthetised by placing a nose cone containing a few drops of 
Methoxyflurane (Medical Developments International) in cotton wool over the mouses 
head. Depth of unconsciousness was monitored by observing the respiration rate of the 
mouse. The mouse was weighed then given an intra-peritoneal injection of Nembutal 
(10% Pentobarbitone, 0.1 ml per 10 g body weight in saline solution). Absence of the 
pedal reflex was confirmed before surgical procedures were performed. 
 
After cardiac puncture was performed the arterial tree was pressure perfused for 4 mins 
with warmed heparinised PBS (1:500 dilution) that had been pre-warmed to 37°C, then 
with 4 % paraformaldehyde (Sigma-Aldrich), also pre-warmed to 37°C for 6 mins. The 
heart, aortic arch and arterial tree was excised from the mouse and stored in 4% 
paraformaldehyde (Sigma-Aldrich) for 24 hrs. The tissue was washed with PBS and then 
placed in 70% ethanol for long-term storage. The superior section of the heart was 
embedded in paraffin wax for sectioning and staining. The atherosclerotic lesions in the 
aortic arch and arterial trees were visualised using enface Oil Red O staining. 
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2.3 Histochemistry 
 
2.3.1 Sectioning of aortic sinus  
The embedded aortic sinus tissue was serially sectioned (5 µm), using a microtome 
(Microm HM-325: Lomb Scientific, Taren Point NSW Australia), until the first valve 
leaflet was located for orientation and standardisation (allowing comparisons between 
animals). Duplicate sections every 100 µm were then mounted on positively charged 
microscope slides (Superfrost Plus, Menzel-Glaser, Braunschweig, Germany) and dried 
overnight at 40°C. 
 
2.3.2 Haematoxylin and Eosin staining (H&E) 
The slides were deparaffinised using two changes of Histolene (Fronine, Taren Point 
NSW Australia) (10 mins). The slides were then rehydrated by incubating slides for 2 
mins each in a series of graded alcohols starting from 100% ethanol then 95% ethanol, 
90% ethanol and 70% ethanol. Slides were then rinsed in water before placing them in 
Harris’ haematoxylin solution (Fronine) for 3 mins before being washed thoroughly in 
water to remove all excess stain. Sections were then rinsed quickly (30 secs) with an 
acid/alcohol solution (Section 2.1, Materials) then water before being placed in Scott’s 
blueing reagent (Fronine) for 30 secs. Slides were then washed in water for 2-5 mins 
before placement in 70% ethanol prior to two washes in 1% alcoholic eosin (CI 45380, 
Fronine) for 30 secs each. They were then rapidly dehydrated through 90%, 95% and 
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100% ethanol to Histolene (Fronine), and coverslipped using DPX Mountant (Fluka 
Chemie, Buchs/Switzerland). 
 
Images of the aortic sinus were digitally captured with a BH-2 Olympus microscope 
(Olympus, North Ryde NSW Australia) and Nikon COOLPIX 4500 digital camera 
(Nikon, Lidcombe NSW Australia) using Nikon View Pro software (Nikon) at 4X 
magnification. The plaque area within each image was quantitated using Adobe 
Photoshop version 7.0. The plaque was traced with the magnetic lasso tool and a pixel 
count of the selected area was obtained. Pixel counts were confirmed independently by 
two other people who were blinded to the conditions of treatment. Determining the 
number of pixels per 1µm2, the pixel counts were converted to metric units. The plaque 
lesions were represented by an average lesion size of each section. 
 
2.3.3 Oil Red O Staining 
The arterial tree was dissected longitudinally and pinned open on a black plastic 
background. The tissue was briefly washed with 50% alcohol, before Oil Red O staining 
solution was applied for 10 mins. Excess stain was washed away with distilled water, 
and the tissue was counter-stained with Haematoxylin (Fronine) for 5 secs then washed 
with water. The tissue was rinsed with an acid/alcohol wash (Section 2.1, Materials) for 
5 secs, and then rinsed with water before Scots blueing reagent was applied for 1 min. 
The tissue was rinsed in water and all excess water was completely removed by blotting. 
A series of images were then captured with a Nikon COOLPIX 4500 digital camera 
attached to a Nikon SMZ-2T dissecting microscope (Nikon). The images were collected 
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at 10X magnification. Images were captured at the computer level using Nikon View 
Pro software (Nikon). The series of images captured began at the aortic arch and then 
followed the descending aorta to the mesenteric region defined by the orientation of the 
kidneys. The plaque area within each image was quantitated using Adobe Photoshop 
version 7.0. The plaque was traced with the magnetic lasso tool and a pixel count of the 
selected area was obtained. The pixel counts were confirmed independently by two other 
people who were blinded to the conditions of treatment.  
 
2.4 Immunohistochemistry 
 
Paraffin sections of the aortic sinus were re-hydrated from Histolene (Fronine) through a 
series of graded alcohols (100%, 95%, 90%, 70% ethanol) to water. The slides were then 
placed in antigen retrieval buffer (section 2.1) and microwaved on high for 12 mins. 
Slides were cooled to room temperature then placed in TBS-T (Section 2.1). 
Sections were stained using a Dako autostainer (Dako Australia: Kingsgrove NSW 
Australia), and all steps were carried out at room temperature. Sections were first treated 
with methanol: hydrogen peroxide (0.03% H2O2) for 20 mins to block endogenous 
peroxidase activity. Slides were washed with TBS-T prior to incubation in 0.5 % TNB 
blocking buffer (Perkin Elmer, Melbourne, Australia) for 20 mins. The sections were 
incubated for 6 hrs with primary antibody SRC-1 rabbit polyclonal IgG (1/50 dilution in 
TBS, 200 µg/mL, sc-8995, Santa Cruz Biotechnology, Santa Cruz, U.S.A.). The method 
control replaced the primary antibody with TNB buffer. The sections were washed with 
TBS-T then incubated with biotinylated secondary antibody (goat anti-rabbit IgG, 1/200 
 80 
dilution in TBS, DakoCytomation, Carpinteria, CA) for 30 mins. Slides were then rinsed 
with TBS-T. The IgG control replaced the primary antibody with TNB buffer. 
 
Visualisation of the bound antibody was through Avidin-Biotin Conjugate (Vectastain, 
ABC kit; Vector Laboratories, Burlingham, CA, USA) which was applied to the slides 
and incubated for 30 mins. Sections were again rinsed with TBS-T (3 x 5 mins). 
Antibody conjugate was then visualised by incubating for 10 mins with 
diaminobenzidene (DAB) (Cat # SK-4100 Dako, Glastrop, Denmark). Slides were 
washed with water then counterstained for 1 min with 0.1% malachite green (Fronine). 
Slides were blotted dry before being immersed in two changes of Histolene (Fronine) 
and coverslipped with DPX mountant (Fluka Chemie). 
 
Immunohistochemistry staining of SRC-1 was analysed semi-quantitatively by 6 
independent researchers that were blinded to the conditions using a histologic score 
(HSCORE) test [257, 258]. This is calculated using the following formula; HS = ∑ Pi (i 
+1) where Pi denotes the percentage of stained cells and i denotes the intensity of 
staining. The staining intensity ranged from 0, no staining; 1, slight staining; 2, medium 
staining; 3, strong staining [259-261]. 
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2.5 Cell culture 
 
2.5.1 Isolation and culturing of human umbilical vein endothelial cells (HUVEC) 
Human umbilical vein endothelial cells (HUVEC) were isolated from infant umbilical 
cords by the collagenase dispersion method using aseptic techniques and processed in a 
laminar flow hood [150]. A sterile metal cannulae was inserted manually into the 
umbilical vein and tied off with a plastic tie. The vein was then flushed slowly with 20 
mL M199 to remove blood clots and debris. The other end of the cord was cannulated 
and an empty syringe attached. Collagenase (15 mL at 1 mg/mL; Sigma-Aldrich) was 
injected into the cord. The cord was then wrapped in aluminium foil and incubated at 
37°C for 15 mins. The cord was uncovered and massaged gently to detach the 
endothelial cells. The vein was injected with 15 mL M199 supplemented with 20% 
human serum, 0.5% endothelial growth promoter (Starrate, Bethungra, Australia) and 
antibiotic solution (1:100 dilution, Section 2.1) to inactivate the collagenase. The 
perfusate was removed via the attached syringe and transferred to a 50 mL Falcon tube. 
Cells were pelleted by centrifugation at 1000 rpm for 5 mins. The flasks were treated 
with 1 mL/5 cm
2 
gelofusine (diluted 1:250 in PBS, B Braun, Bella Vista, N.S.W. 
Australia) and incubated at 37°C for 10 mins. All excess solution was removed by 
pipetting. The cell pellet was resuspended in M199 (Sigma-Aldrich) supplemented with 
20% human serum, 0.5% endothelial growth promoter and antibiotic solution (1:100 
dilution, section 2.1) and seeded in 175 cm
2 
gelatin-coated flasks.  
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HUVEC were maintained in M199 supplemented with 20% human serum, 0.5% 
endothelial growth promoter and antibiotic solution (1:100 dilution). HUVEC were 
cultured until 80% confluent. Media was then removed and cells washed with sterile 
PBS. Cells were treated with Trypsin/EDTA (Thermo Electron Corporation, Noble Park, 
Victoria, Australia) to detach the cells from the flask. The cell mixture was then 
centrifuged at 1000 g for 5 mins to pellet the cells. At passage 3, when cells were 90% 
confluent, the cells were seeded in gelatine-coated 12-well plates at a cell count of 1 x 
10
5
 cells/mL for experimental procedures. 
 
2.5.2 Monocyte elutriation & culturing of human monocyte-derived macrophages 
(hMDM)  
Monocytes were isolated by density gradient separation [149, 262] from human blood 
obtained from healthy human volunteers (Australian Red Cross Blood Bank). Blood was 
transferred into a flask and warmed with calcium free Hanks balanced-salt solution 
(HBSS) added at a ratio of 1: 3 dilution. Aliquots of the blood mixture, 30 mL were 
transferred to 50 mL falcon tubes and 15 mL of Lymphoprep solution (Nycomed 
Pharma) was underlaid using a sterile cannular. Density gradient separation was used to 
collect the white blood cells. Counter flow centrifugation elutriation was carried out at 
20°C using a Beckman J2-21 M/E centrifuge equipped with a JE-6B elutriation rotor 
and a 4.2 mL elutriation chamber (Beckman Instruments, Inc). The elutriation buffer 
was HBSS buffer supplemented with EDTA (0.1 g/L) and 1% heat-inactivated human 
serum. The system and tubing was washed with a mixture of 70% ethanol, endotoxin-
free water, 6% hydrogen peroxide and then elutriation buffer. The Lymphoprep-derived 
 83 
mononuclear cell fractions were loaded at 9 mL/min into the elutriation chamber and 
centrifuged at 2020 rpm at 20°C. Flow rate was increased by 1 mL/min every 10 mins, 
the monocytes were typically eluted at 16 and 17 mL/min. The monocyte/lymphocyte 
layer was carefully isolated and examined by Wright’s stain (Diff-Quick, Laboratory-
Aids). The cells were resuspended in serum free RPMI medium (1.5-2.0 x 10
6
/mL) 
seeded in 12-well plates, and incubated in a humidified atmosphere with 5% CO2, at 37 
°C. The cells were left for 2 hours to allow the cells to adhere to the plates, then the 
media was changed to RPMI medium supplemented with 10 % heat-inactivated foetal 
bovine serum (FBS) (Invitrogen, Mount Waverley VIC Australia). The medium was 
changed every 3 days. The monocyte differentiated into macrophages at day 8, therefore, 
on day 9 the medium was changed to 1 mL phenol red-free RPMI (Sigma-Aldrich) 
supplemented with 10 % charcoal stripped FBS (Invitrogen) in preparation for 
treatment. 
 
2.5.3 Charcoal-stripped serum 
To remove steroids in either foetal bovine serum (FBS) (Invitrogen) or human serum 
(Red Cross Blood Service), the serum was treated with charcoal to remove endogenous 
hormones and heat–inactivated to denature binding proteins. Activated charcoal (250 
mg) was resuspended in PBS (100 mL) and then centrifuged at 3000 rpm for 5 mins and 
supernatant removed. Serum (20 mL) was then incubated with the charcoal at 55°C for 
30 mins. The charcoal was removed by centrifugation at 3000 g for 5 mins and the 
serum filter sterilised through a 0.2 µm filter (Corning Inc, MA USA) and stored at -
20°C until use. 
 84 
 
2.5.4 Cell treatments 
At the time of treatment, HUVEC were seeded into 12-well plates at a concentration of 1 
x 10
6 
cell/well in phenol red free M199 (Sigma-Aldrich) with charcoal-stripped HS and 
0.5% endothelial growth promoter and antibiotic solution (1:100 dilution Section 2.1). 
hMDM media was changed to phenol red free RPMI (Sigma-Aldrich) media 
supplemented with 10 % charcoal stripped FBS (Invitrogen). Cells were treated with 
either 1 µL of 100% ethanol at 0.1% as vehicle control or 1 µL 400 mM DHT in 1mL of 
media for 24 hrs (HUVECs) or 48 hrs (HMDMs). The media was either harvested at 24 
hrs or the media was replenished at 24 hrs for the 48 hrs treatment. 
2.6 RT-PCR analysis 
 
2.6.1 RNA extraction  
Total RNA was extracted from treated cells with TRI Reagent (#T9424, Sigma-Aldrich). 
Cells were first washed twice with PBS before 330 µL TRI Reagent (Sigma-Aldrich) 
was added to each well. Cells were dislodged using a cell scraper, before the TRI 
Reagent /cell solution from 3 replicate wells was transferred to a single Eppendorf tube. 
100 µL Bromo-chloro-propane (Sigma-Aldrich) was added to each tube and the 
solutions were mixed by vortexing for ~ 10 secs. Tubes were then centrifuged for 15 
mins at 10000 g at 4°C (Centrifuge-5804R, Eppendorf, North Ryde Australia). 
The clear top layer of the suspension containing the RNA was transferred to a clean tube 
and an equal volume 500 µL of isopropanol (Sigma-Aldrich) was added and briefly 
vortexed. Samples were centrifuged for 15 mins at 10000 g at 4°C. The supernatant was 
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removed, and the pellet washed by adding 1 mL of chilled 75% ethanol and mixing 
gently. After centrifuging for 10 mins at 10000 g at 4°C, the remaining ethanol was 
removed and the RNA air dried for 10 mins. The pellet was then dissolved in nuclease-
free water depending on pellet size (20-50 µL) and mixed well by vortexing. Samples 
were then stored at -80°C. 
 
2.6.2 SYBR green II RNA assay 
To quantitate total RNA, a standard curve ranging from 31.25 ng - 500 ng/µL, nuclease 
free water was used to serially dilute the RNA ladder (1 µg/µL Life Technologies, 
Invitrogen) at a ratio of 1:1. Each RNA sample was diluted and normalised to a 
concentration of 100 ng/µL. In a 96 well plate 1 µL of each of the RNA standards and 
treatment samples were loaded in triplicates. To each well 200 µL of working solution 
of SYBR Green II (Invitrogen) was added (Section 2.1). The fluorescence was measured 
at 510 nm excitation and the transmission was read on a Fluoroskan Acent FL, Thermo 
Labsystems Machine (GMI Inc, Minnesota, USA). 
 
The emitted fluorescence was converted to RNA concentration with Acent Software 
version 2.6. The concentration of each RNA sample was then calculated from the 
standard curve derived from the serially diluted RNA ladder. Equation of the line was 
accepted if the trend line R2 value was close to 1. Prior to RT-PCR analysis the 
experimental samples all had RNA values within 10% of each other (+/- 5) ng/µL. 
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2.6.3 Synthesis of cDNA 
RNA was converted to cDNA using the iScript Select cDNA Synthesis Kit (Cat # 170 
8897, Bio-Rad). The reaction consisted of 4 µL of iScript buffer which was added to 1 
µL iScript Reverse Transcriptase, and 2 µL of 100 ng/µL RNA, with nuclease free water 
making a total volume of 20 µL. Samples were incubated in a PCR machine for 5 mins 
at 25°C, 30 mins at 42°C, 5 mins at 85°C and cooled to 4°C. The reverse-transcription 
product (cDNA) was stored at –20°C.  
 
2.6.4 PCR  
cDNA was amplified by PCR. Each reaction mixture consisted of 17.75 µL nuclease 
free water, 2.5 µL 10x Red Taq Buffer (Sigma-Aldrich), 0.5 µL dNTP (Sigma-Aldrich) 
sense and anti-sense primers (see Table 5.1), 1.25 µL Red Taq and 2 µL cDNA 
template. Samples were heated for 3 mins at 94°C, followed by 16-35 cycles of 20 secs 
at 94°C, 30 secs at 55-58°C (dependent on optimum annealing temperatures of primers), 
and 1 min at 72°C, followed by a final incubation at 72°C for 10 mins and then cooled to 
4°C. PCR products were stored at 4°C until electrophoreses on a 2% agarose gel (w/v). 
PCR products were loaded and run on a 2% (w/v) agarose gel (PCR grade, Bio-Rad 
Laboratories, Gladesville, Australia) in 1x TAE (Section 2.1) buffer containing ethidium 
bromide (Sigma-Aldrich) (0.5 µg/mL). Electrophoreses was performed at 100 volts for 
40 mins or until desired band separation was observed. 
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2.6.5 Visualisation & quantification of PCR products 
PCR products were visualised by UV illumination and an image was directly captured 
using UV Gel Doc software, Quantity One software version 4.6.1 (Bio-Rad 
Laboratories, Sydney, Australia). Quantity One Software was used to measure the band 
density from all treatment groups. Expression levels were normalised based on 
housekeeping gene 18S and β2-microglobulin expression. Results are expressed relative 
to control samples. n=3 donors per group. Statistical significance was analysed using 
one-way ANOVA with Bonferroni’s Post-Hoc test 
 
 
2.7 Western blotting analysis 
2.7.1 Protein extraction 
The vascular cells were seeded in 12-well plates; after treatment the medium was 
removed and the cells were washed with PBS (Section 2.1). The cells were dislodged 
using a cell scraper with PBS and then centrifuged at 1000 g for 2 mins. The PBS was 
removed and the cells were resuspended in 300 µL RIPA lysis buffer (Section 2.1), 
using 3 replicate wells per single Eppendorf tube. The cell suspension was then 
incubated on ice for 30 mins, vortexed and centrifuged at 4°C for 30 mins at 10,000 g. 
The supernatant was collected and stored at -80°C until needed. 
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2.7.2 Protein quantification 
Protein concentration was estimated using the BSA protein assay kit II (Bio-Rad) is 
derived from the Bradford staining methodology. Samples to be analysed were diluted 1 
to 5 or 1 to 10 and 5 µL of each sample was added in triplicate to a 96 well plate. A 
standard curve was created by using 1:1 serial dilutions of 10 mg/mL BSA (Cat # 
A2153, Sigma-Aldrich, Missouri, USA), and this curve was used to convert absorbance 
to mg/mL. The BSA protein assay stock reagent (Bio-Rad) was diluted at 1:5 in water. 
Standard curve and treatment samples had 10 µl loaded in triplicates to the wells of a 96-
well plate. Then 200 µl of the working solution was added to the samples. The plate was 
incubated at room temperature for 15 mins and the absorbance was measured at 595 nm 
using a Sunrise plate reader (Tecan, QLD, Australia) and evaluated using X-read plus 
software. 
 
2.7.3 Reducing SDS PAGE electrophoreses  
Protein was separated using a 7% SDS PAGE gel. The resolving gel (section 2.1) was 
allowed to set between glass plates overlayed with saturated Butanol (Sigma-Aldrich). 
Then the stacking gel was layered on top of the resolving gel with a 10 well comb and 
allowed to set. The protein samples were denatured by boiling at 100°C for 5 mins in 
protein loading buffer (Section 2.1) and then rapidly cooled to 4°C, by placing the 
samples on ice. Each protein sample was normalised to 1 mg/mL (section 2.7.2), then 
had 20 µL (20 µg) loaded per well. The gel was run at 120 volts in protein 
electrophoresis buffer (section 2.1) for 1.5 hrs or until desired separation of the protein 
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Kaleidoscope Precision Plus protein standard ladder (Bio-Rad Laboratories, Gladesville, 
Australia). 
 
2.7.4 Western blotting 
A wet transfer system was used to transfer protein from the SDS-PAGE gel to a PVDF 
membrane (Millipore Corporation, North Sydney, Australia). The membrane was 
prepared by placing in methanol briefly then soaking it in transfer buffer until wet. The 
transfer was run at 100 volts for 1 hr at 4°C. Once completed, the membrane was stained 
with Ponceau S stain (Cat # P3504 Sigma-Aldrich) to check for the desired transfer of 
protein. The membrane was then rinsed briefly in TBS-T, and blocked with 5% skim 
milk in TBS-T for 1 hr. The membrane was then rinsed with TBS-T and incubated 
overnight at 4°C with the primary antibody (anti-SRC-1 antibody: rabbit polyclonal IgG, 
sc-8995, Santa Cruz Biotechnology, 1:500 diluted in TBS-T). 
 
The primary antibody was washed off with TBS-T (3 x 5 min) then incubated with 
secondary antibody (goat anti-rabbit IgG conjugated to horseradish peroxidase (HRP), 
sc-2004, Santa Cruz Biotechnology, 1:20 000 dilution) for 2 hrs at RT with rocking, 
before being washed with TBS-T (3 x 5 min). ECL western blotting detection reagent 
(Cat# RPN2106, Amersham, Piscataway, NJ, USA) was then applied for 1 min. The 
ECL reagent was drained and the membrane exposed to hypersensitive film (Amersham, 
Piscataway, NJ, USA) in a dark room for 5 mins to 1 hr, prior to developing. 
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Membranes were stripped prior to re-probing in membrane stripping solution (section 
2.1). The membrane was incubated with stripping solution warmed to 55°C rocking at 
room temperature for 30 mins, then washed twice with TBS-T and blocked with 5 % 
skim milk for 1 hr. Membranes were then re-probed with primary antibody (β-Actin 
loading control antibody: rabbit polyclonal IgG, 50 µg, ab-8227, (Abcam, Cambridge, 
MA, USA), 1:2000 dilution). 
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CHAPTER 3 - Establishment of En face Oil Red O Staining 
for the detection of Atherosclerotic Plaque in the Arterial Tree 
of ApoE
-/- 
Mice 
 
3.1 Introduction 
 
The first aim of this body of work was to examine the effects of male hormones on 
atherosclerotic lesion development in ApoE knockout mouse (ApoE
-/-
) [263, 264] as a 
model of atherosclerosis to examine hormonal effects. Animal models of atherosclerosis 
have been developed and widely used to understand the pathogenesis of atherosclerosis 
and/or to test hormonal treatments for their efficacy in inhibiting disease incidence. 
Mice, in particular, have been used extensively to study atherosclerosis and vascular 
pathology [265]. The use of mice has obvious advantages over the use of larger animals: 
they require smaller housing facilities, they rapidly produce large numbers of offspring; 
and their small size requires decreased amounts of drugs or agents for experimental 
testing. A vast amount of genetic information is also known about mice enabling 
significant genetic manipulation which, to date, has been responsible for elucidating the 
involvement of many genes in the development of various diseases, including 
atherosclerosis [266].  
 
Wild-type mice themselves do not develop atherosclerotic plaques, even when fed a high 
fat/cholesterol diet, however, inbred mice strains, such as the C57Bl/6 strain, do develop 
limited atherosclerotic plaques in the aortic root when fed a high-fat diet [267]. To 
accelerate plaque development in mice, genetic manipulation and inbreeding has been 
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used to develop mouse models that exhibit more extensive atherosclerosis. The three 
most commonly used models are the ApoB transgenic (ApoB
++
) [268], the LDL receptor 
knockout (LDLR
-/-
) [269-271] and the ApoE
-/-
 mouse models [263, 264]. In the ApoB 
mouse, apolipoprotein B is over-expressed resulting in an increase in plasma VLDL and 
LDL concentrations, a lipid profile that increases atherosclerosis. This model is rarely 
used as there is only limited plaque formation, occurring only in the aortic root when the 
mice are fed high-fat diets, similar to wild-type C57Bl/6 mice [272]. 
 
By contrast, the two knockout mouse models, LDLR
-/-
 and ApoE
-/-
, have been used 
extensively to examine the efficacy of treatments on atherosclerosis [270, 273]. Both of 
these mouse models exhibit extensive plaque formation throughout the entire arterial 
tree. In the LDLR-/- mouse, LDL receptor deficiency results in a moderately 
hypercholesterolemic lipid profile that accelerates atherosclerotic lesion development 
very rapidly when the animals are fed a high-fat diet [274].  
 
The ApoE
-/- 
mouse model has a deletion of the apolipoprotein E gene that also promotes 
altered lipoprotein metabolism, resulting in five times the normal plasma cholesterol 
concentration [264]. The ApoE protein is a ligand for low density lipoprotein (LDL) 
receptors and plays an essential role in receptor-mediated uptake of all triglyceride-rich 
lipoprotein particles, including VLDL, chylomicrons and their remnants [275]. One 
advantage of this mouse model is that even when not fed a high-fat diet, these mice 
develop extensive atherosclerotic lesions that develop reproducibly with age and form 
fibro-fatty plaques in a manner reflecting lesion development in humans [276, 277]. On 
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a high-fat diet, plaque formation is even more rapid and extensive with lesions showing 
macrophagocytic foam cells and necrotic cores [278].  
 
A major disadvantage of using mice, however, is the relative difficulty in performing 
surgical procedures and in vivo imaging. It is necessary that reliable methods are 
available to accurately measure atherosclerotic plaque areas in the vasculature when 
using mouse models of atherosclerosis as a research tool. There are a number of staining 
techniques currently used to evaluate atherosclerotic lesion area in the arterial tree of 
mouse animal models. The best described technique is the sectioning of fixed, paraffin-
embedded aortic tissue and subsequent staining with haematoxylin and eosin (H&E) 
[279, 280]. In our own laboratory, this H&E method has been established and used by 
researchers to examine the effects of androgens on atherosclerosis [122]. Whilst the 
approach led to reproducible findings, it involves tissue fixing, sectioning and staining 
prior to any analysis. Sectioning of the aortic sinus or other regions of the aorta of each 
individual mouse takes many days to complete and is very labour intensive. 
 
A second and increasingly popular technique is the en face method of staining the whole 
arterial tree using Oil Red O [278] for the rapid visualisation of atherosclerotic plaque. 
This method is based on the Oil Red O staining of lipids and allows direct staining of 
whole aortas, thereby, eliminating the need for tissue sectioning. This chapter outlines 
the establishment in this laboratory of the en face Oil Red O method to measure 
atherosclerotic plaque area, and compare the advantages and disadvantages of the Oil 
Red O method versus the traditional H&E method. 
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The specific aims of this chapter were:  
(1)  To establish the en face Oil Red O method to measure atherosclerotic 
  plaque area in ApoE
-/-
 mice; 
 
(2)  To compare the advantages and disadvantages of the Oil Red O method 
  with the traditional H&E method.  
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3.2 Methods and Results 
 
3.2.1  Experimental design 
The disease focus of this project was atherosclerosis. Therefore, the experimental design 
centred on isolating the arterial tree, and developing robust, but efficient, methods to 
measure atherosclerotic plaque formation area. The dissection methods that follow were 
based on that described by Martinic, G et al (2003) [279]. 
 
3.2.2 Cardiac puncture and perfusion 
The mouse was anaesthetised by placing a nose cone with Methoxyflurane (Medical 
Developments International, 5-6 drops in cotton wool) over the mouse head (Figure 3.1). 
The depth of unconsciousness was monitored by observing the respiration rate of the 
mouse. The mouse was weighed then given an intra-peritoneal injection of Nembutal 
(10% pentobarbitone, 0.1 ml per 10 g body weight in saline solution). Depth of 
unconsciousness was again monitored by the mouse respiration rate and this time tested 
by squeezing the toes with tweezers to try and elicit a pain reflex. If no reflex was 
observed, the mouse was assumed to be unconscious.  
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Figure 3.1 Anaesthesia of the mouse by Methoxyflurane administered via a nose 
  cone 
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After the mouse had been anaesthetised, the feet were pinned to the dissecting board. 
The chest and abdomen were sprayed with 70% ethanol to sterilise the area. An incision 
was made in the abdomen, a couple of centimetres below the diaphragm. The 
intraperitoneal muscle was then carefully opened. A longitudinally incision was made up 
the mid-line of the abdomen through the skin and muscle layer up to the level of the 
diaphragm. When the diaphragm was visualised, the liver was pushed to the side so as 
not to damage this tissue then an incision was made carefully through the diaphragm, 
ensuring that the lungs, liver and underlying vasculature were not damaged. The chest 
cavity was then opened by moving away from the midline to the left hand side of the 
chest then slicing through the rib cage. This allowed the ribs to be folded back and 
pinned to the dissecting board thereby exposing the organs and heart within the thoracic 
cavity to allow easy access to the heart to perform cardiac puncture (Figure 3.2). 
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Figure 3.2 Exposing the heart of an ApoE
-/- 
mouse for cardiac puncture  
The chest cavity was opened to obtain access to the heart for a more accurate cardiac 
puncture and to perfuse the arterial tree. 
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Heart 
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Large 
intestines 
Left hand 
side 
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Circulating blood was collected by gently inserting a 26 G needle using a 1 mL syringe 
into the right ventricle (Figure 3.3). Half of the blood collected was placed into 5 mL of 
RNA/DNA Stabilization reagent for Blood/Bone Marrow (Roche-Boehringer 
Mannheim, Castle Hill NSW Australia) in a 50 mL Falcon centrifuge tube and mixed 
well by shaking. The blood/stabilisation reagent mixture was placed on ice until the end 
of the procedure for all the mice and then the samples were stored at -80 °C until 
analysis. The remainder of the blood was transferred into 1.5 ml Eppendorf tubes and 
spun at 4º C for 10 mins at 1000 rpm. The serum was then transferred to a fresh tube and 
stored at -80 °C. 
 
After cardiac puncture, the arterial tree was perfused with heparinised PBS (1:500 
dilution) followed by 4% (w/v) paraformaldehyde (Sigma-Aldrich, Castle Hill NSW 
Australia) to fix the vascular tissue. Before performing the perfusion, the right atrium 
was snipped to allow drainage of the vascular system. 
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Figure 3.3 Cardiac puncture of the right ventricle of the heart  
The needle was inserted into the right ventricle; the removal of the blood was performed 
at a slow rate, allowing for the return of blood from the peripheral circulation.  
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The paraformaldehyde and heparinised PBS were warmed in a water bath at 37°C. The 
heated solutions were placed in holding containers set in Retort stands 1 m above the 
dissecting board to deliver fluids at a constant pressure of 100 mmHg (Figure 3.4). The 
tubes were joined by a tap so the solutions could be switched over from the heparinised 
PBS to the paraformaldehyde. The tubing outlet was connected to a 25 G needle for 
perfusion of solutions through the vascular system.  
 
The base of the heart was held with a pair of tweezers and the needle was gently inserted 
into the left ventricle (Figure 3.5). Heparinised PBS solution was perfused through the 
tree for 4 mins to remove any blood clots. The solutions were then switched over by 
turning the connective tap and paraformaldehyde was perfused through the animal for 6 
mins.  
 
3.2.3 Isolation and excision of the arterial tree 
After the vascular system had been perfused with paraformaldehyde, the organs within 
the abdominal and thoracic cavities were removed, with the exception of the kidneys. 
The kidneys were left in position to allow orientation of the arterial tree in later 
procedures. The front rib cage was also removed to allow better access to the underlying 
tissue. (Figure 3.6) 
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Figure 3.4 Equipment set up for cardiac perfusion 
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Figure 3.5  Diagram of relevant areas of the heart 
Blood was extracted via the right ventricle while perfusion was performed through the 
left ventricle. 
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Figure 3.6 Image of an ApoE
-/- 
mouse after perfusion of the vasculature
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To remove the entire arterial tree including the carotids and subclavian arteries, the 
tissue over the superior vessels was removed. The clavicles lie above the aortic arch and 
over the carotid arteries and thus required removal. Diligence was needed to prevent the 
small bones of the clavicles from tearing the arteries during removal. The tissue 
surrounding the throat was then removed including the trachea and the oesophagus 
(Figure 3.7). The carotid and subclavian arteries were located and isolated using 8 cm 
micro-dissecting scissors and 8 cm sharp fine dissecting forceps. The surrounding 
connective and fatty tissue was excised from the outside of the arterial tree and the 
arterial tree was separated from the surrounding connective tissue. In this way, the entire 
descending aorta was removed, keeping the kidneys and heart attached. The heart was 
cut at the base of the aortic arch and the superior section was fixed for 24 h in 4% (w/v) 
paraformaldehyde and then placed in 70% (v/v) ethanol for at least a further 24 h prior 
to paraffin embedding. The arterial tree was also placed in 4% paraformaldehyde 
overnight and then stored in 70% (v/v) ethanol until Oil Red O staining was performed.
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Figure 3.7  Image of exposed vasculature in situ 
The muscles in the neck, oesophagus and trachea were removed so that the carotid 
arteries, subclavian arteries and aortic arch could be isolated.  
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3.2.4  H&E staining of the aortic sinus 
The principle of the Harris’s Alum Haematoxylin and Eosin (H&E) staining method 
relies on the specific staining specificities of the two dyes that are used. The 
haematoxylin stain is used to differentiate the nuclei of the cells by dyeing the chromatin 
within the nucleus a purple-blue colour. The eosin is then used as a contrasting dye that 
stains the cytoplasmic material including connective tissue and collagen a pink colour. 
Red blood cells are stained an intense red colour by eosin. The colour differences within 
the tissues are used to identify the different cell and matrix types.  
 
Due to the specificities of the H&E stain, hydrophobic structures tend to remain clear. 
Therefore, the central section of an atherosclerotic plaque that is heavily laden with 
lipid-filled cells does not stain well. However, H&E does stain the cells and matrix 
structure that surround the plaque, thereby allowing the identification of plaque regions.  
 
The paraffin-embedded heart tissue was serially sectioned every 5 µm until the first 
valve leaflet was located. Once the first valve leaflet was located, duplicate sections 
every 100 µm were set aside for atherosclerotic plaque assessment, resulting in a total of 
6 sections for lesion analysis (Figure 3.8). The cutting was performed on a microtome 
(Microm HM-325: Lomb Scientific, Taren Point NSW Australia) and were mounted on 
positively charged microscope slides (Mezel-Glaser; Superfrost Plus slides, 
Braunschweig, Germany) and dried overnight at 40 °C. The sections were then H&E 
stained as follows. 
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Briefly, the slides were placed in Histolene (Fronine, Taren Point NSW Australia) to 
remove the paraffin from the section and then hydrated through 100% ethanol, 95% 
ethanol, 90% ethanol, 70% ethanol and finally, water. The slides were then placed in 
haematoxylin for 3 mins and washed thoroughly in water to remove all excess stain. The 
slides were then immersed quickly into an acid/alcohol wash (see section 2.1, Materials) 
to remove some of the haematoxylin stain. The slides were then washed thoroughly 
again before being treated with Scott’s blueing reagent (Fronine) (30 sec) to bring out 
the blue stain of the nucleus. The slides were counterstained using Eosin staining 
solution (Fronine, Methods section 2.3.2) and then dehydrated through 95% and 100% 
ethanol to Histolene (Fronine). The slides had a cover-slip fixed in placed using DPX 
Mountant (Fluka Chemie, Buchs/Switzerland) and were left overnight to dry.  
 
Images were digitally captured using a BH-2 Olympus microscope (Olympus, North 
Ryde NSW Australia) and Nikon COOLPIX 4500 digital camera (Nikon, Lidcombe 
NSW Australia) using Nikon View Pro software (Nikon) at 10X magnification. The 
plaque area was quantitated using Adobe Photoshop version 7.0. Briefly, the plaque was 
traced with the magnetic lasso tool and a pixel count of the selected area was obtained 
(Methods 2.3.2).    
 
The H&E images (Figure 3.8) show the atherosclerotic plaque as it is formed within the 
aortic sinus of the mice with the visualisation of the valve leaflets. The morphological 
changes can be observed the first valve leaflet in image E shows that there is a 
calcification present. With more plaque development there are greater morphological 
changes observed within the plaque itself. 
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Figure 3.8  Representative images of H&E stained sections of the aortic sinus in 
20-week old ApoE 
-/- 
mice: Serial 5 µm sections of the aortic sinus were taken every 
100 µm, using the valve leaflets as reference points. A) Appearance of first valve leaflet, 
B) Appearance of second valve leaflet, C) Appearance of third valve leaflet, D) - F) 
Sections taken every 100 µm in the aortic sinus until the leaflets disappear. The total 
area of plaque was quantified across the 6 sections using Adobe Photoshop (version 7.0) 
(see methods 2.3.2). 
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3.3 Optimisation of En face Oil Red O staining   
 
3.3.1  Oil Red O staining 
Oil Red O (C26H24N4O) is a lysochrome (fat-soluble) diazo dye used for staining of 
triglycerides and lipids in tissue sections.[281] Oil Red O contains Sudan Red 5B, a 
compound that shows high affinity for fats and gives the stain a deep red colour that 
allows easy visualisation of lipid-rich regions within tissues.  
 
3.3.2 Dissection of the arterial tree 
After euthanasia of the mouse, the chest cavity was opened and the arterial tree was 
removed. Excess connective and fatty tissue was then excised and the tissue was fixed in 
4% (w/v) paraformaldehyde for 24 hrs. The tissue was then placed in 70% (v/v) ethanol 
for storage, until staining. When ready to stain, the tissue was removed from the ethanol 
and placed on a dissecting microscope stage. Any excess fatty and connective tissue that 
was not excised earlier was now thoroughly removed from the exterior of the tree, again 
using micro-dissection scissors and forceps. Next, the arterial tree was dissected along 
the superior side from the lower region of the artery towards the aortic arch to allow the 
maximum area of the inner arterial walls to be exposed to the staining dye. The tree was 
orientated as shown in Figure 3.9. The dotted line represents the route the scissors took 
to dissect open the artery. Once the artery was opened, the edges of the artery were 
pinned to a backing board.  
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Figure 3.9  Schematic diagram showing the orientation of the arterial tree 
during Oil Red O staining 
The dashed line represents the path that was cut in order to open up the tree. The arrows 
indicate the direction used to open up the tissue. The tissue was then pinned open to 
allow maximum surface area for Oil Red O staining. 
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3.3.3  Artery pinning procedure 
A number of different pins were trialled to optimise the securing of the fragile artery 
tissue. First, sewing pins were used but were found to be too large as they were difficult 
to manipulate and once placed in the tissue, their large head size obstructed the view of 
the artery through the microscope eye piece. Therefore, a needle or pin with a smaller 
head diameter was sought. Acupuncture needles were trialled as these pins are smaller 
and finer than sewing pins. It was found that the smaller diameter of the needles allowed 
easier manipulation of placement and the needles could be placed such that the view of 
the image was not obstructed through the eye piece and importantly, they did not tear the 
delicate tissue upon insertion. 
 
3.3.4 Maximising Oil Red O dye absorption 
The Oil Red O staining procedure was adapted from protocols previously described in 
the literature [271]. In these established protocols, the Oil Red O dye was diluted in 
water. However, in the current experiments it was found that diluted solutions failed to 
stain the plaque. Thus, for these studies, undiluted working solution was used, after 
filtration to remove solid particles. Published staining protocols varied in staining times, 
so a range of times including 5, 10, 20 and 30 mins were tested. The descending aorta 
and aortic arch were completely covered with the Oil Red O staining solution. A 5 min 
staining time did not result in sufficient colouration of the plaque. The 10, 20 and 30 min 
time points all resulted in similar staining intensity, hence a staining time of 10 mins was 
chosen for use in the final Oil Red O staining protocol (Figure 3.10). After staining, the 
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tissue was rinsed with water and counterstained with haematoxylin. The haematoxylin 
was then visualised with Scots blueing agent. 
 
3.3.5 Choosing optimal backboard colour for imaging 
The next step in the optimisation of the Oil Red O staining procedure was to trial 
different background colours to test which produced the highest quality images. Initially, 
white plastic was used as it was thought that a white background would provide the best 
contrast for the red stain in the tissue. However, after several attempts, it was found that 
the white background created too much reflection from the external light needed to 
illuminate the red stain, resulting in over-exposed images. Next, a black background was 
used to try and reduce the background and reflection problem. The black background 
proved to be effective, allowing better contrast images to be produced.  
 
In addition to the backboard colour, the image quality was affected by the water 
covering the tissue. Initially, tissues were immersed in water to prevent drying of the 
tissue. The use of water however, created an oily film over the tissue and this distorted 
the image due to light reflection. Therefore, all excess water was blotted from the tissue 
prior imaging.  
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Figure 3.10  Oil Red O staining of the aortic tree from a 40-week old ApoE 
-/-
 
male mouse: After the tissue was dissected longitudinally and pinned to black plastic, 
Oil Red O stain was applied for 10 mins, before the tissue was counterstained with 
haematoxylin. Atherosclerotic plaque areas were visualised as red-stained tissue 
indicated by arrow B. Images were captured using a Nikon COOLPIX 4500 digital 
camera attached to a Nikon SMZ-2T dissecting microscope (Nikon). A = acupuncture 
needles, B = plaque, C = aortic arch, D = right subclavian artery, E = right carotid artery, 
F = left carotid artery, G = left subclavian artery, H = descending aorta.  
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Figure 3.11  Staining of the arterial tree with Oil Red O method 
This is a representative image of the aortic arch and descending aorta from a 40-week 
old ApoE 
-/-
 mouse. The tissue was stained with Oil Red O and counter-stained using 
Haematoxylin staining solution. The dark red areas are atherosclerotic plaque indicated 
by arrow A.  Arrow B indicates an acupuncture needle securing tissue to backing and 
arrow C; a pool of water covering the arterial tissue. 
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3.3.6 Final staining protocol 
As just described, the arterial tree was dissected longitudinally and pinned open on a 
black plastic background. The tissue then was briefly washed with 50% alcohol. The Oil 
Red O staining solution was applied to the arterial tree drop by drop until the tissue was 
completely covered. The stain was left for 10 mins. As the diluent for Oil Red O was 
isopropanol, to counteract evaporation the stain was continually topped up during the 10 
min incubation. After staining, excess stain was washed away with filtered water. The 
tissue was counter-stained with haematoxylin for 5 secs and then washed with water. 
The tissue was rinsed with an acid/alcohol wash (Material, section 2.1) for 5 secs, rinsed 
with water, then Scots blueing reagent (Fronine) was applied for 1 min to turn the 
haematoxylin blue (Fronine). The tissue was then rinsed with water and all excess water 
was completely removed by blotting. A series of images were then captured, beginning 
at the aortic arch and following the descending aorta to the mesenteric region. All 
images of the stained tissue were captured using a Nikon COOLPIX 4500 digital camera 
attached to a Nikon SMZ-2T dissecting microscope at 10 X magnifications (Nikon). 
Plaque area in these images was quantitated as described (Methods 2.3.2). Results are 
expressed as the percentage of plaque area relative to the total area of the arterial tree.
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3.4  Discussion 
 
This chapter has described the establishment of en face atherosclerotic plaque analysis in 
this laboratory. Next, en face analysis was compared to the traditional H&E sectioning 
method that has previously been used in this laboratory to quantify plaque levels in 
ApoE 
-/-
 mouse models. Our aim for this, and the subsequent chapter, was to use both 
techniques to determine the effects of androgen treatment on atherosclerotic plaque in 
the ApoE 
-/-
 mice. The discussion here will centre upon the technical advantages and 
disadvantages of the en face method versus the H&E methods. In the next chapter, a 
comparison of the two methods will be interpreted with respect to whether plaque area 
determined was comparable between the two methods. 
 
3.4.1  Advantages of the en face method for atherosclerotic plaque area 
 measurements 
The primary advantage of en face plaque analysis compared to the H&E staining method 
was undoubtedly the time taken. En face staining was a much faster technique from start 
to finish. The dissecting of the tissue, pinning, staining and imaging was done within an 
hour. By comparison, H&E staining took more than 1 day as there are many steps such 
as overnight fixation, sectioning, deparaffinisation, staining and coverslipping.  
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A second advantage of the en face method is that it shows a greater perspective of 
plaque formation as it allows visualisation of plaque along the entire length of the tree. 
This contrasts with the snapshots that are captured by sectioning and H&E staining. Of 
course, sectioning of the entire tree can and has been done, however, this is significantly 
time consuming, and in studies of younger mice, lack of plaque in lower aortic regions 
would make this method a considerable waste of time [264]. It has also been shown that 
diets enriched in saturated fats and cholesterol can accelerate lesion development at 
various sites throughout the aortic tree [276]. Therefore, the en face method can 
determine whether such treatments have site-specific effects on lesion development. 
 
It has been shown that atherosclerotic plaque formation occurs at specific site of the 
arterial tree, such as the aortic arch, and adjacent arterial branches. These sites are 
thought to be conditioned by hemodynamic parameters, such as regions exposed to 
oscillatory or turbulent flow [282]. As the animals age atherosclerotic plaque formation 
progresses, with more plaque found within the thoracic and abdominal aortic regions. 
Although en face Oil Red O staining is not an exact measurement of plaque growth as 
lesion thickness is not evaluated [283], the en face technique allows plaque to be 
evaluated in all regions of the arterial tree. Therefore, overall this gives a more real 
assessment of plaque levels in the arterial tree relative to sectioning and H&E staining, 
which essentially just delivers a snap shot of specifically chosen regions. The en face 
staining is thus a more efficient technique for evaluation of plaque levels when the 
endpoint of a study is the effect of a treatment on the progression of atherosclerotic 
plaque formation.  
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3.4.2 Disadvantages of the en face Oil Red O staining technique 
A major disadvantage of using the en face Oil Red O staining is the inability to define 
morphological features of plaque or the expression of RNA/DNA and proteins 
expression levels respectively when in situ hybridisation or immunohistochemistry is 
employed. The techniques associated with sectioning are important to gain a better 
understanding of the mechanism behind the pathogenesis of atherosclerosis formation. 
Therefore, the disadvantage of the en face Oil Red O staining is that it only analyses the 
levels of plaque formation.  
 
3.4.3  Technical difficulties associated with the en face method of plaque analysis 
There were some technical difficulties associated with the en face methodology. First, 
dissecting the arterial tree longitudinally proved to be a major challenge because (1) the 
small size of the tissue required all dissections to be performed using a dissecting 
microscope and (2) the fragility of the tissue often led to tearing. Tearing meant that 
pinning open of the tissue was difficult and resulted in a loss of structure. More 
importantly, tearing sometimes led to loosening of the plaques from the tissue, which 
would lead to inaccurate findings.  
 
Staining with Oil Red O is also a relatively subjective technique; therefore, more than 
one independent observer is required to measure the plaque formation. The en face Oil 
Red O method, however, gave more reliable and consistent results within, and between, 
the different treatment groups (to be discussed in Chapter 4). In support of these findings 
from this thesis, Tangirala RK et al (1995) [278] compared both en face staining using 
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different stain Sudan IV and H&E staining of sectioned tissue in quantitating 
atherosclerosis in LDLR
-/-
 and ApoE
-/- 
mice [278]. These investigators found performing 
the en face technique more challenging than histological sectioning of the aortic root as 
all procedures were done under a microscope and care had to be taken to not dislodge 
the lesions [280, 284], although they also reported that it was difficult to isolate the 
aortic valve cusps that is required for H&E staining. They also found that the en face 
method was less time consuming than histological sectioning.  
 
3.4.4 Comparison of the en face Oil Red O and H&E methods with other 
techniques 
The ideal standard for using animal models is to have a technique that is non-invasive 
allowing animals to be studied in real time for several months whereby the progression 
of disease could be monitored. This would reduce the number of animals needed for the 
different time points as well as giving consistent results for each animal instead of using 
different animals for each time point the same animal can be used for all of them. A 
magnetic resonance imaging (MRI) technique has been developed for small animal 
models including mice that allow imaging of arteries and atherosclerotic plaque 
formation in vivo [285]. As recently reviewed, the major advantages of MRI are that 
multiple measurements at different times of the treatment can be taken thus reducing the 
number of animals required for testing [286, 287]. Another non-invasive technique uses 
antibody-based molecular imaging of atherosclerotic plaques using radioiodine or 
fluorescent dyes to observe atherosclerotic plaque development [288]. Such non-
invasive methods may become standard for lesion quantification in the future. Although 
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techniques such as MRI exist more readily for human investigations, there are few MRI 
machines designed for small animal studies. This is because the equipment is expensive 
to buy and the installation of extra infrastructure needed to support the weight of the 
large magnet needed for the imaging. Both of the methods used in the current study are 
invasive methods, which limits the ability to look at time-dependent changes in plaque 
development.  
 
3.5 Summary and conclusions 
 
In this chapter, en face Oil Red O staining methodology was established in this 
laboratory to enable quantitation of atherosclerotic plaque in the arterial tree of ApoE-/- 
mice. The en face method was compared to the H&E staining method that has 
previously been used in the laboratory.  
 
This current study showed the en face method to have both disadvantages and 
advantages in comparison to the H&E staining method. The disadvantages of the en face 
method included the inability to perform in situ hybridisation or immunohistochemistry 
staining for atherosclerotic markers as well as obtaining critical information about the 
morphology of the plaque. Additionally, technical issues including the fragility of the 
tissue and the potential dislodgement of plaque are major issues with this method. 
However, en face method was a very quick and more time and labour efficient compared 
to the H&E staining. It is a very powerful method for determining quickly the amount of 
plaque in the entire tree. 
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CHAPTER 4 - Dose-Dependent Effects of Androgens on 
Atherosclerotic Plaque Formation in ApoE
-/- 
Mice 
 
4.1 Introduction 
 
In the developed world, CVD is the major contributor to morbidity and mortality, with 
one risk factor being male gender [1, 2]. Men being predisposed to CVD may be a major 
clue to the pathogenesis of CVD. Although there are many differences between men and 
women, different sex hormonal milieus could be an underlying factor that drives the 
gender dichotomy in the incidence of CVD. The atheroprotective properties of estrogens 
on the vasculature in women have been the major focus of research investigating sex 
hormones and CVD. The opposing theory that androgens may accelerate CVD [27] in 
males, has been given relatively little attention and the information gathered to date has 
not conclusively shown whether androgens are considered to be athero-protective or pro-
atherogenic (as discussed in section 1.3). Men and women have constant progression of 
atherosclerosis as they age with men having higher incidence and earlier onset compared 
to women shown by Tunstall-Pedoe et al [21]. With the onset of menopause, CVD 
incidence increases in women where the men demonstrate no change in the growth 
pattern of CVD incident. 
 
In vitro, androgens have been shown to regulate genes associated with atherosclerosis 
[4]. Dihydrotestosterone (DHT) and/or testosterone (T) are known to promote 
inflammatory processes such as monocyte adhesion to endothelial cells [150], the 
activation of the pro-inflammatory regulator, NF-κB in endothelial cells [151], 
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endothelial cell apoptosis [289], induce smooth muscle cell proliferation [7, 8] and 
increases macrophage foam cell formation [152], consistent with the theory that 
androgens are pro-atherogenic. Yet in the majority of animal studies, exogenous T 
administration to male animals has resulted in decreased atherosclerotic plaque 
formation [50, 57, 96-98, 100, 105, 122], findings that would argue against the pro-
atherogenic theory. Clinically, an increased incidence of CVD is associated with lower, 
rather than higher, serum T [290, 291]. For example, men with hypogonadal status 
and/or low serum T levels present with increased carotid artery intimal media thickness, 
a marker of sub-clinical atherosclerosis, and higher rates of adverse cardiovascular 
events, although the causality of these observations remains uncertain [20-22]. By 
contrast to what is observed in males, in animal studies using females, exogenous 
androgen treatment tends to increase atherosclerotic plaque formation [23-25]. This 
finding is somewhat consistent with hyperandrogenemia in women, associated with an 
increased incidence of atherosclerosis, such as those with polycystic ovary syndrome 
(PCOS) [77, 79, 292]. However, whether the increased risk is due to the high androgen 
levels per se or due to metabolic abnormalities associated with PCOS remain unclear 
[292, 293].  
 
Recent results from our laboratory examined the effect of exogenous treatment with 
crystalline T and DHT on plaque development in young ApoE-/- mice. It has been 
demonstrated in the literature [263] and by this study that the female ApoE
-/-
 mice have 
higher atherosclerotic plaque formation then the males ApoE
-/-
 mice. The gender 
difference in plaque formation will not have a significant impact on the results of this 
hormone study. The results are consistent with previously published animal studies 
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mentioned above. In the study conducted by M. Hill (2006) [122] the dose used was a 1 
cm silastic implant, inserted subcutaneously. The T treatment in the orchidectomised 
male mice was shown to decrease plaque formation by 2-fold (p<0.05) in the aortic arch 
of 12-week old ApoE-/- mice. However, in ovariectomised female mice treated with 1 
cm T for a similar time-frame, plaque formation was significantly increased by 2-fold 
(p<0.05) in the aortic arch (Figure 4.1 B). In contrast to the results found with T, 
treatment with 1 cm DHT did not show athero-protection in male mice but instead 
showed a trend toward an increase in plaque formation in both the aortic sinus and arch 
(Figure 4.1 A: B), although the results did not reach significance. In the female mice, 
treatment with 1 cm DHT showed a significant reduction in plaque levels by 2-fold 
(p<0.05) compared to the ovariectomised group (Figure 4.1).  
 
The previous findings from this laboratory, together with published findings, suggests 
gender-specific effects of androgens on the vasculature may be related to circulating 
levels and/or locally produced sex hormones. Therefore, in this study, the aim was to 
investigate whether varying the dose of T or DHT treatment elicited different effects on 
atherosclerotic plaque formation in ApoE
-/- 
mice.  
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Figure 4.1  Plaque development in the (A) Aortic sinus and (B) Aortic arch of 
ApoE
−/− mice treated with androgens for 8 weeks  
At 3-4 weeks of age, ApoE
−/−
 mice were orchidectomised (odx), ovariectomised (ovx) or 
left intact (intact). Groups of mice (n=8) were then treated for 8 weeks with crystalline T 
or DHT by implantation of hormone-filled silastic implants. Atherosclerotic plaque 
development was analysed using the H&E method of staining, as was described in 
Chapter 3 (∗ p<0.05 odx vs odx + T and DHT; ovx vs ovx + T and DHT).  
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4.1.1 Aims 
 
Our current understanding of the effects of exogenous male sex hormones, T and DHT, 
on atherogenesis remain unclear.  
 
The hypotheses for this study were that: 
(1) In males, T at physiological concentration is atheroprotective, however, at lower 
doses may promote atherosclerosis. In females, high concentrations of T, 
promotes atherosclerosis and may also be atherogenic at lower treatment 
concentrations. 
(2) DHT administered at high doses may promote atheroscelosis in males, where 
low doses promotes atherosclerosis in both males and females. 
 
To test these hypotheses, the specific aims of the study were: 
 
Aims: 
1. To test the dose response effect of T treatment on early atherosclerosis formation 
in the ApoE 
−/−
 mouse model; 
2. To compare the effects of the non-aromatisable androgen, DHT, with the 
aromatisable androgen, T, on the formation of atherosclerotic plaque in the 
ApoE
−/−
 mouse model; 
3. To test for gender-specific effects of DHT and T treatment on atherosclerotic 
plaque development in the ApoE−/− mouse model. 
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4.2 Materials and Methods 
4.2.1 Animals 
Male and female ApoE
−/−  
(C57Bl/6 background) mice were used in this study and were 
housed and maintained at the Heart Research Institute (HRI) Animal Facility. Mice were 
fed ad libitum a normal chow diet with acidified water and housed in 55 ± 5 % relative 
humidity at a temperature of 20 ± 2°C with a 12-hour light cycle. The mice were kept in 
cages of no more than 6 mice per cage. The study and procedures performed were 
approved by the Sydney South West Area Health Services Animal Welfare Committee, 
ethics number 2004/002 (Heather). 
4.2.2 Experimental design 
Previous data from our laboratory [122] showed that male ApoE
−/−
 mice treated with 1 
cm DHT silastic implants for 8 weeks showed a trend towards increased plaque 
formation, however the results did not reach statistical significance (Figure 4.1). There 
were several explanations for the failure of the data to reach significance: (1) that the 
results produced from this study were true and that DHT does not significantly increase 
atherosclerosis in males and that the trend was an abberation; (2) DHT does promote 
atherosclerosis, in the initial experiment but not enough time was allowed for significant 
changes in plaque development; (3) the 1 cm DHT implant led to high circulating doses 
that induced vasodilatory effects in the male vessels, thereby balancing any atherogenic 
effects of DHT. To address such issues in the current work, the experimental design was 
amended to include both a longer treatment time of 16 weeks (vs 8 weeks) and lower 
treatment concentrations 
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Figure 4.2 Experimental time line 
 
Male and female ApoE
−/−
 mice at 3-4 weeks age were randomly allocated to different 
treatment groups (n=6). Mice were left intact, ovariectomised or orchidectomised, 
untreated or treated with silastic implants of 0.25 cm, 0.5 cm or 1 cm T or DHT for a 
further 16 weeks. At 20 weeks of age, mice were sacrificed and plaque area in the 
arterial tree was measured as described in Chapter 2 (Materials and Methods section 
2.4). 
 
 
 
 
Weeks 
Birth 
± Ovariectomy or 
Orchidectomy 
± Implant 
(0.25 cm, 0.5 cm 
or 1 cm) 
 
Sacrifice &  
Tissue harvesting 
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Male and female ApoE
-/-
 mice were randomly allocated to different treatment groups 
(n=6 /group) at weaning (3-4 weeks of age) as shown in Table 4.1. Mice were left intact, 
ovariectomised (ovx) (Methods 2.2.4) or orchidectomised (odx) (Methods 2.2.3) and 
split into untreated or treated groups. Treatment involved implanting 0.25 cm, 0.5 cm or 
1 cm T or DHT silastic implants. The silastic implants filled with either crystalline T or 
DHT were supplied by Professor David Handelsman, (ANZAC Research Institute, 
Concord, Australia) [256] (Methods 2.2.5). The implants, once inserted subdermally, 
slowly release androgens at a constant rate. This rate is determined by the length of the 
implant [256].  
 
In order to investigate the effects of exogenous T and DHT treatment in ApoE
-/-
 mice on 
the formation of atherosclerotic plaque the animals were either left intact or 
gonadectomised to remove all endogenous sex hormones. The gonadectomised animals 
were then left untreated or administered different doses of exogenous androgens to 
replace the sex hormones, ranging from a high to an intermediate to a more 
physiological dose. Previously Kemp CJ et al [294] showed that physiological serum T 
levels in female and male C57Bl/6J mice are 0.29 ± 0.06 ng/mL and 6.7 ± 0.4 ng/mL, 
respectively. However, Pandey KN et al [295] showed that physiological serum T levels 
was 80 ± 10 ng/mL in F1 hybrid 129 crossed C57Bl6 male mice. Singh et al [256] also 
investigated physiological serum T and DHT levels in C3H/HeH crossed 101/H male 
mice with measurements of 3.17 ± 0.9 ng/mL and 0.049 ± 0.017 ng/mL, respectively. 
Therefore, in using the implants it is hoped that circulating concentrations of T are in the 
range of 3-80 ng/mL, in keeping with the estimated physiological concentrations.  
 134 
Previously, it has been determined the T serum concentration obtained from exogenous 
T treatment with the silastic implants can be calculated from the formula [T] = 68.6 + 
58.5 log10 (length*) (r = 0.981), (*=cm). Similarly the DHT serum concentration 
delivered by the silastic implants can be acquired using the formula [DHT] = 2.1+1.5 
log10 (length*) (r = 0.934), (*=cm). Therefore, above equations predict that for T and 
DHT concentrations delivered by the implants are as follows: 1 cm T ~ 60 nM (17.3 
ng/mL), 0.5 cm T ~ 45 nM (13 ng/mL) and 0.25 cm T ~ 30 nM (8.65 ng/mL)  and 1 cm 
DHT ~ 2.4 nM (0.697 ng/mL), 0.5 cm DHT ~ 1.8 nM (0.523 ng/mL) and 0.25 cm DHT 
~ 0.75 nM (0.218 ng/mL), respectively [256].  
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Table 4.1 Treatment groups used in this study 
Groups*  Number of mice 
Implant 
(size/hormone) 
Expected circulating 
concentration  
MALE MICE    
Intact (untreated) 6 -  
Odx (untreated) 6 -  
Odx + T 6 1 cm T 60 nM 
#
 
Odx + T 6 0.5 cm T 45 nM 
#
 
Odx + T 6 0.25 cm T 30 nM 
#
 
Odx + DHT 6 1 cm DHT 2.4 nM 
#
 
Odx + DHT 6 0.5 cm DHT 1.8 nM 
#
 
Odx + DHT 6 0.25 cm DHT   0.75 nM 
#
 
    
FEMALE MICE    
Intact (untreated) 6 -  
Ovx (untreated) 6 -  
Ovx +T 6 1 cm T  
Ovx + T 6 0.5 cm T  
Ovx + T 6 0.25 cm T  
Ovx + DHT 6 1 cm DHT  
Ovx + DHT 6 0.5 cm DHT  
Ovx + DHT 6 0.25 cm DHT  
 *Odx, orchidectomised; Ovx, ovariectomised; #, [256]. 
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4.2.3 Assessing plaque formation in ApoE
-/-
 mice 
The ApoE
-/- 
mice were sacrificed at 20 weeks of age. The aortic sinus and arterial tree 
were isolated (Section 3.2.3-4) then, analyses were performed using H&E and Oil Red O 
en face staining techniques, respectively (Section 3.3.6). Images of the aortic sinus were 
digitally captured with a BH-2 Olympus microscope (Olympus, North Ryde NSW 
Australia) and Nikon COOLPIX 4500 digital camera (Nikon, Lidcombe NSW Australia) 
using Nikon View Pro software (Nikon) at 4X magnification. The plaque area within 
each image was quantitated using Adobe Photoshop version 7.0. The plaque was traced 
with the magnetic lasso tool and a pixel count of the selected area was obtained. Pixel 
counts were confirmed independently by two other people who were blinded to the 
conditions of treatment. Determining the number of pixels per 1 µm2, the pixel counts 
were converted to metric units. The plaque lesions were represented by an average 
lesion size of each section. 
 
4.2.4 Statistical analysis 
Results of experiments are reported as mean ± SEM compared to the intact controls. 
One-way ANOVA with Dunn’s post-test was used to detect differences between 
experimental groups for plaque area. P<0.05 was considered statistically significant. 
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4.3 RESULTS 
 
 
The effects of the primary male hormones, T and DHT, on plaque formation in the 
arterial tree of ApoE
-/-
 mice were examined. Atherosclerotic plaque formation in the 
aortic sinus was quantitated using the H&E method described in Chapter 3. En face Oil 
Red O analysis was used to measure plaque in the aortic arch and the descending aorta 
giving a total plaque area (henceforth referred to as the arterial tree) and the area of the 
plaque measured in the aortic arch (henceforth referred to as the aortic arch), also 
described in Chapter 3. The aortic sinus region was analysed separately as it has 
previously been shown that compounds can have significantly different effects on plaque 
development in this region [278].  
 
4.3.1 Testosterone has dose-dependent effects on plaque formation in male  
 ApoE
-/-
 mice 
Overall, the effects of T and DHT on plaque development were highly reproducible 
between regions in the male mice (Figures 4.3 and 4.4). Representative photographs 
taken from the untreated and T treatment groups are shown illustrating the plaque that is 
identifiable using the different staining methods. 
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In general, orchidectomy increased plaque development in the arterial tree. En face Oil 
Red O studies showed that orchidectomy had a 3-fold increased of plaque area in the 
arterial tree of male mice (P<0.05) (Figure 4.5 A) compared to intact control mice. 
Similarly, 1.4-fold increase in plaque area was measured in the aortic sinus (P<0.05) 
(Figure 4.6). 
 
In all regions, there was an inverse relationship between plaque area and the 
administered dose of T (Figures 4.5 and 4.6). At the highest T concentration (1 cm), 
plaque area decreased by 3-fold in the tree (P<0.05) and 1.7-fold in the sinus (P<0.05) 
relative to the orchidectomy group (Figure 4.5). By contrast, the lowest dose 
administered (0.25 cm) significantly increased plaque levels in the arch and tree by 1.7 
and 2-fold, respectively (P<0.05) (Figure 4.5) and 1.2-fold in the aortic sinus (P<0.05) 
(Figure 4.6). The treatment with the intermediate dose of T (0.5 cm) showed no 
significant change in plaque area compared to the orchidectomy group.  
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Figure 4.5  Mean plaque area in the aortic arch (A) and arterial tree (B) of 
androgen-treated male ApoE
-/-
 mice using the en face Oil Red O staining method 
Mice at 3-4 weeks of age were left intact or orchidectomised (odx) then the odx animals 
were untreated or treated with increasing concentrations of T or DHT. Plaque area was 
measured in the arterial tree and aortic arch of each animal as described (Section 4.2.3). 
Values are a ratio of the plaque area/total area given as mean ± SEM (n=6). Significant 
differences between controls and treated groups were analysed by one-way ANOVA 
with Dunn’s post-test. P<0.05 (# odx vs intact; * odx + 0.25 cm T, odx + 0.25 cm DHT 
& odx + 1 cm T vs odx) 
* 
* 
* 
* 
* 
* 
# 
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Figure 4.6  Mean plaque area in the aortic sinus of androgen-treated male  
ApoE
-/- 
mice using H&E stain 
Mice at 3-4 weeks of age were left intact or orchidectomised (odx) then the odx animals 
were untreated or treated with increasing concentrations of T or DHT. Plaque area was 
measured in the aortic sinus of each animal as described (Section 4.2.3). Values are 
given as mean ± SEM (n=6). Significant differences between controls and treated groups 
were analysed by one-way ANOVA with Dunn’s post-test, with groups displayed 
relative to the odx animals, taken as 100%. P<0.05 (# odx vs intact; * odx + 0.25 cm T, 
odx + 0.25 cm DHT & odx + 1 cm T vs odx) 
 
* 
# 
* 
* 
 143 
4.3.2 DHT has dose-dependent effects on plaque formation in male ApoE
-/- 
mice
 
As found for T, results showed that DHT at the lowest treatment dose (0.25 cm) 
increased plaque levels by 1.3-fold (sinus, P<0.05), 1.4-fold (arch, P<0.05) and 1.6-fold 
(tree, P<0.05). The two higher doses (0.5 cm and 1 cm) showed the same pattern 
between the en face and H&E methods but showed no significant change compared to 
the orchidectomised group (Figure 4.5 & 4.6).  
 
4.3.3 Testosterone treatment has little influence on atherosclerotic plaque 
 development in female ApoE
-/-
 mice  
Female ApoE
-/-
 mice at 3-4-weeks of age were left intact, ovariectomised (ovx) and/or 
implanted with 0.25 cm, 0.5 cm, 1 cm T or DHT silastic implants. Treatment was 
continued until the mice were sacrificed at 20 weeks of age. The amount of plaque in the 
arterial tree was analysed as described in Chapter 3, both en face Oil Red staining of the 
arterial tree and H&E staining of the aortic sinus. Representative photographs of stained 
sections taken from female mice in each treatment group are shown (Figure 4.7 & 4.8).  
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Similar results to male mice were found, trends between treated groups were 
comparative between each region of the aortic tree studied in the female mice regardless 
of whether H&E staining (aortic sinus) or Oil Red O staining (arterial tree) was used. 
Ovariectomy increased plaque area by 1.4-fold in the sinus (P<0.05) and 4-fold in the 
arterial tree (P<0.05), compared to intact females. No dose-dependent effect was 
apparent in females treated with T in any region studied. (Figures 4.9 and 4.10) 
 
4.3.4 DHT has dose-dependent effects on plaque formation in female ApoE
-/-
 mice 
In striking contrast to the lack of effect of T on plaque development in female mice, 
DHT showed dose-dependent effects on plaque area (Figures 4.9 and 4.10), with 
increased DHT concentrations progressively decreasing lesion area. Treatment with the 
highest concentration of DHT (1 cm) decreased plaque area in all regions measured with 
1.3-fold in the arch (P<0.05), 1.6-fold in the tree (P<0.05), and 1.7-fold in the sinus 
(P<0.05). Treatment with the intermediate concentration of DHT (0.5 cm) showed a 
decrease of 2-fold in the tree, (P<0.05) and 1.3-fold in the sinus, (P<0.05). In contrast, 
DHT treatment at the lowest dose (0.25 cm) had no effect on lesion area relative to 
ovariectomised controls (Figures 4.9 and 4.10). 
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Figure 4.9  Total plaque area in the aortic arch (A) and tree (B) in 20-week old 
androgen-treated female ApoE
-/-
 mice using the en face Oil Red O staining method 
Mice at 3-4 weeks of age were left intact or ovariectomised (ovx) then ovx animals were 
untreated or treated with increasing concentrations of T or DHT. Plaque area was 
measured in the arterial tree and aortic arch of each animal as described (Section 4.2.3). 
Values are a ratio of the plaque area/total area given as mean ± SEM (n=6). Significant 
differences between controls and treated groups were analysed by one-way ANOVA 
with Dunn’s post-test.  P<0.05 (# ovx vs intact; * ovx + 0.25 cm DHT & ovx + 0.5 cm 
DHT vs ovx) 
* 
* 
# 
* 
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Figure 4.10 Mean plaque area in the aortic sinus of androgen-treated female  
ApoE
-/-
 mice using H&E stain 
Mice at 3-4 weeks of age were left intact or ovariectomised (ovx) then ovx animals were 
untreated or treated with increasing concentrations of T or DHT. Plaque area was 
measured in the aortic sinus of each animal as described (Section 4.2.3). Values are 
given as mean ± SEM (n=6). Significant differences between controls and treated groups 
were analysed by one-way ANOVA with Dunn’s post-test. Groups are displayed relative 
to the ovx animals, taken as 100%.  P<0.05 (# ovx vs intact; * ovx + 0.25 cm DHT & 
ovx + 0.5 cm DHT vs ovx). 
* # 
* 
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4.4 Discussion 
 
In this chapter, male and female ApoE-/- mice were administered three different doses of 
the two primary male hormones, testosterone (T) and dihydrotestosterone (DHT) to 
determine whether androgen dose had significantly different effects on the progression 
of atherosclerosis. The effects of a high dose (1 cm silastic implant), an intermediate (0.5 
cm implant) and a low dose (0.25 cm implant) were examined. In the male mice, T at the 
high dose reduced plaque formation, whereas the lowest dose increased plaque 
formation. T had gender-specific effects as there were no differences in plaque levels in 
the T-treated female mice. DHT treatment affected males only at the lowest dose of 0.25 
cm. However, for females, DHT at the higher doses reduced plaque formation. 
 
The novel results found in this study were that varying the dose of exogenous T and 
DHT had significant effects on the progression of plaque development in the aortas of 
ApoE
-/-
 mice and that, T and DHT effects were gender-specific. The observations with 
the exogenous sex hormone treatments, in the 3 regions of the arterial tree from this 
study are summarised in Table 4.2. It was found that in orchidectomised male mice, T 
treatment with an implant that gave the highest circulating levels, estimated to be 60 nM 
[256], showed decreased plaque development, however in mice given the lowest dose of 
0.25 cm T, estimated at 30 nM [256] there was increased plaque area compared to 
untreated, orchidectomised control mice. By contrast, in this study, T had no effect on 
plaque progression in female mice treated for 16 weeks at any dose. Dosage effects were 
found with DHT treatment in both sexes. The males only demonstrated changes at the 
lowest dose of 0.25 cm with an increase in plaque formation. Contrastingly, the females 
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showed that the higher doses of 1 cm and 0.5 cm DHT progressively reduced plaque 
area, compared to controls. 
 
To examine the effectiveness of the methodology employed for this study the en face Oil 
Red O and H&E staining results are summarised in Table 4.2. The en face method gave 
similar results to the H&E staining producing equivalent data sets, therefore, making the 
methods comparable. For almost all measurements, the en face Oil Red O method gave a 
larger fold-difference most probably reflective of a larger amount of plaque that could be 
measured, possibly increasing the accuracy. As discussed in Chapter 3, both methods 
have their advantages and disadvantage in analysing plaque area. For this study the en 
face Oil Red O method, even though it is technically more difficult, was less time 
consuming and labour intensive. Therefore, the en face methodology would be the 
preferred technique used to investigate plaque formation between the treatment groups. 
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Table 4.2  Summary of T and DHT effects on plaque formation in male and 
female ApoE
-/- 
mice  
  Testosterone* DHT* 
Gender Region 0.25 cm 0.5 cm 1 cm 0.25 cm 0.5 cm 1 cm 
Female Tree ↔ ↔ ↔ ↔ ↓ ↓ 
 Aortic Arch ↔ ↔ ↔ ↔ ↔ ↓ 
 Aortic sinus  ↔ ↔ ↔ ↔ ↓ ↓ 
Male Tree ↑ ↔ ↓ ↑ ↔ ↔ 
 Aortic Arch ↑ ↔ ↓ ↑ ↔ ↔ 
 Aortic sinus  ↑ ↔ ↓ ↑ ↔ ↔ 
*Arrows indicate increasing (↑), decreasing (↓), or no effect (↔) on plaque area in 
response to T and DHT treatment (P<0.05) compared to the ovariectomised or 
orchidectomised controls. 
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4.4.1 Testosterone dose affects plaque formation in male mice in a dose-
 dependent manner 
This is the first time that dosage effects have been tested on atherosclerotic lesion 
development. The results show an inverse relationship between plaque area and T dose 
in male mice. Final serum T levels have not been determined in this study as the 
experiments are in the progress of being completed. However, it has been estimated 
from previous studies that a 1 cm implant in the orchidectomised male gives an 
approximate serum T value of 60 nM, a 0.5 cm implant an approximate T value of 45 
nM, and a 0.25 cm implant an approximate T value of 30 nM [256]. Therefore, the 1 cm 
T implant would deliver T at approximate 5 times physiological concentration of intact 
males [256]. This high dose resulted in decreased plaque area. This result correlates well 
with previous studies examining T treatment in animal models that have also 
demonstrated a beneficial effect on plaque development [50, 57, 96-98, 100, 122] 
(reviewed in Table 1.4). For example, New Zealand white rabbits fed a high fat diet and 
treated with high doses of T showed a decrease in atherosclerosis formation at the end 
point of the study [50, 99, 100, 102, 104]. A series of mouse studies using male 
C57Bl/6, LDLR
-/-
 and ApoE
-/-
 mice found that high dose T treatment decreased 
atherosclerotic plaque formation [57, 98, 105, 122]. In addition, the current results are 
entirely consistent with previous results obtained in this laboratory, which also showed 
that a 1 cm T implant decreased early atherosclerotic plaque formation in young male 
ApoE
-/-
 mice that were treated for 8 weeks [122]. There are a number of explanations for 
the atheroprotective effect of high dose T that will be discussed in detail later but it 
could be that (1) T is being metabolised via aromatase to E2 and that E2 is 
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atheroprotective via the ER and/or (2) high doses of T induces a protective vasodilatory 
effect that reduces plaque formation. 
 
In male mice, the lowest dose of T was found to increase plaque area, while the 
intermediate dose had no effect, relative to the orchidectomised controls. These results 
are in agreement with a series of previous studies that showed T to have either no effect 
or increase plaque formation [40, 48, 54, 56, 93-95, 103]. The final concentrations of 
serum T were often not reported therefore it is difficult to conclude that the effect on 
plaque were due to lower T concentrations. The route of T administration that was used 
to deliver the hormone varies from study to study and it maybe that oral vs injection vs 
diffusion all lead to different effects. For example, the studies that administered T orally 
tended to have increased rates of plaque development [54, 103]. This may be because T 
needs to pass through the gut and liver before it reaches the blood therefore final 
circulating T concentrations are reportedly lower [54, 103]. Additionally, significantly 
greater systemic metabolism of the hormone would be expected via this route than via 
subcutaneous implantation or intramuscular injections. Therefore, it may be no 
coincidence that the oral administered studies were consistent with the results found for 
the lower administered doses in the current study. This now needs to be explored further. 
 
What can be concluded from the results in this study is that regardless of what final 
concentrations of serum T may have been obtained in the previous studies, T has varying 
effects on plaque development that depend on final circulating serum concentrations. 
Thus, dose is highly important and this has been clearly demonstrated in this study by 
examining multiple doses concurrently.  
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Interestingly, the pro-atherogenic effects of low T and the protective effects of T found 
with higher doses are highly consistent with effects found clinically. Numerous studies 
have found that it is low concentrations of endogenous hormones that are associated 
with increased CVD risk [19, 88, 90, 291, 296, 297]. Also, supraphysiological doses of 
T have been shown to be of vascular benefit in men with an increase in arterial dilation 
that increased blood flow as well as increased vascular tone in patients with coronary 
heart disease and patients with a history of myocardial ischemia [86, 89, 298-300].  
 
4.4.2 The effect of testosterone on lesion development in females 
In contrast to the atheroprotective effects of T treatment in males found in previous 
studies, in females, T has rarely been found to be protective, but more consistently 
results in increased plaque formation [43, 50, 106, 122]. Previous studies showed T to be 
atherogenic in female chicks, monkeys and rats. Toda et al [54] showed that female 
chickens given 0.1% T orally resulted in an adverse lipid profile, increased smooth 
muscle cell (SMC) death and increased lipid vacuole accumulation in the interlamellar 
connective tissue and SMC in the aorta. Cholesterol-fed female cynomolgus monkeys 
treated with T implants also showed an increase in atherosclerotic lesions [43]. In 
contrast to results found in our previous laboratory study [122], where a 1 cm implant 
increased plaque significantly after 8 weeks of treatment, increasing treatment time to 16 
weeks in this study did not further increase the rate of plaque development, rather there 
was no significant difference found between plaque area in controls and T-treated 
female mice. In fact, it was found that at no concentration of T administered was there a 
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significant effect on atherosclerosis development in female mice. It is unclear why this 
null result was obtained but it may be that this result is due to the stage of lesion 
development with much more plaque evident in 20-week old mice overall than in 12-
week old mice. T may increase early fatty streak formation however have no effects on 
plaque progression.  
 
One investigator showed a null effect of T treatment on atherosclerosis in female 
animals, similar to that found in the current study. The results from Chen et al (1996) 
[56] used Sprague-Dawley rats which were either left intact or ovariectomised then 
divided into untreated or treated groups. Balloon injury treatment was performed in the 
carotid arteries of rats. The balloon injury methodology causes an early phase of 
atherosclerosis model where the denuding of the endothelium induces migration and 
proliferation of SMC in the affected area of the vessel causing myocardial thickening. 
The animals were then treated by subcutaneously implanting 1.5 cm silicone elastomer 
capsules filled with crystalline
 
testosterone propionate or left empty and treated for 2 
weeks. There was a significant increase in myointimal thickening in the ovariectomised 
females not observed in the intact animals. The T replacement did not further enhance 
this response [56] showing that T had a null effect.  
 
A reason for the null effect observed in the T treated females in this study may be due to 
the high doses of T administered. The females were given the same doses as the male 
animals. Kemp, CJ et al [294] showed that physiological T levels in female C57Bl/6J 
mice were much lower than the males with a circulating serum concentration of 0.29 ± 
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0.06 ng/mL and 6.7 ± 0.4 ng/mL, respectively. The three doses administered to the 
female mice, would all be at very supraphysiological levels. The high doses might 
account for the null effect observed by acting as a vasodilator and offset the atherogenic 
effects of T that has been shown in other studies. 
 
From the previous study completed in our laboratory, M. Hill (2006) [122] had 
conflicting results in the 1 cm treatment in female groups. The aortic sinus showed a null 
effect with T treatment on plaque levels whereas the aortic arch showed a significant 
increase in plaque levels. In the present study, neither the arterial tree nor the aortic sinus 
showed any effect with T treatment. The difference between the two studies is the length 
of treatment time. It may be that T accelerates early plaque formation in the aortic arch 
and that this difference has been lost by 16-weeks when more plaque has formed.  
 
4.4.3 Atheroprotective effects of T via the metabolism to estradiol 
An explanation for the atheroprotective effects of T in male mice may lie in the ability 
of T to be converted to E2 via aromatisation. The enzyme, cytochrome P450 aromatase 
(referred to as aromatase), is expressed in the vasculature by endothelial cells, smooth 
muscle cells and monocyte-derived macrophages in both males and females [107, 301]. 
Estrogens have demonstrated cardioprotective influences via changes in serum lipid 
profiles, direct actions on lipid accumulation in the vascular endothelium and effects on 
vascular motility and contractility [34, 302]. E2 has been shown to reduce the 
development of atherosclerotic plaque in animal models and epidemiological studies 
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[44, 46, 49, 51, 53, 57, 105, 303]. Thus, it is hypothesised that T is being aromatised to 
E2 and that E2 is then acting via the ER pathway to be atheroprotective [57, 97]. 
 
This theory was revealed in studies performed by Nathan et al (2001) [57], where male 
LDLR-/- mice treated with T showed a decrease in plaque formation and a decrease in 
VCAM-1 expression [57, 116]. When an aromatase inhibitor, anastrozole, was used in 
conjunction with T the effect was attenuated indicating a role for aromatisation in this 
effect. Other studies have shown a similar effect with aromatase and ER inhibitors [97, 
102]. Unpublished [122] findings from our laboratory have shown that reduction of 
plaque area in males in response to high doses of T was associated with an increase in 
aromatase expression. Together, these results suggest that T actions via the ER are 
protective. Local pre-receptor mechanisms involving T metabolism therefore appear to 
be important in regulating plaque formation and may play a significant role in the 
differential effect of T on plaque formation between genders.  
 
In this study, the expression of aromatase was not examined. We postulate that the 
variable effects of T dose found may be a result of variable aromatase activity induced at 
the different concentrations. Enzyme activities are known to be regulated around 
substrate concentrations and the relevant Km of each enzyme [304]. At the lower doses 
of T administered, the local concentration of T may be too low for activation of the 
aromatase enzyme, resulting in limited T metabolism to E2, and therefore, a direct 
pathway of T action via the atherogenic AR pathway, rather than via the protective ER 
pathway. It may be that T via the ER is protective and T via the AR is atherogenic. This 
now needs to be explored further. 
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4.4.4 The effect of DHT on plaque formation in male mice 
A previous study in our laboratory showed DHT induced a trend to increase plaque 
levels in male mice, however, the result did not reach statistical significance [122]. To 
investigate further the potential atherogenic effect of DHT, a longer DHT treatment time 
of 16 weeks was tested in both male and female mice.  
 
As just discussed, we speculate that the atheroprotective effects in male mice were due 
to the conversion of T to E2 via aromatase [57, 97, 122]. DHT, the non-aromatisable 
androgen was included in the study as it has been used as a potent androgen in in vitro 
studies investigating the effects of androgens via the AR on vascular cells [149-151]. As 
DHT is non-aromatisable, it acts only via the AR to induce a genomic response. 
Therefore, it was thought that a response seen would be a purely androgenic response.  
 
However, recent findings show that DHT can be metabolised to 5α-androstane-3β, 17β-
diol (3β Adiol) by 3α/3β-hydroxysteroid dehydrogenase (3β-HSD) [305-307]. This 
metabolite 3β Adiol of DHT has been shown to be active in the prostate and can act as a 
ligand for the ER, with a much higher binding affinity for ERβ [308]. There have been 
no studies to confirm if 3β-HSD is expressed or active in the vasculature [119, 121] and 
whether there is local production of 3β Adiol. For the current study, the effects of 3β 
Adiol and 3β-HSD within the vasculature can not be excluded and may help explain the 
atheroprotective effect of high dose DHT in female mice. The role of 3β-HSD now 
needs to be investigated further. 
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In the current study, high exogenous dose of DHT did not produce a significant effect on 
atherosclerotic lesion development in males. However, the lowest dose showed 
significantly increased plaque formation. Male mice have a naturally circulating 
concentration of  0.17 nM ± 0.06 in an intact model, therefore, the low dose of 0.75 nM 
[256] may still have delivered a high physiological dose, even approaching 
supraphysiological. The results from this study could possibly be higher concentrations 
of DHT being converted to estrogenic metabolites as well as non-genomic vasodilatory 
protective effects [107, 108, 301].  
 
DHT treatment in male animal models have been shown to be atheroprotective and 
atherogenic. Stokes et al (2000) [96] treated male rats with 40 mg DHT implants for 13 
weeks, showed a decrease in total cholesterol, indicating a potential protective effect on 
CVD. Conversely, another investigation, examined male Macaca fascicularis monkeys 
treated with DHT ranging from 0.25-2mg/kg/d intra musclar injections for 8 weeks and 
saw a decrease in HDL. HDL serum levels affect total serum lipid profiles, the decrease 
in HDL levels are suggestive of levels that would produce a proatherogenic effect [93]. 
At the lower concentration, DHT effects observed are more likely through actions via 
AR, although this theory still remains to be tested. 
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4.4.5 The effect of DHT on plaque development in females 
By contrast, to the DHT treated males, the females treated with DHT produced a similar 
pattern to the T treated males. At the higher doses of DHT there was a decrease in the 
amount of plaque formation. This may be due to the conversion of the DHT to 3β Adiol 
via 3β-HSD, having an effect via the ER, producing a decrease in atherosclerotic plaque 
formation. Alternatively the high doses of DHT may also be acting as a vasodilator and 
thus, the dilated vessels cause less resistance may be a reason for the decrease in plaque 
formation. 
 
The results from this study were consistent with previous studies from our laboratory M. 
Hill (2006) [122] that showed a significant decrease in atherosclerotic plaque area after 8 
weeks of DHT treatment in the female mice. Therefore, it appears DHT at high doses 
has atheroprotective effects in the female but is potentially atherogenic in males. In both 
male and females, the effects of DHT at higher concentrations that were tested were 
either null or atheroprotective. These effects may have been due to the conversion of 
DHT to 3β Adiol. 
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4.4.6 Pathways of atherosclerosis formation 
This study has shown dose response effects of T and DHT treatment on plaque 
formation that are gender-specific. It is unclear what mechanisms are being used to 
regulate the formation of atherosclerosis. Androgens act via several pathways to regulate 
gene expression that can influence vascular cell responses. They interact with AR 
directly to up-regulate transcription of AR specific genes and are also able to interact 
with AR and induce a non-genomic effect. At high concentrations, T has been shown to 
increase vasodilatation in coronary arteries of rats [298, 309, 310], with direct calcium 
antagonism via the MAPK pathways. Therefore, concentrations of the hormone may 
define which pathway is dominantly activated. We speculate that the different doses of 
androgens can differentially act via the genomic pathway or a non-genomic pathway. 
 
Alternatively, to this proposal, T can be metabolised to E2 [107, 108], which has 
cardioprotective effects in the vasculature [25, 26, 311]. This raises the question, does 
the concentration of T impact the activations of the enzymes, aromatase or 5α-
reductase? Also is 3β-HSD, responsible for converting T or DHT to its metabolites? 
Androgens, either exogenously introduced to the animal or endogenously expressed 
hormones may influence the effects produced in this study. Evidence from studies such 
as M. Hill (2006), Nathan et al (2001) and Nettleship et al (2007) [57, 97, 122]  showed 
that aromatisation played a major role in the atheroprotective effects observed with the T 
studies, thus aromatase may play a major role in the protective effects observed in the 
male mice from this study. Aromatase expression was not measured in this current study 
but would be worth examining in future studies.  
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Similarly, DHT at the lowest dose of 0.25 cm increased plaque formation in the males. 
This could suggest that DHT is not being metabolised to 3β Adiol and is only acting via 
the AR therefore, unable to act via the ER. It could now be postulated that there may be 
gender-specific expression patterns of 3β-HSD similar to the gender-specific expression 
of aromatase. As with aromatase, this needs further investigation.  
 
It can be speculated that at high doses of androgens the non-genomic pathway is 
stimulated. It has been shown that E2 is able to act via a GPR30 G-coupled receptor to 
induce a signalling cascade via phospholipase C (PLC) and D-myo-inositol-1,4,5-
trisphosphate (IP3) to induce a rise in intracellular Ca
2+ 
and thus increase nitric oxide 
(NO) expression [312]. There is evidence that T and DHT are able to induce the 
phosphotidylinositol 3-kinase (PI3K) pathway via Extracellular-signal-regulated-kinase 
(ERK)/mitogen-activated protein kinase (MAPK) [313] to stimulate the translocation of 
endothelium nitric oxide synthase (eNOS) into the nucleus that in turn increases NO 
production [309, 310, 313]. There is also evidence from investigator Bae et al (2005) 
[314] that treating rat vascular SMC with high doses of T and DHT repressed inducible 
nitric oxide synthase (iNOS) protein and mRNA expression, which is an inflammatory 
marker associated with CVD. NO has demonstrated its ability as a vasodilator in the 
vasculature [90, 315], therefore, different concentrations of androgens may affect the 
synthesis of NO and may be the underlying mechanism in the variance in plaque 
development.  
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4.4.7 Summary and conclusions 
This study has investigated the effects of T and DHT, two naturally occurring male sex 
hormones on atherosclerotic plaque formation, in both male and female Apo E
-/- 
mice. It 
is the first to show that T and DHT have dose-dependent effects on plaque formation in 
male mice, and that similarly DHT has dosage effects in female mice. The data suggests 
that in males, lower T dose treatment acts in a pro-atherogenic manner while higher 
treatment concentrations act in an atheroprotective manner. This is significant as it may 
explain the variable results found in previous studies examining male animals, and it 
emphasises that the dose of T administered is very important to final outcome. We 
speculate a dose-response effect of T may be a result of variable modulation of pre-
receptor mechanisms involving T metabolism prior to activation of sex steroid receptors, 
or receptor-dependent mechanisms that involve differential modulation of non-genomic 
and genomic pathways that are dose-dependent. In females, conversely there was no 
change in plaque formation with any dose of T, which may be due to the gender-specific 
expression of both AR and/or aromatase. These are questions that certainly need to be 
addressed in the future to understand the role of T in the atherosclerosis.  
 
Alternatively, the higher doses of DHT in females had a similar protective effect that 
was shown in previous studies, which was lost at lower doses. The atheroprotective 
effect of DHT at high doses was not observed in males, which may be due to the 
conversion of DHT to 3β Adiol via 3β-HSD. There may be a similar gender-specific 
expression of aromatase with higher expression of 3β-HSD in females compared to 
males. Therefore, the results observed were from DHT being converted to 3β Adiol, 
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acting via the ER. Similarly, to the high T doses, the high doses of DHT could 
potentially have vasodilatory effects. These theories need to be further investigated, to 
get a better comprehension of DHTs role in atherosclerotic plaque formation. 
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CHAPTER 5 - The Effect of Androgen Exposure on the 
Expression of AR Cofactor in Human Endothelial Cells and 
Monocyte Derived Macrophages 
 
5.1  Introduction 
 
As shown in the previous chapter, androgens can have a significant effect on the 
progression of atherosclerosis. While androgens work through their cognate receptor, the 
androgen receptor (AR), to initiate transcription at specific promoters, final AR activity 
is dependent not only on AR gene expression and maintenance of AR protein levels in 
the cell, but also upon a myriad of cofactors that interact with AR at various levels and 
either, activate or repress activity by a variety of mechanisms (described in Chapter 1, 
section 1.5.2).  
 
Loss or limitation of any of these cofactors may suppress the transactivational 
capabilities of AR and there is increasing evidence to show that cofactors have an 
important role to play in the androgen response of many cell types [166, 167, 249, 316]. 
To date, cofactor expression has been examined predominantly as it relates to endocrine 
tissues and their associated diseases where AR cofactors have been shown to be 
ubiquitously expressed in these tissues [248, 250, 254, 317-320]. Expression of a 
number of cofactors has been found to be altered in cells in diseased tissue [244-246, 
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249, 251, 254, 317, 321-324] and hormonal regulation of cofactor expression has been 
reported in breast, prostate and endometrial tissue [246, 248, 249, 251, 254, 255]. 
 
The role of cofactor proteins within the vasculature has not been extensively studied. It 
is not known if any, or all of these, cofactors are expressed in those cell types commonly 
involved in atherogenesis, or whether they are regulated by androgens. AR has been 
shown to play an important role in several facets of atherogenesis, including the up-
regulation of VCAM-1 expression of endothelial cells in response to DHT [151] and in 
foam cell formation in macrophages [152]. It has been demonstrated that cofactor 
expression is important in controlling AR activity in cells [155, 193, 316]. Therefore, it 
is hypothesised in this work that cofactor regulation in the vasculature could potentially 
play an important role in atherogenesis. If hormonal regulation is shown to significantly 
alter the expression of cofactors in vascular cells in vitro, modulation of their expression 
in situ by altering hormonal milieu either by exogenous hormone treatment or even with 
ageing, may play an important role in disease progression. 
 
Therefore, the aim of work in this chapter was to investigate in vitro whether AR 
cofactors were expressed in two vascular cell types important in the development of 
atherosclerosis, and whether their expression in these cells was modulated by treatment 
with the potent male hormone, DHT. A specific subset of AR cofactors was chosen for 
this study based on previous evidence of their hormonal regulation in endocrine tissues 
or their more specific association with the AR. The non-aromatisable androgen, DHT, 
was used rather than T to examine regulation of cofactor expression via the AR as T use 
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is often confounded by its ability to be aromatised to estradiol and hence, act via the 
estrogen receptors (ER).  
 
 
5.1.1  Aims 
 
Specifically, the aims were: 
(1)  To determine whether there was a gender-specific effect of DHT  
  exposure on AR cofactor mRNA expression in human umbilical vein 
  endothelial cells (HUVEC) and human monocyte-derived macrophages 
  (MDM) isolated from male and female donors; 
(2)  To follow up on any finding from (1) by measuring the effect of DHT 
  exposure on cofactor protein levels; 
(3)  To follow up (1) and (2) by investigating whether there was any in vivo 
  regulation of cofactor protein expression in the aortic sinus of ApoE
-/-
 
  male and female mice in response to treatment with both T and DHT. 
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5.2 Methods  
 
5.2.1  DHT treatment of HUVEC and MDM 
HUVEC were isolated from the umbilical cords of 3 male and 3 female donors (as 
described in Methods 2.5.1) Briefly, cells were cultured until passage 3 when they were 
seeded in 12-well plates at 1 x 10
6
 cells/well. The cells were treated for 24 hrs with 
either 0.1% (v/v) ethanol (vehicle control) or 400 nM DHT in phenol red-free M199 
complete medium with 20% (v/v) charcoal stripped human serum (Methods 2.5.3). After 
treatment, cells were washed twice with ice-cold PBS and total RNA was isolated using 
TRI reagent (Methods 2.6.1). 
 
Monocytes were elutriated from human buffy coats (obtained from the Australian Red 
Cross) from 3 male and 3 female donors (Method 2.5.2). Isolated monocytes were 
seeded in RPMI complete medium in 12-well plates at 1 x 106 cells/well. The cells were 
cultured for 8 days during which time the monocytes differentiated into macrophages 
(MDM). At day 8, MDM were treated with 400 nM DHT every 24 hrs for 48 hrs. Total 
RNA was isolated as described (Methods 2.6.1). 
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5.2.2  RNA quantitation and analysis 
All total RNA samples were quantitated and normalised to 100 ng/µL using the SYBR 
Green II assay (2.6.2). Reverse transcription-PCR (RT-PCR) (Methods 2.6.3) was used 
to produce cDNA. The products were then amplified with PCR (Methods 2.6.4), n=3, in 
triplicate to measure cofactor expression using the 10 primer pairs listed in Table 5.1. 
Androgen receptor (AR) mRNA levels were also measured. 
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Table 5.1 AR cofactor primer sequences used in this study 
Gene/ 
Cofactor Primer Primer Sequence (5’-3’) 
Annealing  
Temperature (°C)1 Cycles2 
      HUVEC MDM  HUVEC MDM
18S Sense  CGG CTA CCA CAT CCA AGG AA 55 55 16 16 
 Anti-sense  CGT GGA ATT ACC GCG GCT     
β2 Sense  CAT CCA GCG TAC TCC AAA GA 55 55 29 29 
 Anti-sense  GAC AAG TCT GAA TGC TCC AC     
AR Sense CGG CTA CCA CAT CCA AGG AA 55 55 33 35 
 Anti-sense ATG GCT GTC ATT CAG TAC TCC     
FHL2 Sense CGG CTG TGA CTG CAA GGA CTT 55 55 24 35 
 Anti-sense AGC AGT CGT TAT GCC ACT GCC     
SMRT Sense TAG GTG CCA TCT CCC AAG GAA 58 55 38 31 
 Anti-sense GAC GCA GGT AGT CCT CCT GT     
ARA55 Sense TCT GTG AGC TAG ATC GGT TGC 54 55 28 38 
 Anti-sense AAG GCG GTG GTC ACG ATC TTG TGT     
ARA70 Sense GCT TTG CAG AGT GTG TGT GTG 58 58 34 34 
 Anti-sense GGG GAA GTT ATG TTC CTC CG     
ARA160 Sense GTC TGG CAG CAG GTA CTT CAT 54 54 28 28 
 Anti-sense AGG AGT TCC ACT TCG TCC ACT     
ARA54 Sense GGA AGA GAC CCT AGC ATA CTT 52 52 26 26 
 Anti-sense TCT CTG CAG TCA CCT TAC ATG     
NCoR1 Sense TGA TGG GCT CTC TGA GCA GGA 55 55 29 29 
 Anti-sense TGC TGC CCA GTT ACG ACC ATG     
A1B1 Sense GGC AGA ATG GAA CCT ATG AAT 52 52 26 26 
 Anti-sense AGG GAA TTC GTA AGA AGA GGC     
ARA24 Sense ACG ACC TTC GTG AAA CGT CAT 52 52 26 26 
 Anti-sense ACA GGT CAT CAT CCT CAT CCG     
p300 Sense  CAG CAA CCA CAG CAG CAA CTC 55 55 32 32 
 Anti-sense  GTC GTC TCA AGA TGT CTC GGA ATT     
1
 optimal annealing temperatures 
2
 cycle numbers used in the end point analysis 
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PCR products were separated on 2% (w/v) agarose gels in 1 X TAE buffer containing 
ethidium bromide (0.625 mg/mL). DNA bands were visualised by UV illumination and 
an image was captured directly using UV Gel Doc software. Quantity One software 
version 4.6.1 (Bio-Rad Laboratories, Sydney, Australia) was then used to measure the 
band density from all treatment groups. All expression levels were normalised based on 
the expression of housekeeping genes, 18S and β2-microglobulin. Results are expressed 
relative to control samples. n=3 donors per group. Statistical significance was analysed 
using one-way ANOVA with Bonferroni’s Post-Hoc test, GraphPad Prism 5.0. 
 
5.2.3  Western blot of SRC-1 protein expression 
Protein extracted from HUVEC and MDM were separated by SDS-Page gel 
electrophoresis (Methods 2.7.3) and transferred to a PVDF membrane (Methods 2.7.4). 
The expression of SRC-1 protein was normalised to the control primary antibody, β-
actin (Methods 2.7.4). Statistical significance was analysed using one-way ANOVA 
with Bonferroni’s Post-Hoc test, GraphPad Prism 5.0. 
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5.2.4 Immunohistochemistry 
Aortic sinus sections (5 µm) were collected from male and female ApoE-/- mice treated 
with DHT and T, as described previously (Chapters 3 & 4). The sections were probed 
for SRC-1 protein levels using the method described in detail in Chapter 2 (Methods 
2.4). Each section was digitally captured using a Nikon Coolpix 100 camera connected 
to a BH-2 Olympus bifocal microscope at 10X magnification. Immunohistochemistry 
staining of SRC-1 was analysed semi-quantitatively by 6 independent researchers that 
were blinded to the conditions using a histologic score (HSCORE) test. This is 
calculated with the following formula; HS = ∑ Pi (i +1) where Pi denotes the percentage 
of stained cells and i denotes the intensity of staining. The staining intensity ranged from 
0, no staining; 1, slight staining; 2, medium staining; 3, strong staining [259-261]. 
Results of this experiment are reported as mean ± SEM compared to the ovariectomised 
(ovx) or orchidectomised (odx) control groups. Nonparametric Kruskal-Wallis test was 
used to detect differences between experimental groups.  
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5.3 Results 
 
5.3.1 The effect of DHT treatment on AR cofactor expression in HUVEC 
HUVEC were treated with 400 nM DHT for 24 hours. DHT treatment modulated some, 
but not all, AR cofactor expression examined in this cell type (Figures 5.1 to 5.3). The 
mRNA levels of ARA24, ARA54, ARA160 and SRC-1 were decreased between 1.1 to 
1.2-fold in both male and female cells in response to DHT treatment (P<0.05, n=3). 
Whereas the cofactor ARA24 for a male cells showed a 1.2-fold decrease (P<0.05, n=3) 
with DHT treatment, however, the females had a null effect (Figure 5.1). In contrast, 
DHT treatment increased p300 mRNA expression (1.1-fold for males and females, 
P<0.05) and NCoR1 mRNA levels 1.3-fold for female donors, (P<0.05) and 1.15 fold 
for male donors (P<0.05) (Figure 5.2). DHT treatment had no effect, however, on the 
mRNA expression levels of A1B1, ARA70, FHL2 and SMRT (Figure 5.3).  
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Figure 5.1 DHT treatment decreases mRNA levels of ARA24, ARA160, ARA54, 
and SRC-1 in HUVEC  
HUVEC were exposed for 24 hrs to 400 nM DHT or 0.1 % ethanol (vehicle control; C). 
Total RNA was extracted, normalised, and mRNA levels of ARA24 (a), ARA160 (b), 
ARA54 (c), and SRC-1 (d) were measured by RT-PCR. Results are expressed relative to 
male or female control treated cells and normalised to the housekeeping gene, 18S. 
Values are given as mean ± SEM, n=3. Significant differences between controls and 
treated groups were analysed by one-way ANOVA with Bonferroni’s Post-Hoc test, 
with P<0.05 (*) considered significant. 
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Figure 5.2 DHT treatment increases mRNA levels of p300 and NCoR1 in 
HUVEC 
HUVEC were exposed for 24 hrs to 400 nM DHT or 0.1 % ethanol (vehicle control; C). 
Total RNA was extracted, normalised, and mRNA levels of p300 (a), NCoR1 (b) were 
measured by RT-PCR. Results are expressed relative to male or female control treated 
cells and normalised to the housekeeping gene, 18S. Values are given as mean ± SEM, 
n=3. Significant differences between controls and treated groups were analysed by one-
way ANOVA with Bonferroni’s Post-Hoc test, with P<0.05 (*) considered significant. 
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Figure 5.3 DHT has no effect on AR, A1B1, ARA70, FHL2 and SMRT mRNA 
levels in HUVEC. HUVEC were exposed for 24 hrs to 400 nM DHT or 0.1 % ethanol 
(vehicle control; C). Total RNA was extracted, normalised, and mRNA levels of AR (a), 
A1B1 (b), ARA70 (c), FHL2 (d), SMRT (e), were measured by RT-PCR. Results are 
expressed relative to male or female control treatment cells and normalised to the 
housekeeping gene, 18S. Values are given as mean ± SEM, n=3. Significant differences 
between controls and treated groups were analysed by one-way ANOVA with 
Bonferroni’s Post-Hoc test, with P<0.05 (*) considered significant. 
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5.3.2  The effect of DHT treatment on AR cofactor expression in MDM. 
The effect of 400 nM DHT treatment on cofactor expression in MDM was far less 
significant than that found for HUVEC. Several weak trends were observed in the 
regulation of mRNA expression in these cells but statistical significance was not reached 
in any instance (Figures 5.4 and 5.5).  
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Figure 5.4 Effect of DHT exposure on cofactor mRNA levels in MDM (I) 
MDM were exposed for 48 hrs to 400 nM DHT or 0.1% ethanol (vehicle control; C). 
Total RNA was extracted, normalised, and mRNA levels of ARA54 (a), ARA70 (b), 
FHL2 (c), AR (d), SRC-1 (e) and p300 (f) were measured by RT-PCR. Results are 
expressed relative to male or female control treated cells and normalised to the 
housekeeping gene, β2-microglobulin. Values are given as mean ± SEM, n=3. 
Significant differences between control and treated groups were analysed by one-way 
ANOVA with Bonferroni’s Post-Hoc test, with P<0.05 (*) considered significant. 
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Figure 5.5 Effect of DHT exposure on cofactor mRNA levels in MDM (II)  
MDM were exposed for 48 hrs to 400 nM DHT or 0.1% ethanol (vehicle control; C). 
Total RNA was extracted, normalised, and mRNA levels of NCoR1 (a), SMRT (b), 
ARA24 (c), A1B1 (d) and ARA160 (e) were measured by RT-PCR. Results are 
expressed relative to male or female control treatment cells and normalised to the 
housekeeping gene, β2-microglobulin. Values are given as mean ± SEM, n=3. 
Significant differences between control and treated groups were analysed by one-way 
ANOVA with Bonferroni’s Post-Hoc test, with P<0.05 (*) considered significant. 
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5.3.3  SRC-1 protein expression in DHT-treated HUVEC 
HUVEC isolated from male and female donors showed a decrease in SRC-1 mRNA 
levels in response to DHT treatment. The availability of an antibody against SRC-1 
enabled the examination of SRC-1 protein levels in these same cells by western blot 
analysis (Methods 2.5). SRC-1 protein levels did not reflect that found for mRNA levels 
in these cells. SRC-1 showed a strong gender difference with control male donor cells 
having 2-fold greater expression than control female donor cells (P<0.05) (Figure 5.6). 
SRC-1 expression in response to DHT treatment was also gender-specific. DHT 
treatment increased SRC-1 protein levels in male cells (1.1-fold, P<0.05), but had no 
effect in female cells (Figure 5.6). 
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(A) SRC-1 expression in HUVEC 
 
 
 
 
 
 
 
 
Figure 5.6  SRC-1 levels from DHT-treated HUVEC 
HUVEC were treated with 400 nM DHT or 0.1% ethanol (vehicle control; C) for 24 hrs. 
Total protein was extracted and 20 µg electrophoresed on an SDS-PAGE gel, transferred 
to a nitrocellulose membrane and probed with anti-SRC-1 or anti-β-actin antibody (A). 
Band intensity was quantified using Quantity One software (Bio-Rad). SRC-1 protein 
expression was normalised to the housekeeping protein β-actin and expressed relative to 
the female control (100%) (B). Values were given as mean ± SEM, n=3. Significant 
differences between control and treated groups were analysed by one-way ANOVA with 
Bonferroni’s Post-Hoc test, with P<0.05 (*) considered significant. 
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5.3.4     The effects of T and DHT treatment on SRC-1 protein levels in the aortic 
sinus of 20-week old ApoE
-/-
 mice 
Sections taken from the aortic sinus of treated and untreated mice as previously 
described (Methods 2.2) were used to examine the effect of androgen treatment on SRC-
1 expression in vivo. Male and female mice (n=4) were compared by 
immunohistochemistry also previously described (Methods 2.4). Groups included intact 
(normal), ovariectomised (ovx) or orchidectomised (odx), untreated or treated with 0.25 
cm, 0.5 cm or 1 cm T or DHT implants for 16 weeks.  
 
Immunohistochemical staining for SRC-1 protein expression in the aortic sinus of 
female ApoE
-/-
 mice showed that there was no change in SRC-1 expression in 
ovariectomised female mice treated with any concentration of DHT, relative to the 
ovariectomised control group (Figure 5.7, 5.8). In contrast to DHT effects, T 
administration to ovariectomised female mice at the lowest dose tested (0.25 cm 
implant) increased SRC-1 expression 1.7-fold (P<0.05) (Figure 5.7, 5.8). This effect was 
lost, however, at the higher doses of T (1 cm implant) and a small, but significant, 
decrease, in SRC-1 expression was seen with the medium T treatment (0.5 cm implant).  
 
In the males SRC-1 expression increased 1.5 to 2-fold (P<0.05) compared to the 
orchidectomised control mice treated with the lower doses of DHT (0.25 cm, 0.5 cm), 
relative to the orchidectomised controls. There was, however, no detectable change in 
SRC-1 expression in mice treated with the highest 1 cm dose (Figure 5.9, 5.10).  
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The orchidectomised male mice treated with T showed dose-dependent increases in 
SRC-1 protein expression with 0.5 cm and 1 cm T implant treatment had 1.2 fold and 
2.2 fold increase respectively (P<0.05) (Figure 5.9, 5.10).
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Figure 5.8  Mean SRC-1 protein levels in aortic sinus of androgen treated female 
ApoE
-/- 
mice using immunohistochemistry 
Each section was digitally captured using a Nikon 100 camera connected to a BH-2 
Olympus bifocal microscope at 10X magnification. The immunohistochemistry staining 
intensity and percentage of stained cells of the images were scored by 6 people and the 
H-score calculated as described (Methods section 5.2.4). Results of this experiment are 
reported as mean ± SEM compared to the ovariectomised (ovx) control group. 
Nonparametric Kruskal-Wallis test was used to detect differences between experimental 
groups. Statistical significance was expressed relative to the female ovx controls, 
*P<0.05.  
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Figure 5.10 Mean SRC-1 protein levels in aortic sinus of androgen treated male 
ApoE
-/- 
mice using immunohistochemistry 
Each section was digitally captured using a Nikon 100 camera connected to a BH-2 
Olympus bifocal microscope at 10X magnification. The immunohistochemistry staining 
intensity and percentage of stained cells of the images were scored by 6 people and the 
H-score calculated as described (Methods section 5.2.4). Results are reported as mean ± 
SEM compared to the orchidectomised (odx) control group. Nonparametric Kruskal-
Wallis test was used to detect differences between experimental groups. Statistical 
significance was expressed relative to the male odx controls, *P<0.05. 
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5.4  DISCUSSION 
 
Androgens play an essential role in mediating physiological responses in a wide 
variety of tissues [325]. Androgens typically exert their effects in cells via activation 
of their cognate receptor, and it has been shown that alteration of AR levels has an 
effect on final levels of androgenic action [326]. Androgen regulation of AR, more 
specific regulation by the non-aromatisable androgen, DHT, has been shown to be 
important in modulating several atherogenic processes, including VCAM-1 
expression on endothelial cells [151] and cholesterol accumulation in macrophages 
[149]. The activity of the liganded AR molecule at hormone-responsive promoters is 
itself, dependent on an array of cofactors that can either enhance or inhibit 
transcriptional activation [166, 230]. Modulation of cofactor expression in both 
healthy and diseased tissue has been shown to be important for androgen/AR action 
[194]. Analogous to the auto-regulation of receptors by their respective hormones, 
hormonal regulation of cofactor expression may also be a mechanism whereby, 
androgen action can be controlled in a tissue or cell-specific fashion [185, 193, 242, 
327].  
 
To date, there is no information in the literature regarding hormonal regulation of 
cofactors in the vasculature. Work in this chapter presents novel results showing that 
specific cofactors are expressed in vascular cells and that they can be regulated by 
DHT. The hormonal regulation of several androgen receptor cofactors was examined 
in two atherogenic cell types. There was a distinct difference in regulation of 
cofactor mRNA expression between the two cell-types investigated by the potent, 
non-aromatisable androgen, DHT. Several of the cofactors studied showed hormonal 
A B 
C 
 190
regulation in HUVEC, however, in MDM only weak trends were observed but no 
significant regulation of any of the cofactors was seen.  
 
5.4.1 Hormonal regulation of AR cofactors in HUVEC 
In HUVEC treated with DHT, AR cofactors showed both up- and down-regulation of 
mRNA expression levels compared to controls and gender-specific effects were also 
observed. Table 5.2 shows a summary of the regulatory trends found in this study for 
cofactor expression in both HUVEC and MDM in response to DHT treatment.  
 
Treatment of HUVEC with DHT for 24 hrs resulted in the down-regulation of 
cofactors SRC-1, ARA54 and ARA160 mRNA expression, in both male and female 
donors. The DHT treatment increased expression of p300 and NCoR1 in both 
genders. ARA24 was down-regulated in response to DHT but only in male, not 
female-derived, cells. There was a lack of DHT regulation observed in HUVEC for 
the cofactors FHL2 and A1B1, and the co-repressor SMRT.  
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Table 5.2  Summary of DHT effects on cofactor expression in MDM and 
HUVEC 
Receptor/ 
Cofactor 
MDM 
(mRNA) 
HUVEC 
(mRNA) 
HUVEC 
(protein) 
 Male Female Male Female Male Female 
AR ↔ ↔ ↔ ↔ ND ND 
ARA160 ↔ ↔ ↓ ↓ ND ND 
ARA24 ↔ ↔ ↓ ↔ ND ND 
ARA54 ↔ ↔ ↓ ↓ ND ND 
ARA70 ↔ ↔ ↔ ↔ ND ND 
FHL2 ↔ ↔ ↔ ↔ ND ND 
SRC-1 ↔ ↔ ↓ ↓ ↑ ↔ 
P300 ↔ ↔ ↑ ↑ ND ND 
A1B1 ↔ ↔ ↔ ↔ ND ND 
SMRT ↔ ↔ ↔ ↔ ND ND 
NCoR1 ↔ ↔ ↑ ↑ ND ND 
Arrows indicate an increase (↑), decrease (↓) expression in response to DHT 
treatment, no effect (↔) and not determined ND. 
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Hormonal regulation of ARA160 has not previously been examined, however, the 
down-regulation of SRC-1 and ARA54 in response to DHT was consistent with 
previous observations in a preneoplastic epithelial cell line (PNT2) [246]. DHT (5 
nM) suppressed these cofactors after 2 and 6 hrs treatment, returning to base line 
after 24 hrs. In the same study, both cofactors were up-regulated in response to 250 
nM estrogen and this response was sustained for 24 hrs. ARA70 was significantly 
down-regulated by DHT  [246], however, other investigators found that DHT 
increased, rather than decreased, ARA70 expression [254]. The findings presented 
here however, showed ARA70 expression did not alter with DHT treatment. A 
similar lack of effect was also found in response to T, DHT and estrogen (E2) in 
several prostate cancer cell lines at 24 hrs [246, 249, 255]. Regulation of the ARA70 
cofactor therefore, appears to be cell-type dependent. 
 
SRC-1 and p300 are well-characterised co-activators which, can act within the 
nucleus of the cell to recruit transcription factors enhancing AR binding to the ARE 
and increasing AR transactivational ability [328]. SRC-1 has been identified to act on 
chromatin remodelling to activate transcription of AR target genes [159, 329]. Over-
expression of p300 has been associated with altered enzymatic activity and protein-
protein interaction, and also augment AR target gene transcription [200]. Both of 
these cofactors were selected in this study because of their documented interaction 
not only with hormone receptors such as progesterone receptor (PR), ER, thyroid 
receptor (T4R) and AR [330] but also with an array of other transcription factors 
[331-333] that includes activating protein-1 (AP-1), serum response factor, nuclear 
factor-κB (NF-κB) and CAMP regulatory element binding protein (CREB) [334].  
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In this study, p300 mRNA levels in HUVECs showed a significant increase in 
response to DHT treatment in both genders while SRC-1 mRNA levels were 
significantly decreased. Misiti et al (1998) [249]  investigated the expression patterns 
of SRC-1 and p300 RNA in different cell lines and in different types of rat tissue and 
observed their response to thyroid hormone (T3) and estrogen treatment. In vitro, 
studies using GH3 cells (rat pituitary) found SRC-1 was the most regulated with both 
hormonal treatments while p300 expression remained unchanged. T3 (100 nM) 
induced a significant increase in SRC-1 mRNA at 6 and 24 hrs returning to basal 
levels at 48 hrs post-treatment. Conversely, estrogen treatment showed a down-
regulation of SRC-1 mRNA of 34% and 28% at 6 and 24 hrs, respectively 
[249].When in vivo studies were performed using estrogen (0.5 µg/100 g body 
weight) in male Sprague-Dawley rats, SRC-1 recapitulated the in vitro results 
showing an initial decrease in mRNA expression of 56% of the control at 4 hrs, 65% 
at 6 hrs and then returning to basal levels of expression at 48 hrs. Once again, the 
p300 mRNA levels showed no significant changes in vivo in the pituitary tissue. 
Results from both studies show that these two cofactors can be differentially 
regulated in the same cell type. Both are hormonally regulated in a hormone and 
tissue-type specific fashion and consistently their regulation is in a variable manner 
to one another. 
 
In this study, the hormonal regulation of two co-repressor proteins NCoR1 and 
SMRT has been examined. These 2 cofactors interact with AR and have been shown 
to suppress AR target gene expression when up-regulated in prostate cancer cell lines 
[231]. These findings showed that DHT treatment significantly increased the mRNA 
levels of NCoR1 in HUVEC compared to male and female control donor cells. This 
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is the first study to show that NCoR1 can be hormonally regulated in any cell type in 
response to androgens. By contrast, in this study DHT treatment had no effect on 
SMRT expression in HUVEC or MDM. This is in keeping with a previous study in 
rat pituitary cells where SMRT expression was unaffected by 48 hrs DHT treatment 
[249]. However, in the same study it was demonstrated that SMRT expression 
changes with time in response to E2 treatment, with a 1.8-fold increase in mRNA 
levels after 2 hrs but then a reduction to 65% of the control at 6 hrs post E2  
treatment [249], with levels then remaining repressed for up to 48 hrs. Such 
hormonal regulation of SMRT by E2 was not observed in rat uterus [248]. Together, 
the results suggest that hormonal regulation of SMRT is hormone-, and cell/tissue 
type-, specific.  
 
In this study, DHT treatment did not change the expression of FHL2 and A1B1 in 
HUVEC. There have been no prior studies examining the hormonal regulation of 
A1B1 expression in endothelial cells. Conversely, Muller et al (2000) [225], used 
immunoprecipitation experiments to demonstrate that nuclear extracts from cell line 
293 transfected with AR flagged-FHL2 showed DHT treatment increased AR 
coimmunoprecipitation with FHL2. This indicated that DHT treatment increased the 
conjugation of the proteins that may influence transcriptional activity [225]. The 
current study however, showed no change in FHL2 expression with DHT treatment 
compared to the control cells. 
 
The current study also demonstrated for the first time that DHT treatment regulated 
ARA24 and ARA160 mRNA levels. ARA24 expression was down-regulated in a 
gender-dependent fashion, with mRNA levels decreased after 24 hrs of DHT 
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treatment in HUVEC isolated from male, but not female, donors. Although more 
work is required, especially the need to measure protein levels, it appears that 
ARA24 is both gender- and hormonally-regulated.  
 
ARA24 is a G protein that acts as a general nuclear export factor also known as 
RanGTPase [335]. Kahana et al (1999) [335] showed that ARA24 may play a role 
for the export of importin proteins from the nucleus [336]. Therefore, an increase in 
ARA24 expression may act to enhance the transport of proteins into and out of the 
nucleus. Hsiao et al (1999) [161] demonstrated that ARA24 is able to interact with  
AR  and may enhance AR recycling from the nucleus back into the cytoplasm. These 
investigators showed that ARA24 interaction with AR may play an important role in 
the transcriptional activity of the AR.  
 
5.4.2  Cofactor expression in MDM is not altered by DHT 
It seemed incongruous that some cofactors were regulated by DHT treatment in 
HUVEC but not MDM. The majority of cofactors used in this study were chosen 
specifically because they have previously been shown to be hormonally regulated in 
various non-vascular tissues as described above. 
 
While it may be possible that there is no hormonal regulation of cofactors in 
macrophages, the lack of effect of DHT on AR expression was in conflict with a 
similar study run concurrently in our laboratory [122]. While a similar lack of effect 
of 400 nM DHT on AR mRNA levels was observed in female-derived macrophages, 
McCrohon et al (2000 & 1999) [149, 150] demonstrated that male donor cells, DHT 
increased AR mRNA levels [122]. The discrepancy between the two studies may lie 
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in the treatment time. In the study by McCrohon et al (2000 & 1999) a 48 hrs time 
point was used. The different results indicate that treatment effect may be transient 
and several early time points may be required to observe short-term regulatory 
effects. In keeping with this theory, Misiti et al (1998) [249] and Mestayer  et al 
(2003)  [246] demonstrated time-dependent expression of AR cofactors in different 
cell types exposed to different sex hormones.  
 
The concentration of androgen used to treat cells may also be an important 
consideration. For example, Mestayer et al (2003) [246], showed that treating cells 
with 5 nM DHT significantly decreased SRC-1 and ARA54 levels 2 hrs post 
treatment. However, at 6 hrs post treatment the levels were no longer significantly 
different to the controls [246]. The current study used a much greater concentration 
of DHT (400 nM) to treat the cells, as previous used in our laboratory [151]. This 
high dose of DHT may have a different post-treatment regulatory effect on the 
cofactor proteins compared to the Mestayer et al (2003) [246] study inducing a 
greater response over a longer period of time. Given the time-, hormonal-, and cell-
type specific responses found in other co regulatory studies, it may be that the lack of 
regulation of MDM in this study was due to methodology rather than a true lack of 
hormonal response in this cell type. This needs further investigation. 
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5.4.3  DHT regulation of SRC-1 protein expression  
SRC-1 was included in this study as it is known to interact, not only with the AR, but 
also with the inflammatory modulator, NF-κB [337]. Previous studies in our 
laboratory showed that VCAM-1 is increased in HUVEC in response to DHT via an 
AR/NF-κB pathway [151]. As DHT was shown to increase SRC-1 at the mRNA 
level, protein levels were next examined. 
 
It was found from the western blotting experiments that DHT increased SRC-1 
protein expression in male-, but not female-, HUVEC. This finding was consistent 
with previous results from the laboratory which showed that there is similar male-
specific expression of AR and VCAM-1 [151]. This result was, however, opposite to 
that found for mRNA, where DHT treatment resulted in decreased SRC-1 mRNA in 
both male and female HUVEC. Therefore, SRC-1 expression is regulated by DHT at 
both the transcriptional and post-translational levels. AR has similarly been shown to 
be regulated at various levels [156-158, 338]. Studies have shown a down-regulation 
of AR mRNA in response to T treatment in prostate cancer cells [339], with a 
simultaneous up-regulation of AR protein [158]. Androgen treatment has been shown 
to regulate the stability of the AR protein, thus even in the presence of decreasing 
mRNA levels, protein levels can increase [340, 341]. 
 
In order to measure the SRC-1 expression in vivo, we used male and female ApoE
-/-
 
mice, left intact, ovariectomised (ovx) or orchidectomised (odx), untreated or treated 
with 0.25 cm, 0.5 cm or 1 cm testosterone or DHT treated for 16 weeks (Chapter 4). 
Sections were taken from the aortic sinus and SRC-1 protein levels were examined 
 198
between the treatment groups using immunohistochemistry and results are 
summarised in Table 5.3.  
 
In vivo, SRC-1 protein expression reflected that seen in HUVECs in vitro. Females 
showed no change in SRC-1 protein levels with DHT treatment however there was 
an up-regulation of SRC-1 protein expression levels in the DHT-treated male mice 
compared to the control group with effects observed only using the 0.25 cm and 0.5 
cm implants. 
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Table 5.3 T and DHT effects on SRC-1 protein levels in the aortic sinus of 
male and female ApoE
-/-
 mice 
  Testosterone DHT 
 Intact 0.25 cm 0.5 cm 1 cm 0.25 cm 0.5 cm 1 cm 
Female ↔ ↑ ↓ ↔ ↔ ↔ ↔ 
Male ↔ ↔ ↑ ↑ ↑ ↑ ↔ 
Arrows indicate an increase (↑) or decrease (↓), or no effect (↔) in protein levels in 
response to treatment. All changes in SRC-1 levels were significant (P < 0.05) 
relative to their ovx/odx controls. 
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T treatment in these mice also increased SRC-1 expression in male mice in a dose-
dependent manner. In female mice, while DHT failed to regulate SRC-1 at any dose, 
T treatment up-regulated SRC-1 at the lowest 0.25 cm dose, down-regulated at the 
0.5 cm dose and had no effect at the highest 1 cm dose administered. Again this 
result shows a very gender-specific effect of SRC-1 regulation, because although T 
up-regulated SRC-1 in males and females, T dose regulated in an opposing manner, 
with lower doses up-regulating SRC-1 in female mice, and higher doses up-
regulating SRC-1 in male mice.  
 
5.4.4  Summary and conclusions 
To date, there is little information in the literature regarding the presence and 
hormonal regulation of cofactors in the vasculature. This chapter, therefore, presents 
novel results showing that specific cofactors are expressed in vascular cells and that 
they can be regulated by DHT in HUVEC. Further more, the results have shown that 
some cofactors can be regulated in a gender-specific manner and that regulation at 
transcriptional and post-translational levels may occur.  
 
A multitude of studies have shown how these cofactors can augment AR 
transactivation [251, 254, 255, 342] and that regulation of their expression can have 
significant effects on androgen responsiveness [161]. Over-expression of co-
activators has been shown to increase AR activity in several cell types [160, 161, 
199, 343], while over-expression of co-repressors has been shown to decrease AR 
transactivation [230]. Given the post-translational effects seen for SRC-1, it would be 
difficult to assume that the increases in cofactor expression or decrease in co-
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repressor expression seen in this study would translate into increased AR activation 
as final levels of protein expression may be quite different. The variable 
mRNA/protein regulation seen in this study for SRC-1 suggests that multiple levels 
of regulation may exist for each cofactor, similar to that found for AR, and highlights 
that regulation of AR transactivation in response to hormone is a highly complex 
regulatory system involving regulation of both receptor and cofactor levels. This 
complex level of control of cofactors may play some role in the cell and tissue-
specificity of AR action. In particular, the finding that various cofactors can be 
differentially regulated within the same cell type or the same cofactor differentially 
regulated between genders shows how hormone treatment can have complex effects 
on final AR activity between the sexes. Therefore, cofactor expression and 
subsequent activity may play an important role in differential expression of genes 
between genders. This now needs to be explored in more detail. 
 
Important steps in early atherogenesis have been shown to be regulated by DHT in 
an AR-dependent manner [149-151]. Modulation of AR cofactors by hormone may 
thus also modulate AR transactivation. The fact that in this study SRC-1 has been 
shown at a protein level to be similarly regulated to the NF-κB/AR pathway in 
HUVEC [337] now warrants further investigation to determine if SRC-1 has any 
effect at all on the gender-specific inflammatory effects of DHT on HUVEC. 
Understanding the regulatory pathways of cofactors in specific cell types may allow 
more specific targeting of therapies for diseases such as atherosclerosis where 
hormones play a significant role.  
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CHAPTER 6 - Final Discussion 
 
Cardiovascular disease (CVD) is the main cause of morbidity and mortality in the 
developed world. There is a gender bias with men having a higher incidence and 
earlier onset of CVD than age-matched women [21, 344]. Atherosclerosis is the 
major CVD and studies investigating gender bias in CVD have focused on the 
hypothesis that female sex hormones, estrogens, are protective against 
atherosclerosis, since women develop more lesions after estrogen levels decline with 
the onset of menopause. In this current study, we explored the alternative theory that 
male sex hormones, androgens are the underlying cause for the gender bias and 
responsible for influencing atherosclerosis formation in males. The aim of this study 
has been to examine the effect of exogenous T and DHT treatment at a range of 
pharmacologic doses on atherosclerotic lesion formation in male and female ApoE
-/-   
mice. This study has demonstrated that T and DHT have gender- and dose- specific 
effects on atherosclerotic plaque levels in ApoE
-/-   
mice. To complement the in vivo 
data, we showed that DHT treatment was able to hormonally regulate androgen 
receptor cofactors in vascular cells and tissue.  
 
6.1 Assessing atherosclerotic plaque formation in ApoE
-/-
 mice 
In Chapter 3, the study investigated the characteristics of two different 
methodologies that can be used to analyse atherosclerotic plaque formation in the 
arterial tree of ApoE
-/-
 mice [280]. The limitations that were identified for the classic 
H&E method of plaque assessment are summarised in Table 6.1. The Oil Red O en 
face staining technique proved to be a much faster and more efficient method to 
quantitate plaque formation.  
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The major advantage of the en face Oil Red O staining was that it was a much faster 
technique. The entire procedure including longitudinal dissection, pinning, staining 
and image acquisition for each arterial tree could be performed in less than one hour. 
The en face method also allowed for different areas of the arterial tree to be assessed 
for plaque levels. Unfortunately, this method was not problem-free. The major 
disadvantages of the en face method were that the tissue was prone to tearing when 
being pinned open and/or the dislodgement of lesions during staining, as well as 
evaporation of the Oil Red O stain (Table 6.1).   
 
The major advantage of the H&E method is that it is able to show the morphological 
changes such leukocyte infiltration, fibrosis and necrotic cores within the plaque. 
Additionally, sectioning the aortic sinus allowed for the assessment by 
immunohistochemistry of specific protein expression levels (for e.g. SRC-1 in 
Chapter 5). The major disadvantage of the H&E staining method was that it was very 
time consuming and labour intensive: it is necessary to stain, coverslip, photograph 
and then analyse each section. The technique to completion took approximately 48 
hrs more to complete than the Oil Red O method.  
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Table 6.1 Advantages and disadvantages of H&E and Oil Red O en face 
staining 
Oil Red O H&E Staining 
technique Advantages Disadvantages Advantages Disadvantages 
Preparation 
of tissue 
Less time 
needed (20 
mins, to cut and 
pin open 
arterial tree of 
one animal). 
Tissue prone to 
tearing. Cutting 
tissue can be 
difficult. 
Sectioning 
easier then 
pinning tissue 
(no tearing). 
Time consuming, 
labour intensive. 
1 day for 
processing and 
embedding. 
30-60 mins to 
section one 
animal’s aortic 
sinus. 
Staining 
procedure 
Easy protocol 
with few steps.  
Evaporation of 
stain. 
Dislodgment of 
plaques. 
Easy protocol 
that can be 
automated. 
Multiple step 
staining procedure 
with coversliping. 
Time consuming. 
Images 
acquisition 
Completed on 
the same day. 
Prone to 
problems (eg 
reflectivity.) 
Easy to capture 
images of 
sections. 
Time consuming 
as coverslip drying 
time involved. 
Plaque 
assessment 
View and 
analyse plaque 
along entire 
tree. 
Not able to 
assess 
morphological 
changes. 
Can determine 
morphological 
changes. 
Can only measure 
plaque formation 
in selected 
sectioned regions 
(eg. aortic sinus, 
aortic arch.) The 
more areas chosen 
for analysis, the 
more time 
consuming & 
labour intensive. 
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Thus although the Oil Red O method was much faster to perform, the results were 
not as detailed as with the H&E staining. The two staining methods, between 
treatment groups showed similar results from the aortic sinus and tree, with the same 
significant changes in plaque levels. The results from the arterial tree were consistent 
with the results from the aortic sinus, with the magnitude of fold differences for the 
most part greater for arterial tree than the aortic sinus (Chapter 4). The direction of 
the change was always the same. The arterial tree most likely gave a larger fold-
difference as there was more plaque area in the tree. The levels were lower in the 
aortic sinus due to the small area of tissue analysed compared to the tree, giving 
smaller variances in the sinus data. The tree has a much larger area to produce 
greater areas of plaque, hence, more advanced lesions and the increase in the time 
these animals were treated allowed for the differences to develop. Therefore, the 
results obtained from the two different methods are very comparable and allow for 
identical conclusions. This means that the decision of which method to use is really 
dependent on the proposed study end points. If the investigator is interested in only 
quantitating plaque levels and looking for a difference in plaque growth as a result of 
a specific treatment, then the en face Oil Red O method would be the method of 
choice because of its simplicity and time/labour efficiency. However, if 
morphological assessment of lesions is required, then H&E method would be a much 
better choice as a lot more information can be obtained from the sections, either by 
histological or immunohistological means. In the present study, the primary interest 
was how exogenous treatment with T and DHT affected plaque levels; therefore, the 
Oil Red O method was used. 
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6.2 The effects of T treatment on atherosclerotic plaque formation  in ApoE
-/-
 
mice 
To date studies have shown both adverse and protective effects of T on 
atherosclerosis in male animal models. However, the different studies have used a 
multitude of different T doses, routes of administration and animal species. For 
example, these include those administered orally (30-150mg), by subdermal implants 
(7.5-40mg and 1-1.5 cm), or by intra-muscular injections (0.12-25 mg) weekly or 
twice weekly. The different species of animals included chicks, monkeys, mice, 
rabbits and rats [50, 55, 57, 93, 95-98, 100, 104, 105, 345]. Given that the dose of T 
led to a different outcome in the present study it is very likely that the varied 
conditions used in published studies accounts for the different reported results. 
Therefore, the present study has tried to address all these issues by administering 3 
different doses from a high dose of 1 cm silastic implant through to lower doses of 
0.5 cm and 0.25 cm (corresponding to high, medium and low) via the same route, 
allowing a more sensible interpretation of the results.  
 
In Chapter 4, we explored the effects of T on atherosclerotic plaque formation in 
ApoE 
-/-
 mice. The findings demonstrated that T had a dose-dependent and gender-
specific effect on atherosclerotic plaque formation. In the females, exogenous T 
treatment had absolutely no effect on plaque formation. This was a little surprising as 
previous studies from this laboratory showed that females at the higher 1 cm T dose 
had an increase in plaque formation in the aortic arch but a null effect in the aortic 
sinus. It is unclear why this null result was obtained but one reason for the disparity 
between the studies may be that this result is due to the stage of lesion development 
with much more plaque evident in the older 20-week mice. That the earlier time 
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point showed early fatty streak formation however have no effects on plaque 
progression. The null effect of this study is similar to another investigation which 
used an early atherosclerotic animal model with balloon injuries of the carotid 
arteries showed that T treatment had no effect in females, where T had a null effect 
in the female Apo E
-/- 
plaque development [56]. 
 
In contrast to the female mice, there was a change in atherosclerotic plaque 
formation with exogenous T treatment of male mice. The highest dose of T that was 
tested (1 cm implant) decreased the formation of plaque in both the sinus (H&E) and 
the tree (Oil Red O). The administration of high T dose is in keeping with prior 
animal studies where treatment with exogenous T demonstrated athero-protective 
effects [50, 57, 96-98, 100, 105, 122].  
 
This study aimed to address the inconsistent findings within the literature, where 
treatment with T has demonstrated both adverse and beneficial effects on plaque 
formation in males. In a few studies the protective effects of T against plaque 
formation are attenuated by the co-treatment of an aromatase inhibitor [57, 97, 116]. 
Therefore it is assumed from these studies, that the protective effects in the male 
animals maybe due to the aromatisation of T to E2, allowing for the T treatments to 
act through ER not AR.  
 
Previous data from our laboratory showed that T treatment induced a down-
regulation and an up-regulation of the AR expression in male and female animal’s 
respectively. [122]. The same study also investigated the levels of aromatase in the 
male and female ApoE
-/-
 mice. This showed an increase in the males, with a decrease 
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in the females. These previous results are important and relevant to this current study 
as it may account for the gender differences of T treatment with the high dose acting 
via ER in the males and AR in the females, showing T as having some protective 
effect on atherosclerotic plaque formation in males. The only pathway for T to act is 
via the AR especially without the enzyme aromatase to metabolise T to E2.  
 
A novel result of this study revealed that as the exogenous doses of T treatment was 
reduced the males showed an increase in plaque levels in the aortic sinus (H&E) and 
the tree (Oil Red O). Therefore, the lowest dose of T (0.25cm) was shown to be 
atherogenic. This was also observed with the 0.25 cm dose of DHT. These results 
imply that the lower doses may have been acting via the AR and having an 
atherogenic effect. 
 
In this study the gonadectomised male and female groups that had no circulating 
endogenous sex hormones showed that there was an increase in plaque formation 
compared to the intact group. This study is in keeping with other investigations that 
observe an increase in atherosclerosis in gonadectomised animals compared to the 
intact animals [57, 122, 346]. These results correlate with clinical studies where 
hypogonadal men with low to no endogenous levels of T, have higher CVD 
incidence compared to age matched men with normal physiological concentrations of 
T [27, 87, 290]. Women have been shown to have some cardio-protection compared 
to men which is reduced with the onset of menopause, where the lowering of 
endogenous estrogen levels shows an increased incident of CVD [21-23, 344]. 
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These findings have significant clinical implications when developing T-based 
hormone therapy for men and women. From previous HRT studies conducted in 
women, the evidence showed that E2 replacement had beneficial effects but as more 
studies were conducted those women with pre-existing atherosclerosis experienced a 
limited to reduced effect. Therefore hormone therapy, designed for men as a 
replacement for their endogenous T, will have to take into account the dose of T that 
is administered especially for those with pre-existing CVD. In retrospect, the only 
studies examining the effects of male sex hormones on atherosclerotic plaque 
formation are case studies investigating androgen abuse, with anabolic steroid doping 
for athletic purposes and body building. There have been no studies looking at T as a 
therapeutic HRT regime used by both men and women for pre/post meno- and andro- 
pause treatment respectively. Investigating the effects of exogenous androgen 
treatment on atherosclerotic plaque formation needs further investigation. 
 
6.3 The effects of DHT treatment on atherosclerotic plaque formation in 
 ApoE
-/-
 mice 
The current study also examined the effects of DHT on plaque formation to see how 
the non-aromatisable androgen affected the formation of atherosclerotic plaque. The 
findings from this study have shown that the higher doses of 1 cm and 0.5 cm DHT 
treatment decreased atherosclerotic plaque formation in female mice with the lowest 
dose having a null effect. This result correlates with previous investigations in this 
laboratory showing that DHT treatment with a 1 cm implant in the females for 8 
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weeks opposed to the 16-weeks in this study had significant effect on reducing 
plaque area in the females [122].  
 
Therefore, the DHT at high doses is protective in females. DHT is a non-
aromatisable androgen which allows us to see a purely androgenic effect working 
only via the AR. Recent studies have been shown that DHT can be metabolised to 
3β-androsterone (3β-A) via 3β- hydroysteroid hydrogenase (3β-HSD) in endocrine 
tissue such as the prostate and the brain. This metabolite of DHT has been shown to 
have high affinity to act via the ERβ [119, 121]. A possible mechanism for DHT is to 
also act via ER instead of AR which would give a reason for the atheroprotective 
effects observed in the female animals in this study. 
 
Conversely, the males treated with DHT showed no changes apart from the lowest 
dose that had a significant increase in plaque area. It was speculated from the 
previous results that the non-significant result from the male mice treated with 1 cm 
DHT was due several factors including; treatment time and dosage or the result from 
previous studies from the laboratory were correct and there was a null effect with the 
1 cm DHT implant. This study has shown that longer treatment time, of an extra 8 
weeks (total of 16 weeks) did not effect the results with no change in plaque area for 
the 1 cm DHT (supporting M. Hill 2006 results [122]). However, these results were 
different from other studies which suggest DHT is atherogenic [149], [151]. There 
may be a number of reasons for the differences observed in this study: such as a non-
genomic pathway being activated, or DHT being metabolised and using a different 
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receptor pathway, similar to T being aromatised to E2. These theories need further 
investigation.  
 
6.4 The gender-specific effects of exogenous androgen treatment 
Chapter 4 showed some novel, gender-specific effects with T and DHT treatment. T 
treatment proved to be atheroprotective in males at high doses. The novel effect of 
these hormone treatments showed that the males had adverse effects with low doses 
of both T and DHT. This suggests in male the high dose of T is most likely being 
converted to E2 via aromatase especially since the medium dose of the T has a null 
effect compared to the controls. This gave the appearance of the T doses having an 
inverse relationship with plaque formation. The results from this study saw that T 
treatment had no effect in females.  
 
Instead of the adverse effect of DHT, that was assumed with the high dose of 1 cm in 
the male animals, the 1 cm dose showed no significant change. It was in the females 
that showed an athero-protective effect with the 0.5 cm and 1 cm DHT treatment was 
observed. This then leads one to ask what underlying mechanism is behind these 
results, with the doses giving different outcomes.  
 
6.5 The dose-specific effects of exogenous androgen treatment 
From these current results we speculate that aromatase is the key to the protective 
effects of T. The doses of T administered have a dose response affect in males which 
may be due to the metabolic rate of change between T and E2 via aromatase. With 
more substrate the Km value will move to convert more T to E2 to reach equilibrium. 
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Therefore, the higher the concentrations of androgens in the animal, the more that 
will be converted if there is a high supply of the catalyst, which in this scenario is 
aromatase thus affecting how the androgen T is metabolised. The higher exogenous 
doses of T and DHT may shift the equilibrium with the different concentrations of 
hormones: thereby increasing the expression of enzymes responsible for hormone 
metabolism and allowing the metabolites to act via different pathways (Figure 6.1). 
However, the females have been shown to express less aromatase than the males. 
Therefore, in females the results show no change between groups with high to low 
dose of T.  T may not be converted to E2 due to low levels of aromatase leading to T 
having a purely androgenic effect, via the AR (Figure 6.2). 
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Figure 6.1 Effect of high doses of T and DHT on gene expression 
High doses of T and DHT can act via the AR to have genomic or non-genomic 
effects within the vasculature. Through the conversion of testosterone (T) to estradiol 
(E2) via aromatase and/or DHT to 3β-androsterone (3β-A) via 3β- hydroysteroid 
hydrogenase (3β-HSD), the metabolites may act via the ER, which has been shown 
to have athero-protective effects. The metabolites acting via ER might account for 
the atheroprotective effects observed in Chapter 4 of this study. 
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Figure 6.2 Regulation of lower doses of T and DHT on gene expression  
The lower dose of androgens does not induce the mechanism to metabolise T and 
DHT to E2 or 3β-A, via aromatase and 3β-HSD respectively as it would at the higher 
doses. Therefore, as they are unable to act via the ER, the effects of the treatment are 
not via the ER which may be seen at the higher doses and therefore there is a 
resultant increase in atherosclerotic plaque. At more physiological concentrations, T 
and DHT may have purely androgenic effects acting only via the AR.   
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Androgens have been shown to activate the non-genomic pathway which allows it to 
induce nitric oxide (NO) production via endothelium nitric oxide synthase (eNOS) 
(Figure 6.3). The generation of NO causes a direct vasodilatory effect in the vessels 
reducing the formation of atherosclerotic plaque formation [90, 347]. NO is also 
known for its properties in reducing leukocyte adherence to the endothelium, 
retarding the early steps of atherosclerosis [348]. The high doses of DHT in the male 
and female mice may chronically activate the non-genomic pathway inducing the 
increased production of NO causing a reduction in atherosclerotic lesions (Figure 
6.3). 
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Figure 6.3 Androgen activation of the non-genomic pathway 
The non-genomic pathway involves the AR/androgen complex activating the 
phosphoinositide 3-kinase (PI3K), AKT protein kinase enzyme and the endothelial 
nitric oxide synthase (eNOS) pathway to produce nitric oxide (NO). The increased 
NO production induces vasodilatation, inhibits platelet aggregation, leukocyte 
adhesion, and smooth muscle cell proliferation, which reduces atherosclerotic plaque 
formation. The genomic pathway induces the dimerisation of the AR/androgen 
complex and activates translation of AR targeted genes (Adapted from Furukawa et 
al [347]). 
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6.6 DHT can hormonally regulate androgen receptor cofactors 
The results from this thesis and other investigators, suggest that T and/or DHT can 
influence the development of atherosclerosis [149-152]; therefore, it is important to 
understand the regulation of AR activity by investigating the role of AR cofactors in 
the vasculature. T/DHT can act through AR to influence cellular mechanisms such as 
gene activation. However, AR does not act alone and interacts with a multitude of 
cofactors that act to either activate or inhibit AR transactivation.  
 
In this study it has been shown that DHT can hormonally regulate cofactor mRNA 
expression in HUVECs but not in hMDMs. This is the first time that hormonal 
regulation of these cofactors has been demonstrated in vascular endothelial cells. It 
was found that AR cofactors p300 and NCoR1 mRNA levels were increased, 
whereas ARA24, ARA54, ARA160 and SRC-1 were decreased in DHT treated 
HUVECs. There was some level of gender-specificity shown with a decrease in 
mRNA levels in HUVECs from male but not female donors. 
 
Unlike the above cofactors there was no hormonal regulation of A1B1, ARA70, 
FHL2 and SMRT. The results from this chapter are important as they show that some 
cofactors in the vasculature are hormonally regulated with DHT treatment and may 
interact with AR to influence transcriptional activity of those genes involved in the 
atherogenic progress. From the list of hormonally regulated genes included in this 
study was SRC-1, a cofactor that interacts with both AR and NF-κB. Both AR and 
NF-κB mediate pro-atherogenic effects in HUVECs [151], and the finding from 
SRC-1 may be involved in AR/ NF-κB interactions. 
 219
 
There were no changes in the mRNA expression in hMDMs. This finding was 
unexpected, as previous results from our laboratory have shown that DHT treatment 
effects the activation of AR and up-regulates gene expression in a gender-specific 
manner in MDMs [149, 152]. A number of reasons could explain why there was little 
effect observed with DHT treatment in hMDMs. Firstly, the dose (400nM) applied to 
the cells may have been too high. Secondly, the treatment time of 48 hrs may have 
been too long and that any transcriptional effects occurred earlier.  
 
6.7 Hormonal regulation of SRC-1 by androgens 
An extensively studied cofactor, SRC-1, has been shown to be involved in increasing 
transcriptional activity in cancerous endocrine tissue [321]. In this current study, 
DHT treatment showed a decrease in mRNA levels in HUVEC from both male and 
female donors. However, protein levels increased in DHT treated HUVEC, a finding 
that was in keeping with increased expression in the aortic sinus of DHT- treated 
ApoE
-/-
 mice. The increase in protein expression was only found in HUVEC male 
donors and male ApoE
-/-
 mice. The results for SRC-1 suggests a similar mechanism 
is operative, similar to that described in the literature for the post-transcriptional 
regulation of the AR protein, with androgens inducing a down-regulation of the 
mRNA but an increase in the protein levels [158, 339-341]. The protein expression 
patterns in the mice studies showed a dose-dependent effect of DHT treatment on 
SRC-1 levels.  
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The SRC-1 cofactor is of particular interest to this study as it is an extensively 
studied cofactor that is able to interact with the AR and other nuclear receptors, 
transcription factors and with the inflammatory modulator, nuclear factor κB (NF-
κB) [337, 349]. Previous studies showed that DHT treatment increased vascular cell 
adhesion molecule-1 (VCAM-1) expression in endothelial cells via the AR/ NF-κB 
pathway [139, 151] (Figure 6.4). Therefore the interaction between SRC-1 and AR/ 
NF-κB may act to increase VCAM-1 expression which has an adverse effect on 
plaque formation. SRC-1 has also been shown to interact with p300, NF-κB and 
cAMP response element binding protein (CREB) in vascular smooth muscle cells to 
induce interleukin -6 (IL-6) expression with angiotensin II (Ang II) treatment. IL-6 is 
a cytokine associated with an increase in vascular inflammation leading to the 
formation of atherosclerosis [350].  Alternatively, a recent study has shown that 
SRC-1 gene deletion in mice reduces the estrogen effect on vascular injury response. 
This demonstrated that SRC-1 expression in the vascular cells facilitates estrogen/ER 
vaso-protection [351] which would act to be atheroprotective and the increase in 
SRC-1 with T doses in the male studies may still be due to the increase in E2 through 
T being metabolised by aromatase.  
 
The results produced in this thesis show that at high doses of T there are 
atheroprotective effects in males. In Chapter 5 the results showed that as T doses 
increase so did the protein expression of SRC-1 increase. This novel finding 
reinforces the theory that as the concentration of T increase it is most likely being 
converted to E2 via aromatase, to then act via the ER. This may in part be due to the 
increase in SRC-1 that has been shown to interact with E2 to have atheroprotective 
effects as are seen in this study. 
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Figure 6.4 SRC-1 interaction with AR and transcription factors influencing 
transcription of AR targeted genes 
SRC-1 is a co-activator that has been shown to associate with AR. It interacts with 
the ligand-bound AR complex, initiating interaction between HAT inducing 
methyltransferase activity disrupting histone-DNA interaction. The access to 
transcription machinery such as RNA pol II enhances the transcription of specific 
targeted genes. SRC-1 is able to also interact with transcription factors activator 
protein-1 (AP-1) and NF-κB.
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6.8 Future directions 
 
This study has shown exogenous T to be atherogenic at low doses, athero-protective 
at higher doses in males and to have adverse effects in females at all doses. This 
thesis also demonstrated that DHT had a similar trend in males and females, with an 
inverse relationship at high doses decreasing plaque formation. As doses decreased 
there was an increase in plaque formation showing a novel response to T and DHT 
treatment in ApoE
-/-
 mice. This thesis also explored the hormonal regulation of AR 
cofactors which demonstrated that DHT was able to regulate the cofactors in 
HUVEC. Some questions arising from this work are listed below: 
 
Can the metabolism of androgens play a protective role in ApoE
-/- 
mice? 
 
Why is T protective in males at high doses but adverse in females? The results from 
this study have not investigated the conversion of T to E2 via aromatase and DHT to 
3β-androsterone via 3β-HSD. Therefore one future study should be to measure the 
circulating concentrations of these metabolites and to investigate the expression 
levels of ER and the enzymes responsible for the conversions of T and DHT, such as 
aromatase, 5α-reductase and 3α-hydroxysteriod dehydrogenase protein expression 
using immunohistochemistry and western blot analysis. These experiments would 
help ascertain if the E2 levels are increased and hence if it is the effects of the 
metabolites acting through the ER, giving the protective effects observed in this 
current study at high dose. This would elucidate if the different doses of hormones 
effect how the androgens are metabolised. 
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Do high doses of DHT treatment activate non-genomic mechanisms to reduce 
plaque formation? 
 
Nitric oxide has been shown to be increased with androgen treatment and has been 
associated with increasing vasodilatation of vessels [352-355]. In this study the high 
doses of DHT in females were shown to be protective. To ascertain if NO plays a 
role the tissue from the ApoE
-/-
 mice experiments could have immunohistochemistry 
experiments designed to investigate changes in protein levels of eNOS, ER and AR 
between the treatment groups. The results from these experiments would give a 
better idea as to which group not only had an increase in there receptor AR/ER but 
also if there is an increase in NO production determining whether the action was 
through the AR- or ER- eNOS pathways.  
 
Do high doses of androgens affect lipid metabolism? 
 
Recent results from our laboratory suggest that high doses of DHT and T may affect 
the lipid profile of the animals increasing HDL [356], similar to estrogen. 
Investigating the lipid profile of the animals tested in the experiment conducted in 
this study would allow us to ascertain if the androgens affect lipid profiles and how 
the profiles changed with different doses of T and DHT treatments. 
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Would exogenous T and DHT treatment administered to intact animals change 
the outcome of plaque formation? 
 
The results from this thesis are novel since they have demonstrated that plaque 
formation is dependent on dose, especially in males. To relate findings back to a 
clinical setting the experiments would have to be more relevant to how humans are 
administered treatments. Therefore, designing the experiment would need to 
administer the equivalent doses of exogenous T and DHT and treating intact mice 
would more accurately convey human HRT as human are not gonadectomised before 
treatments. Hormone replacement therapies, in men and women are usually given to 
patients to increase already low levels of endogenous hormones. This experiment 
would produce a clearer idea of how the endogenous hormones may interact with the 
exogenous hormone treatment ascertaining if the experiment has the same outcome 
as the results observed from this thesis. 
 
Are other AR cofactors hormonally regulated at the post-transcriptional level? 
 
To investigate the mRNA expression of AR cofactors in MDM a dose response of 
DHT treatment needs to be devised, as well as using different time points to ascertain 
the time when the transcription is at its optimum. Further  in vitro investigations into 
the AR cofactor story are needed to examine protein expression of those cofactors 
that were shown to be hormonally regulated such as NCoR1, ARA54, and ARA24, 
in particular investigating the transcription and post transcription regulation by DHT.  
Results from the Chapter 4 in vivo study showed that there was a change in SRC-1 
expression with T treatment. It would therefore be interesting to explore the effects 
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of T on the expression of the cofactors we have already investigated in this study, 
using the same vascular cell types, treating the cells with T at a number of different 
doses. 
 
Does the cofactor SRC-1 influence the expression of other AR cofactors? 
 
The findings from Chapter 5 showed that SRC-1 mRNA and protein were 
hormonally regulated. SRC-1 has been shown to be similarly regulated to the NF-
KB/AR pathway in endothelial cells therefore it would be advantageous to further 
investigate the role of SRC-1 in vascular cells. Therefore, to elucidate if SRC-1 
influences the activity of AR with DHT treatment, the idea of a siRNA tranfection 
system could be used to investigate how AR and other cofactors influence mRNA 
and protein expression is altered when SRC-1 is removed from an in vitro system. 
There is an SRC-1 knocked out animal model [159, 329] that could be used to 
designed experiments to investigate the effects of androgens in vivo without the 
influences of SRC-1. 
 
6.9  Final summary and conclusions 
 
In summary, then, in this study it was shown for the first time that in males T 
treatment was atheroprotective at higher doses and had an adverse effect at the 
lowest dose with no change in atherosclerotic plaque area in females. This is in 
contrast with the DHT studies, where the females showed atheroprotective effects at 
high doses the males had proatherogenic effects only at the lowest dose. The dose 
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response to plaque area is a novel result that is not fully understood. There may be 
underlying mechanisms that are involved, such as the metabolism of T to E2 and 
DHT to 3β-androsterone. In addition the expression of other factors may influence 
how androgens effect gene transcription such as cofactors. The in vitro studies have 
shown that some cofactors are expressed and hormonally regulated in HUVECs. The 
hormonal regulation of these cofactors suggests that androgens may help to influence 
atherosclerosis formation. The discussion of androgens being used for therapeutic 
intervention is still on-going. Therefore, the role of androgens and their effects on 
CVD is still unknown but remains as an intense topic for future research.  
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